case presentation of hepatitis b

• American College of Gastroenterology
• Clinical and Translational Gastroenterology
• ACG Case Reports Journal
• American College of Gastroenterology <
• Subscribe to journal Subscribe
• Get new issue alerts Get alerts

Secondary Logo

Journal logo.

Colleague's E-mail is Invalid

Your message has been successfully sent to your colleague.

Save my selection

Case Report: Acute Hepatitis B Infection in a Healthy South Asian Female Following Exposure at an Urban Pedicure Facility

Tummala, Sanjeev MD

Swetha Tummala, Palo Alto Medical Foundation, Mountain View, CA.

Introduction: Acute hepatitis B is caused by infection with hepatitis B virus (HBV). The incubation period from the time of exposure to the onset of symptoms is 6 weeks to 6 months. Most infections in adults are caused by exposure to contaminated blood. Other potential sources are semen, vaginal secretions, and open wound exudate. Acute infection ranges from asymptomatic or mild disease to, rarely, fulminant hepatitis. Disease is more severe among adults aged >60 years. The fatality rate among acute cases reported to Center for Disease Control (CDC) is 0.5-1%.

Case Report: Here, we describe a case of acute hepatitis B infection in a healthy South Asian female from possible exposure at an urban pedicure facility. A 35-year-old, previously healthy but unvaccinated Indian woman was seen in a gastroenterology clinic for acute jaundice. Her initial blood work showed AST 550 U/l, ALT 1745 U/L, total bilirubin 9.3 mg/dL, direct bilirubin 7.3 mg/dL, and ALP 196 U/l. Previous liver function tests were normal. An ultrasound of her abdomen showed normal-appearing liver without gallstones or biliary dilatation. Her serologies showed positive hepatitis A IgG antibody, negative hepatitis A IgM antibody, positive hepatitis B surface antigen, positive hepatitis B core IgM antibody, negative hepatitis C antibody, hepatitis B DNA 81300 IU/mL, and negative hepatitis B surface antibody. Her creatinine was 0.59 mg/dL and prothrombin time/ INR 1.1. She had no features of encephalopathy or hepatic decompensation. Her husband and children were immune for hepatitis B from previous vaccination. She was taking no other medications at the time of her illness. She had no other risk factors except a visit to an urban pedicure facility in downtown San Jose, 2 months prior to her acute illness. She remembered having a cut and a bruise after her nails were done, and her feet were washed in a bowl that was used to wash other customers’ feet. She was managed conservatively with no antiviral medications. Follow-up blood work revealed normalization of liver enzymes in about 3 months with AST 31 U/l, ALT 56 U/l and total bilirubin 0.4 mg/dL. She achieved seroconversion 3 months after presentation with negative hepatitis B surface antigen and reactive hepatitis B surface antibody, and undetectable hepatitis B virus. She remains asymptomatic and clinically well.

Conclusion: Acute hepatitis B infection can be caused from contamination of blood from open cuts/bruise and stains that can happen at a pedicure facility. The Center for Disease Control recommends any blood spills, including dried blood, which can still be infectious for about 7 days, be cleaned using 1:10 dilution of 1 part household bleach to 10 parts of water for disinfecting the area.

• + Favorites
• View in Gallery

Log in using your username and password

• Search More Search for this keyword Advanced search
• Latest content
• Global health
• BMJ Journals

You are here

• Volume 2017, Issue
• Acute hepatitis B virus infection and severe non-immune haemolytic anaemia: a rare relationship
• Article Text
• Article info
• Citation Tools
• Rapid Responses
• Article metrics

• http://orcid.org/0000-0003-3985-0718 Inês Furtado 1 ,
• Diana Valadares 2 ,
• Filipe Gaio Nery 2
• 1 Internal Medicine Department , Centro Hospitalar do Porto , Porto , Portugal
• 2 Department of Intensive Care , Centro Hospitalar do Porto , Porto , Portugal
• Correspondence to Dr Inês Furtado, inessilvafurtado{at}gmail.com

The clinical presentation of acute hepatitis B virus (HBV) infection is usually related to the onset of liver failure and damage. Anaemia may occur, but it is only rarely attributed to haemolysis. The authors report about the case of a 41-year-old woman with the diagnosis of acute HBV infection and coagulopathy (without encephalopathy) who developed non-immune haemolytic anaemia. Total recovery of the analytical liver profile, coagulopathy and anaemia was achieved through treatment targeting HBV.This case shows that, although rare, non-immune haemolytic anaemia may occur in association with acute HBV infection and that HBV suppression seems to lead to progressive anaemia resolution.

• infectious diseases
• hepatitis and other gi infections
• hepatitis b
• haematology (incl blood transfusion)

https://doi.org/10.1136/bcr-2017-221763

Statistics from Altmetric.com

Request permissions.

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Contributors FGN and DV contributed to the conception or design of the work. IF was responsible for data collection, analysis and interpretation. IF drafted the initial version of the article which was critically revised by FGN and DV. FGN, DV and IF approved the final version of the article to be published.

Competing interests None declared.

Patient consent Obtained.

Provenance and peer review Not commissioned; externally peer reviewed.

Read the full text or download the PDF:

Hepatitis B Clinical Presentation

• Author: Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF, FAASLD, FRCP(Edin); Chief Editor: BS Anand, MD  more...
• Sections Hepatitis B
• Practice Essentials
• Pathophysiology
• Epidemiology
• Patient Education
• Physical Examination
• Approach Considerations
• Diagnostic Tests
• Radiologic Studies
• Liver Biopsy and Histologic Features
• Pharmacologic Management
• Surgical Intervention
• Hepatitis B and Pregnancy
• Vaccination
• Long-Term Monitoring
• 2016 and 2018 AASLD Guidelines
• 2017 and 2018 EASL Recommendations
• 2015 and 2020 WHO Guidelines Summary
• Medication Summary
• Interferons
• Antihepadnaviral, Reverse Transcriptase inhibitors
• Vaccines, Inactivated, Viral
• Questions & Answers
• Media Gallery

Inquire into patients’ sexual history, occupational history, illicit drug use, and any contacts with known infection.

The spectrum of the symptomatology of hepatitis B disease varies from subclinical hepatitis to icteric hepatitis to fulminant, acute, and subacute hepatitis during the acute phase, and from an asymptomatic chronic infection state to chronic hepatitis, cirrhosis, and hepatocellular carcinoma (HCC) during the chronic phase.

Papular acrodermatitis, also recognized as Gianotti-Crosti syndrome , has been associated with hepatitis B, most commonly in children with acute infection. [ 40 ]

The following multisystem manifestations may occur in hepatitis B virus (HBV) infection:

Pleural effusion and hepatopulmonary and portopulmonary syndrome may occur in patients with cirrhosis

Diffuse intravascular coagulation may occur in patients with fulminant hepatitis

Myocarditis, pericarditis, and arrhythmia occur primarily in patients with fulminant hepatitis

Arthralgias and arthritic (serum sickness) subcutaneous nodules may also occur, but these are rare

Guillain-Barre syndrome , encephalitis, aseptic meningitis, and mononeuritis multiplex may occur in patients with acute hepatitis B

Pancreatitis may develop

Aplastic anemia is uncommon, and agranulocytosis is extremely uncommon

A variety of cutaneous manifestations have been recognized during the early course of viral hepatitis, including hives and a fleeting maculopapular rash. These various lesions are episodic, palpable, and, at times, pruritic. A discoloration of the skin can be identified after the resolution of the exanthem, particularly on the lower extremities. Women are more prone to developing cutaneous manifestations.

Acute phase

The incubation period is 1-6 months in the acute phase of hepatitis B infection. Anicteric hepatitis is the predominant form of expression for this disease. The majority of the patients are asymptomatic, but patients with anicteric hepatitis have a greater tendency to develop chronic hepatitis. Patients with symptomatology have the same symptoms as patients who develop icteric hepatitis.

Icteric hepatitis is associated with a prodromal period, during which a serum sickness –like syndrome can occur. The symptomatology is more constitutional and includes the following:

Low-grade fever

Fatigability

Disordered gustatory acuity and smell sensations (aversion to food and cigarettes)

Right upper quadrant and epigastric pain (intermittent, mild to moderate)

Patients with fulminant and subfulminant hepatitis may present with the following:

Hepatic encephalopathy

Disturbances in sleep pattern

Mental confusion

Gastrointestinal (GI) bleeding

Coagulopathy

Chronic phase

Patients with chronic hepatitis B disease can be immune tolerant or have an inactive chronic infection without any evidence of active disease. These patients are generally asymptomatic.

Patients with chronic active hepatitis, especially during the replicative state, may complain of symptomatology such as the following:

Symptoms similar to those of acute hepatitis

Mild upper quadrant pain or discomfort

If progressive liver disease is present, the following symptomatology may be present:

Hepatic decompensation

GI bleeding

The physical examination findings in hepatitis B disease vary from minimal to impressive (in patients with hepatic decompensation), according to the stage of disease.

Patients with acute hepatitis usually do not have any clinical findings, but the physical examination can reveal the following:

Jaundice (10 days after appearance of constitutional symptomatology, lasting for 1-3 mo)

Hepatomegaly (mildly enlarged, soft liver)

Splenomegaly (5-15%)

Palmar erythema (rarely)

Spider nevi (rarely)

The physical examination of patients with chronic hepatitis B virus (HBV) infection can reveal stigmata of chronic liver disease such as the following:

Hepatomegaly

Splenomegaly

Muscle wasting

Palmar erythema

Spider angioma

Vasculitis (rarely)

Patients with cirrhosis may have the following findings:

History of variceal bleeding

Peripheral edema

Gynecomastia

Testicular atrophy

Abdominal collateral veins (caput medusa)

Centers for Disease Control and Prevention. Hepatitis B information for health professionals: hepatitis B FAQs for health professionals. https://www.cdc.gov/hepatitis/HBV/index.htm. Available at https://www.cdc.gov/hepatitis/HBV/index.htm . Updated May 31, 2015; Accessed: May 23, 2017.

Sorrell MF, Belongia EA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med . 2009 Jan 20. 150(2):104-10. [QxMD MEDLINE Link] . [Full Text] .

Nguyen MH, Wong G, Gane E, Kao JH, Dusheiko G. Hepatitis B virus: advances in prevention, diagnosis, and therapy. Clin Microbiol Rev . 2020 Mar 18. 33(2):e2128652. [QxMD MEDLINE Link] . [Full Text] .

World Health Organization. Hepatitis B. July 27, 2021. Available at https://www.who.int/news-room/fact-sheets/detail/hepatitis-b . Accessed: December 2, 2021.

McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med . 2001 Nov 6. 135(9):759-68. [QxMD MEDLINE Link] .

Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med . 1997 Jun 26. 336(26):1855-9. [QxMD MEDLINE Link] .

Fattovich G, Giustina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in western European patients with cirrhosis type B. The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology . 1995 Jan. 21(1):77-82. [QxMD MEDLINE Link] .

Yu MC, Yuan JM, Ross RK, Govindarajan S. Presence of antibodies to the hepatitis B surface antigen is associated with an excess risk for hepatocellular carcinoma among non-Asians in Los Angeles County, California. Hepatology . 1997 Jan. 25(1):226-8. [QxMD MEDLINE Link] .

Yang HI, Yeh SH, Chen PJ, et al. Associations between hepatitis B virus genotype and mutants and the risk of hepatocellular carcinoma. J Natl Cancer Inst . 2008 Aug 20. 100(16):1134-43. [QxMD MEDLINE Link] . [Full Text] .

Te HS, Jensen DM. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis . 2010 Feb. 14(1):1-21, vii. [QxMD MEDLINE Link] .

World Health Organization. Weekly epidemiological record (WER): global routine vaccination coverage. 2011;86(46):509-20. Available at https://www.who.int/wer/2011/wer8646/en/index.html . Accessed: June 13, 2013.

Blumberg BS. Australia antigen and the biology of hepatitis B. Science . 1977 Jul 1. 197(4298):17-25. [QxMD MEDLINE Link] .

Norder H, Courouce AM, Magnius LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology . 1994 Feb. 198(2):489-503. [QxMD MEDLINE Link] .

Lau JY, Wright TL. Molecular virology and pathogenesis of hepatitis B. Lancet . 1993 Nov 27. 342(8883):1335-40. [QxMD MEDLINE Link] .

Chisari FV, Ferrari C. Hepatitis B virus immunopathology. Springer Semin Immunopathol . 1995. 17(2-3):261-81. [QxMD MEDLINE Link] .

Davies SE, Portmann BC, O'Grady JG, et al. Hepatic histological findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology . 1991 Jan. 13(1):150-7. [QxMD MEDLINE Link] .

Kahila Bar-Gal G, Kim MJ, Klein A, et al. Tracing hepatitis B virus to the 16th century in a Korean mummy. Hepatology . 2012 Nov. 56(5):1671-80. [QxMD MEDLINE Link] .

Gish RG, Locarnini S. Chronic hepatitis B viral infection. Yamada T, ed. Textbook of Gastroenterology . 5th ed. Oxford, UK: Blackwell Publishing; 2009. 2112-38.

Azmi AN, Tan SS, Mohamed R. Practical approach in hepatitis B e antigen-negative individuals to identify treatment candidates. World J Gastroenterol . 2014 Sep 14. 20(34):12045-55. [QxMD MEDLINE Link] . [Full Text] .

Jung MC, Diepolder HM, Pape GR. T cell recognition of hepatitis B and C viral antigens. Eur J Clin Invest . 1994 Oct. 24(10):641-50. [QxMD MEDLINE Link] .

Chisari FV. Cytotoxic T cells and viral hepatitis. J Clin Invest . 1997 Apr 1. 99(7):1472-7. [QxMD MEDLINE Link] . [Full Text] .

Kuo A, Gish R. Chronic hepatitis B infection. Clin Liver Dis . 2012 May. 16(2):347-69. [QxMD MEDLINE Link] .

Tong W, He J, Sun L, He S, Qi Q. Hepatitis B virus with a proposed genotype I was found in Sichuan Province, China. J Med Virol . 2012 Jun. 84(6):866-70. [QxMD MEDLINE Link] .

Sonneveld MJ, Rijckborst V, Zeuzem S, et al. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B. Hepatology . 2012 Jul. 56(1):67-75. [QxMD MEDLINE Link] .

Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut . 2000 Mar. 46(3):420-6. [QxMD MEDLINE Link] . [Full Text] .

Wursthorn K, Manns MP, Wedemeyer H. Natural history: the importance of viral load, liver damage and HCC. Best Pract Res Clin Gastroenterol . 2008. 22(6):1063-79. [QxMD MEDLINE Link] .

Heidrich B, Serrano BC, Idilman R, et al. HBeAg-positive hepatitis delta: virological patterns and clinical long-term outcome. Liver Int . 2012 Oct. 32(9):1415-25. [QxMD MEDLINE Link] .

Wang J, Zhao W, Cheng L, et al. CD137-mediated pathogenesis from chronic hepatitis to hepatocellular carcinoma in hepatitis B virus-transgenic mice. J Immunol . 2010 Dec 15. 185(12):7654-62. [QxMD MEDLINE Link] . [Full Text] .

Thursz MR, Thomas HC, Greenwood BM, Hill AV. Heterozygote advantage for HLA class-II type in hepatitis B virus infection. Nat Genet . 1997 Sep. 17(1):11-2. [QxMD MEDLINE Link] .

Jouanguy E, Lamhamedi-Cherradi S, Altare F, et al. Partial interferon-gamma receptor 1 deficiency in a child with tuberculoid bacillus Calmette-Guérin infection and a sibling with clinical tuberculosis. J Clin Invest . 1997 Dec 1. 100(11):2658-64. [QxMD MEDLINE Link] . [Full Text] .

Zhou J, Chen DQ, Poon VK, et al. A regulatory polymorphism in interferon-gamma receptor 1 promoter is associated with the susceptibility to chronic hepatitis B virus infection. Immunogenetics . 2009 Jun. 61(6):423-30. [QxMD MEDLINE Link] .

Frodsham AJ, Zhang L, Dumpis U, et al. Class II cytokine receptor gene cluster is a major locus for hepatitis B persistence. Proc Natl Acad Sci U S A . 2006 Jun 13. 103(24):9148-53. [QxMD MEDLINE Link] . [Full Text] .

Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med . 1989 Sep 14. 321(11):708-12. [QxMD MEDLINE Link] .

Davila S, Froeling FE, Tan A, et al. New genetic associations detected in a host response study to hepatitis B vaccine. Genes Immun . 2010 Apr. 11(3):232-8. [QxMD MEDLINE Link] .

[Guideline] Kowdley KV, Wang CC, Welch S, Roberts H, Brosgart CL. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology . 2012 Aug. 56(2):422-33. [QxMD MEDLINE Link] .

Tripathi N, Mousa OY. Hepatitis B. StatPearls [Internet] . 2021 Jul 18. [QxMD MEDLINE Link] . [Full Text] .

Xie WY, Sun C, He H, Deng C, Sheng Y. Estimates of the prevalence of occult HBV infection in Asia: a systematic review and meta-analysis. Infect Dis (Lond) . 2022 Dec. 54 (12):881-96. [QxMD MEDLINE Link] .

Kim BK, Han KH, Ahn SH. Prevention of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Oncology . 2011. 81 Suppl 1:41-9. [QxMD MEDLINE Link] .

Han YF, Zhao J, Ma LY, et al. Factors predicting occurrence and prognosis of hepatitis-B-virus-related hepatocellular carcinoma. World J Gastroenterol . 2011 Oct 14. 17(38):4258-70. [QxMD MEDLINE Link] . [Full Text] .

Caputo R, Gelmetti C, Ermacora E, Gianni E, Silvestri A. Gianotti-Crosti syndrome: a retrospective analysis of 308 cases. J Am Acad Dermatol . 1992 Feb. 26(2 Pt 1):207-10. [QxMD MEDLINE Link] .

[Guideline] Terrault NA, Bzowej NH, Chang KM, et al, for the American Association for the Study of Liver Diseases. AASLD guidelines for treatment of chronic hepatitis B. Hepatology . 2016 Jan. 63(1):261-83. [QxMD MEDLINE Link] . [Full Text] .

Arora S, Martin CL, Herbert M. Myth: interpretation of a single ammonia level in patients with chronic liver disease can confirm or rule out hepatic encephalopathy. CJEM . 2006 Nov. 8(6):433-5. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Centers for Disease Control and Prevention. 2015 Sexually transmitted diseases treatment guidelines. Viral hepatitis. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/std/tg2015/hepatitis.htm . June 4, 2015; Accessed: May 26, 2017.

Finnish Medical Society Duodecim. Viral hepatitis. EBM Guidelines. Evidence-Based Medicine [Internet] . Helsinki, Finland: Wiley Interscience; 2008.

New York State Department of Health. Hepatitis B virus. New York, NY: New York State Department of Health; 2008. Available at https://guideline.gov/content.aspx?id=12812 . Accessed: June 13, 2013.

[Guideline] U.S. Preventive Services Task Force. Hepatitis B virus infection in adolescents and adults: screening. December 15, 2020. Available at https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/hepatitis-b-virus-infection-screening . Accessed: December 2, 2021.

Barclay L. USPSTF shifts course, favors hepatitis B screening. Medscape Medical News. Available at https://www.medscape.com/viewarticle/825948 . May 30, 2014; Accessed: June 2, 2014.

LeFevre ML, U.S. Preventive Services Task Force. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med . 2014 Jul 1. 161(1):58-66. [QxMD MEDLINE Link] .

Chou R, Dana T, Bougatsos C, Blazina I, Khangura J, Zakher B. Screening for hepatitis B virus infection in adolescents and adults: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med . 2014 Jul 1. 161(1):31-45. [QxMD MEDLINE Link] .

Rajbhandari R, Chung RT. Screening for hepatitis B virus infection: a public health imperative. Ann Intern Med . 2014 Jul 1. 161(1):76-7. [QxMD MEDLINE Link] .

Eckman MH, Kaiser TE, Sherman KE. The cost-effectiveness of screening for chronic hepatitis B infection in the United States. Clin Infect Dis . 2011 Jun. 52(11):1294-306. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology . 2018 Apr. 67 (4):1560-99. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Centers for Disease Control and Prevention. Testing recommendations for hepatitis C virus infection. July 29, 2020. Available at https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm . Accessed: December 2, 2021.

Trinchet JC, Chaffaut C, Bourcier V, et al. Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities. Hepatology . 2011 Dec. 54(6):1987-97. [QxMD MEDLINE Link] .

US Food and Drug Administration. 510(k) Premarket notification: Hepatiq. Available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?ID=K142891 . Accessed: January 11, 2015.

Business Wire. FDA clears Hepatiq [press release]. Hepatiq: Hepatic Quantitation. Available at https://www.hepatiq.com/fdaclearshepatiq.html . Accessed: January 11, 2015.

National Institute of Diabetes and Digestive and Kidney Diseases. HALT-C (Hepatitis C Antiviral Long-term Treatment against Cirrhosis) trial website. Available at https://archives.niddk.nih.gov/haltctrial/displaypage.aspx?pagename=haltctrial/index.htm . Accessed: January 11, 2015.

Srinivasa Babu A, Wells ML, Teytelboym OM, et al. Elastography in chronic liver disease: modalities, techniques, limitations, and future directions. Radiographics . 2016 Nov-Dec. 36(7):1987-2006. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] World Health Organization. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva, Switzerland; WHO. 2015 Mar. [QxMD MEDLINE Link] . [Full Text] .

Nebbia G, Peppa D, Maini MK. Hepatitis B infection: current concepts and future challenges. QJM . 2012 Feb. 105(2):109-13. [QxMD MEDLINE Link] . [Full Text] .

Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology . 2009 Sep. 50(3):661-2. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Papatheodoridis G, Buti M, Cornberg M, et al, for the European Association for the Study of the Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol . 2012 Jul. 57(1):167-85. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int . 2008 Sep. 2(3):263-83. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol . 2007 Jun. 21 Suppl C:5C-24C. [QxMD MEDLINE Link] . [Full Text] .

[Guideline] Kennedy PT, Lee HC, Jeyalingam L, et al. NICE guidelines and a treatment algorithm for the management of chronic hepatitis B: a review of 12 years experience in west London. Antivir Ther . 2008. 13(8):1067-76. [QxMD MEDLINE Link] .

Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol . 2006 Aug. 4(8):936-62. [QxMD MEDLINE Link] .

New York State Department of Health. Prevention of secondary disease: preventive medicine. Viral hepatitis. New York, NY: New York State Department of Health; 2010. Available at https://guideline.gov/content.aspx?id=24043 . Accessed: June 13, 2013.

Pharmasset voluntarily halts clinical studies with clevudine in hepatitis B infected patients. Medical News Today. Available at https://www.medicalnewstoday.com/releases/146749.php . April 21, 2009; Accessed: June 13, 2013.

Mutimer D, Naoumov N, Honkoop P, et al. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol . 1998 Jun. 28(6):923-9. [QxMD MEDLINE Link] .

Gara N, Zhao X, Collins MT, et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther . 2012 Jun. 35(11):1317-25. [QxMD MEDLINE Link] . [Full Text] .

Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology . 2009 Dec. 50(6):2001-6. [QxMD MEDLINE Link] .

Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med . 1993 Aug 15. 119(4):312-23. [QxMD MEDLINE Link] .

Tseng TC, Liu CJ, Su TH, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology . 2011 Aug. 141(2):517-25, 525.e1-2. [QxMD MEDLINE Link] .

Yi Z, Jie YW, Nan Z. The efficacy of anti-viral therapy on hepatitis B virus-associated glomerulonephritis: A systematic review and meta-analysis. Ann Hepatol . 2011 Apr-Jun. 10(2):165-73. [QxMD MEDLINE Link] .

Guillevin L, Mahr A, Cohen P, et al. Short-term corticosteroids then lamivudine and plasma exchanges to treat hepatitis B virus-related polyarteritis nodosa. Arthritis Rheum . 2004 Jun 15. 51(3):482-7. [QxMD MEDLINE Link] .

Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med . 2005 Jun 30. 352(26):2682-95. [QxMD MEDLINE Link] .

Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med . 2004 Sep 16. 351(12):1206-17. [QxMD MEDLINE Link] .

Tenney DJ, Pokornowski KA, Rose RE, et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients [abstract]. J Hepatol . 2009. 50(Suppl 1):S10.

Wong GL, Wong VW, Chan HY, et al. Undetectable HBV DNA at month 12 of entecavir treatment predicts maintained viral suppression and HBeAg-seroconversion in chronic hepatitis B patients at 3 years. Aliment Pharmacol Ther . 2012 Jun. 35(11):1326-35. [QxMD MEDLINE Link] .

Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med . 2006 Mar 9. 354(10):1001-10. [QxMD MEDLINE Link] .

Chang TT, Lai CL, Kew Yoon S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology . 2010 Feb. 51(2):422-30. [QxMD MEDLINE Link] .

Schiff ER, Lee SS, Chao YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol . 2011 Mar. 9(3):274-6. [QxMD MEDLINE Link] .

Schnittman SM, Pierce PF. Potential role of lamivudine (3TC) in the clearance of chronic hepatitis B virus infection in a patient coinfected with human immunodeficiency virus type. Clin Infect Dis . 1996 Sep. 23(3):638-9. [QxMD MEDLINE Link] .

Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med . 1999 Oct 21. 341(17):1256-63. [QxMD MEDLINE Link] .

Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet . 1996 Nov 2. 348(9036):1212-5. [QxMD MEDLINE Link] .

Gatanaga H, Hayashida T, Tanuma J, Oka S. Prophylactic effect of antiretroviral therapy on hepatitis B virus infection. Clin Infect Dis . 2013 Jun. 56(12):1812-9. [QxMD MEDLINE Link] .

Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology . 1996 Sep. 24(3):714-7. [QxMD MEDLINE Link] .

Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol . 1997 Jun. 26(6):1393-5. [QxMD MEDLINE Link] .

Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med . 2003 Feb 27. 348(9):808-16. [QxMD MEDLINE Link] .

Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med . 2005 Jun 30. 352(26):2673-81. [QxMD MEDLINE Link] .

Yang H, Westland CE, Delaney WE 4th, et al. Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology . 2002 Aug. 36(2):464-73. [QxMD MEDLINE Link] .

Villeneuve JP, Durantel D, Durantel S, et al. Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol . 2003 Dec. 39(6):1085-9. [QxMD MEDLINE Link] .

Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology . 2003 Aug. 125(2):292-7. [QxMD MEDLINE Link] .

Chang TT, Lai CL. Hepatitis B virus with primary resistance to adefovir. N Engl J Med . 2006 Jul 20. 355(3):322-3; author reply 323. [QxMD MEDLINE Link] .

Hill A, Hughes SL, Gotham D, Pozniak AL. Tenofovir alafenamide versus tenofovir disoproxil fumarate: is there a true difference in efficacy and safety?. J Virus Erad . 2018 Apr 1. 4(2):72-9. [QxMD MEDLINE Link] . [Full Text] .

Heathcote J, George J, Gordon S, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-positive chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 103) [abstract]. J Hepatol . 2008. 48(suppl 2):S32.

Marcellin P, Jacobson I, Habersetzer F, et al. Tenofovir disoproxil fumarate (TDF) for the treatment of HBeAg-negative chronic hepatitis B: week 72 TDF data and week 24 adefovir dipivoxil switch data (study 102) [abstract]. J Hepatol . 2008. 48(suppl 2):S26.

Marcellin P, Heathcote EJ, Buti M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med . 2008 Dec 4. 359(23):2442-55. [QxMD MEDLINE Link] .

American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 86: Viral hepatitis in pregnancy. Obstet Gynecol . 2007 Oct. 110(4):941-56. [QxMD MEDLINE Link] .

US Preventive Services Task Force. Screening for hepatitis B virus infection in pregnancy: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med . 2009 Jun 16. 150(12):869-73, W154. [QxMD MEDLINE Link] .

[Guideline] World Health Organization. Prevention of mother-to-child transmission of hepatitis B virus: guidelines on antiviral prophylaxis in pregnancy. Geneva, Switzerland. 2020 Jul. [QxMD MEDLINE Link] . [Full Text] .

Eke AC, Brooks KM, Gebreyohannes RD, Sheffield JS, Dooley KE, Mirochnick M. Tenofovir alafenamide use in pregnant and lactating women living with HIV. Expert Opin Drug Metab Toxicol . 2020 Apr. 16(4):333-42. [QxMD MEDLINE Link] .

Lin CL, Kao JH. Hepatitis B: immunization and impact on natural history and cancer incidence. Gastroenterol Clin North Am . 2020 Jun. 49(2):201-14. [QxMD MEDLINE Link] .

Vesikari T, Finn A, van Damme P, et al, for the CONSTANT Study Group. Immunogenicity and safety of a 3-antigen hepatitis B vaccine vs a single-antigen hepatitis B vaccine: a phase 3 randomized clinical trial. JAMA Netw Open . 2021 Oct 1. 4(10):e2128652. [QxMD MEDLINE Link] . [Full Text] .

Vesikari T, Langley JM, Segall N, et al, for the PROTECT Study Group. Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial. Lancet Infect Dis . 2021 Sep. 21(9):1271-81. [QxMD MEDLINE Link] .

[Guideline] Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology . 2018 Apr. 67(4):1560-99. [QxMD MEDLINE Link] . [Full Text] .

Heplisav-B (hepatitis B vaccine [recombinant], adjuvanted) [package insert]. Berkeley, CA: Dynavax Technologies, Corp. November, 2017. Available at [Full Text] .

Malarkey MA, Gruber MF. Biologics License Application (BLA) approval (BL 125428) (hepatitis B vaccine (recombinant), adjuvanted [Heplisav-B]). US Food and Drug Administration. Available at https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm584820.pdf . November 9, 2017; Accessed: November 13, 2017.

Weir J. Biologics License Application (BLA) (BL 125428/1) supplement approval (hepatitis B vaccine (recombinant), adjuvanted [Heplisav-B]). US Food and Drug Administration. Available at https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM602537.pdf . March 22, 2018; Accessed: April 20, 2018.

[Guideline] Schillie S, Harris A, Link-Gelles R, Romero J, Ward J, Nelson N. Recommendations of the Advisory Committee on Immunization Practices for use of a hepatitis B vaccine with a novel adjuvant. MMWR Morb Mortal Wkly Rep . 2018 Apr 20. 67 (15):455-8. [QxMD MEDLINE Link] . [Full Text] .

Centers for Disease Control and Prevention (CDC). Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep . 2011 Dec 23. 60(50):1709-11. [QxMD MEDLINE Link] .

Kakisaka K, Sakai A, Yoshida Y, et al. Hepatitis B surface antibody titers at one and two years after hepatitis B virus vaccination in healthy young Japanese adults. Intern Med . 2019 Aug 15. 58(16):2349-55. [QxMD MEDLINE Link] . [Full Text] .

Juday T, Tang H, Harris M, Powers AZ, Kim E, Hanna GJ. Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment. J Gen Intern Med . 2011 Mar. 26(3):239-44. [QxMD MEDLINE Link] . [Full Text] .

El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and how?. Therap Adv Gastroenterol . 2011 Jan. 4(1):5-10. [QxMD MEDLINE Link] . [Full Text] .

Hoofnagle JH. Reactivation of hepatitis B. Hepatology . 2009 May. 49(5 suppl):S156-65. [QxMD MEDLINE Link] . [Full Text] .

Hagiyama H, Kubota T, Komano Y, Kurosaki M, Watanabe M, Miyasaka N. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. Clin Exp Rheumatol . 2004 May-Jun. 22(3):375-6. [QxMD MEDLINE Link] .

Narvaez J, Rodriguez-Moreno J, Martinez-Aguila MD, Clavaguera MT. Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. J Rheumatol . 1998 Oct. 25(10):2037-8. [QxMD MEDLINE Link] .

Markovic S, Drozina G, Vovk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology . 1999 Sep-Oct. 46(29):2925-30. [QxMD MEDLINE Link] .

Sheen IS, Liaw YF, Lin SM, Chu CM. Severe clinical rebound upon withdrawal of corticosteroid before interferon therapy: incidence and risk factors. J Gastroenterol Hepatol . 1996 Feb. 11(2):143-7. [QxMD MEDLINE Link] .

Navarro R, Vilarrasa E, Herranz P, et al. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol . 2013 Mar. 168(3):609-16. [QxMD MEDLINE Link] .

Germanidis G, Hytiroglou P, Zakalka M, Settas L. Reactivation of occult hepatitis B virus infection, following treatment of refractory rheumatoid arthritis with abatacept. J Hepatol . 2012 Jun. 56(6):1420-1. [QxMD MEDLINE Link] .

[Guideline] European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol . 2017 Aug. 67 (2):370-98. [QxMD MEDLINE Link] .

[Guideline] Abara WE, Qaseem A, Schillie S, McMahon BJ, Harris AM, for the High Value Care Task Force of the American College of Physicians and the Centers for Disease Control and Prevention. Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med . 2017 Dec 5. 167 (11):794-804. [QxMD MEDLINE Link] .

Phillips D. Clinical guideline on HBV released by ACP, CDC. Medscape Medical News. Available at https://www.medscape.com/viewarticle/888975 . November 21, 2017; Accessed: January 16, 2018.

[Guideline] European Association for the Study of the Liver. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. J Hepatol . 2018 Aug. 69 (2):406-60. [QxMD MEDLINE Link] .

[Guideline] European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol . 2018 Jul. 69 (1):182-236. [QxMD MEDLINE Link] .

[Guideline] Gordan JD, Kennedy EB, Abou-Alfa GK, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol . 2020 Dec 20. 38(36):4317-45. [QxMD MEDLINE Link] . [Full Text] .

CDC. Viral hepatitis surveillance report 2018 — hepatitis B. Centers for Disease Control and Prevention. Available at https://www.cdc.gov/hepatitis/statistics/2018surveillance/HepB.htm . 2020 July 27; Accessed: Acessed: October 26, 2020.

Smith BD, Morgan RL, Beckett GA, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep . 2012 Aug 17. 61:1-32. [QxMD MEDLINE Link] . [Full Text] .

Chou R, Cottrell EB, Wasson N, Rahman B, Guise JM. Screening for hepatitis C virus infection in adults: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med . 2013 Jan 15. 158(2):101-8. [QxMD MEDLINE Link] .

Lai CL, Gane E, Liaw YF, et al. Telbivudine (LdT) vs. lamivudine for chronic hepatitis B: first-year results from the international phase III GLOBE trial [abstract]. Hepatology . 2005. 42:748A.

Liaw YF, Gane E, Leung N, et al. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology . 2009 Feb. 136(2):486-95. [QxMD MEDLINE Link] .

Behre U, Bleckmann G, Crasta PD, et al. Long-term anti-HBs antibody persistence and immune memory in children and adolescents who received routine childhood hepatitis B vaccination. Hum Vaccin Immunother . 2012 Jun. 8(6):813-8. [QxMD MEDLINE Link] .

[Guideline] Chustecka Z. Boxed warning on HBV reactivation for blood cancer drugs. Medscape Medical News. Available at https://www.medscape.com/viewarticle/811629 . September 25, 2013; Accessed: October 2, 2013.

[Guideline] FDA. Arzerra (ofatumumab) and Rituxan (rituximab): drug safety communication - new boxed warning, recommendations to decrease risk of hepatitis B reactivation. US Food and Drug Administration. Available at https://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm369846.htm . September 25, 2013; Accessed: October 2, 2013.

Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology . 2006 Dec. 131(6):1743-51. [QxMD MEDLINE Link] .

Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet . 2013 Feb 9. 381(9865):468-75. [QxMD MEDLINE Link] .

Purcell RH. The discovery of the hepatitis viruses. Gastroenterology . 1993 Apr. 104(4):955-63. [QxMD MEDLINE Link] .

Tang KH, Yusoff K, Tan WS. Display of hepatitis B virus PreS1 peptide on bacteriophage T7 and its potential in gene delivery into HepG2 cells. J Virol Methods . 2009 Aug. 159(2):194-9. [QxMD MEDLINE Link] .

Thibault V, Laperche S, Akhavan S, Servant-Delmas A, Belkhiri D, Roque-Afonso AM. Impact of hepatitis B virus genotypes and surface antigen variants on the performance of HBV real time PCR quantification. J Virol Methods . 2009 Aug. 159(2):265-70. [QxMD MEDLINE Link] .

Dan C. FDA approves Vemlidy (tenofovir alafenamide) for chronic hepatitis B in adults. US Department of Health and Human Services. Available at https://www.hhs.gov/hepatitis/blog/2016/11/21/fda-approves-vemlidy-tenofovir-alafenamide-for-chronic-hepatitis-b-in-adults.html . November 21, 2016; Accessed: May 23, 2017.

US Food and Drug Administration. For patients: hepatitis B and C treatments. Available at https://www.fda.gov/forpatients/illness/hepatitisbc/ucm408658.htm . Updated: January 31, 2017; Accessed: May 23, 2017.

Gilead Sciences, Inc. US Food and Drug Administration approves Gilead’s Vemlidy (tenofovir alafenamide) for the treatment of chronic hepatitis B virus infection [press release]. Available at https://www.gilead.com/news/press-releases/2016/11/us-food-and-drug-administration-approves-gileads-vemlidy-tenofovir-alafenamide-for-the-treatment-of-chronic-hepatitis-b-virus-infection . November 10, 2017; Accessed: May 23, 2017.

Zhao Q, Liu K, Zhu X, et al. Anti-viral effect in chronic hepatitis B patients with normal or mildly elevated alanine aminotransferase. Antiviral Res . 2020 Oct 13. 184:104953. [QxMD MEDLINE Link] . [Full Text] .

Tripathi N, Mousa OY. Hepatitis B. StatPearls [Internet] . 2020 Jan. [QxMD MEDLINE Link] . [Full Text] .

Phillips S, Jagatia R, Chokshi S. Novel therapeutic strategies for chronic hepatitis B. Virulence . 2022 Dec. 13 (1):1111-32. [QxMD MEDLINE Link] . [Full Text] .

• Hepatitis B. Under higher-power magnification, ground-glass cells may be visible in chronic hepatitis B virus (HBV) infection. Ground-glass cells are present in 50% to 75% of livers with chronic HBV infection. Immunohistochemical staining is positive for hepatitis B surface antigen (HBsAg.)
• Hepatitis B. Liver biopsy with hematoxylin stain showing stage 4 fibrosis (ie, cirrhosis) in a patient with hepatitis B.
• Hepatitis B. Hepatitis B virus (HBV) is a hepadnavirus, highly resistant to extremes of temperature and humidity, that invades the hepatocytes. The viral genome is a partially double-stranded, circular DNA linked to a DNA polymerase that is surrounded by an icosahedral nucleocapsid and then by a lipid envelope. Embedded within these layers are numerous antigens that are important in disease identification and progression. Within the nucleocapsid are the hepatitis B core antigen (HBcAg) and precore hepatitis B e antigen (HBeAg), and on the envelope is the hepatitis B surface antigen (HBsAg). Transmission electron micrograph (TEM) from Graham Colm and Wikipedia, licensed under the Creative Commons Attribution 3.0 Unported license.
• Hepatitis B. Serologic course of hepatitis B virus (HBV) infection. The flat bars show the duration of seropositivity in self-limited acute HBV infection. The pointed bars show that HBV DNA and e antigen (HBeAg) can become undetectable during chronic infection. Only immunoglobulin G (IgG) antibodies to the HBV core antigen (anti-HBc) are predictably detectable after resolution of acute hepatitis or during chronic infection. Antibody to hepatitis B surface antigen (anti-HBs) is generally detectable after resolution of acute HBV infection but may disappear with time. It is only rarely found in patients with chronic infection and does not indicate that immunologic recovery will occur or that the patient has a better prognosis. ALT = alanine transaminase. (Adapted from Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373(9663):582-92.)
• Hepatitis B. Radiologic studies may be useful in all stages of hepatitis B infection. Ultrasonography, computed tomography (CT) scanning, or magnetic resonance imaging (MRI) may exclude biliary obstruction in acute infection. In chronic disease, ultrasonograms may show nonspecific increased echogenicity of the liver parenchyma. In patients with long-standing disease, CT imaging may be used to detect cirrhosis or hepatocellular carcinoma (as shown).
• Hepatitis B. Long-standing cirrhosis leads to progressive replacement of liver parenchyma with fibrotic tissue. Over time, the liver contracts and develops a lobulated contour. These changes are readily apparent on cross-sectional imaging. This contrast-enhanced computed tomography (CT) scan demonstrates extensive cirrhosis, as well as malignant hepatocellular lesions (arrow).

Contributor Information and Disclosures

Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF, FAASLD, FRCP(Edin) Professor and Chief, Division of Gastroenterology and Hepatology, Professor of Physiology, Pharmacology, and Neuroscience, Medical Director of Liver Transplantation, Rutgers New Jersey Medical School Nikolaos T Pyrsopoulos, MD, PhD, MBA, FACP, AGAF, FAASLD, FRCP(Edin) is a member of the following medical societies: American Association for the Study of Liver Diseases , American College of Gastroenterology , American College of Physicians , American Gastroenterological Association , American Liver Foundation , American Medical Association , American Society for Gastrointestinal Endoscopy , American Society of Transplantation , International Liver Transplantation Society , Transplantation Society Disclosure: Received research grant from: GRIFOLS. BAYER, DURECT, INTERCEPT, BEIGENE, BMS.

Ranya Selim, MD Gastroenterologist/Transplant Hepatologist Ranya Selim, MD is a member of the following medical societies: American College of Gastroenterology Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference Disclosure: Received salary from Medscape for employment. for: Medscape.

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases , American College of Gastroenterology , American Gastroenterological Association , American Society for Gastrointestinal Endoscopy Disclosure: Nothing to disclose.

George Y Wu, MD, PhD Professor, Department of Medicine, Director, Hepatology Section, Herman Lopata Chair in Hepatitis Research, University of Connecticut School of Medicine

George Y Wu, MD, PhD is a member of the following medical societies: American Association for the Study of Liver Diseases , American Gastroenterological Association , American Medical Association , American Society for Clinical Investigation , and Association of American Physicians

Disclosure: Springer Consulting fee Consulting; Gilead Consulting fee Review panel membership; Gilead Honoraria Speaking and teaching; Bristol-Myers Squibb Honoraria Speaking and teaching; Springer Royalty Review panel membership

What would you like to print?

• Print this section
• Print the entire contents of
• Print the entire contents of article

• Hepatitis in Pregnancy
• Treatment Recommendations for HIV-Infected Patients With Co-infections
• Pediatric Vaccines: Global Brands and Country Availability
• Pediatric Hepatitis B
• Polyarteritis Nodosa
• Viral Hepatitis
• Fast Five Quiz: Hepatitis B Epidemiology and Prevention
• US FDA Declines Expanded Use Of Dynavax's Hepatitis B Vaccine on Insufficient Data
• Don't Forget Adult Hepatitis Vaccinations
• Combination Therapy Looks Promising for Hepatitis D

• Drug Interaction Checker
• Pill Identifier
• Calculators

• 2002964662-overviewDiseases & Conditions Diseases & Conditions Pediatric Hepatitis B

• 2001/viewarticle/993770 Hepatitis B Vaccination Rates Lag in Patients With Psoriasis

Ohio State nav bar

The Ohio State University

• BuckeyeLink
• Find People
• Search Ohio State

Patient Case Presentation

Our patient, Mr. Smith, is a 43 year old caucasian male who came in today with complaints of fatigue, anorexia, malaise, nausea, vomiting, abdominal pain, and low grade fever for the past month, and recently has been alarmed by the discoloration of his skin and sclera turning yellow. He states that his urine has become dark and stool has become clay colored.

Past Medical History:  Blood transfusion in 1992 due to major blood loss in a motor vehicle accident, arthralgia, peripheral neuropathy, hospitalization due to drug overdose in 2010. Patient states that he is fully up to date on vaccination.

Social History : Patient is an injectable drug user for the past 12 years and is currently sexually active with multiple male partners and states he uses protection “sometimes”. His current occupation is a car mechanic.

Family History: Mother: history of hyperlipidemia and diabetes father died of myocardial infarction, no other siblings or family history available .

pictured: jaundice on an individual’s eye; “Jaundice.” Assignment Point , 5 Oct. 2017, www.assignmentpoint.com/science/medical/jaundice.html.

Fact sheets

• Facts in pictures

Publications

• Questions and answers
• Tools and toolkits
• Endometriosis
• Excessive heat
• Mental disorders
• Polycystic ovary syndrome
• All countries
• Eastern Mediterranean
• South-East Asia
• Western Pacific
• Data by country
• Country presence 
• Country strengthening 
• Country cooperation strategies 
• News releases
• Feature stories
• Press conferences
• Commentaries
• Photo library
• Afghanistan
• Cholera 
• Coronavirus disease (COVID-19)
• Greater Horn of Africa
• Israel and occupied Palestinian territory
• Disease Outbreak News
• Situation reports
• Weekly Epidemiological Record
• Surveillance
• Health emergency appeal
• International Health Regulations
• Independent Oversight and Advisory Committee
• Classifications
• Data collections
• Global Health Estimates
• Mortality Database
• Sustainable Development Goals
• Health Inequality Monitor
• Global Progress
• World Health Statistics
• Partnerships
• Committees and advisory groups
• Collaborating centres
• Technical teams
• Organizational structure
• Initiatives
• General Programme of Work
• WHO Academy
• Investment in WHO
• WHO Foundation
• External audit
• Financial statements
• Internal audit and investigations 
• Programme Budget
• Results reports
• Governing bodies
• World Health Assembly
• Executive Board
• Member States Portal
• Fact sheets /

Hepatitis B

• Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease.
• The virus is most commonly transmitted from mother to child during birth and delivery, in early childhood, as well as through contact with blood or other body fluids during sex with an infected partner, unsafe injections or exposures to sharp instruments.
• WHO estimates that 254 million people were living with chronic hepatitis B infection in 2022, with 1.2 million new infections each year.
• In 2022, hepatitis B resulted in an estimated 1.1 million deaths, mostly from cirrhosis and hepatocellular carcinoma (primary liver cancer).
• Hepatitis B can be prevented by vaccines that are safe, available and effective.

Hepatitis B is an infection of the liver caused by the hepatitis B virus. The infection can be acute (short and severe) or chronic (long term).

Hepatitis B can cause a chronic infection and puts people at high risk of death from cirrhosis and liver cancer.

It can spread through contact with infected body fluids like blood, saliva, vaginal fluids and semen. It can also be passed from a mother to her baby.

Hepatitis B can be prevented with a safe and effective vaccine. The vaccine is usually given soon after birth with boosters a few weeks later. It offers nearly 100% protection against the virus.

Hepatitis B is a major global health problem. The burden of infection is highest in the WHO Western Pacific Region and the WHO African Region, where 97 million and 65 million people, respectively, are chronically infected. Sixty-one million people are infected in the WHO South-East Asia Region, 15 million in the WHO Eastern Mediterranean Region, 11 million in the WHO in the WHO European Region and 5 million in the WHO Region of the Americas.

Transmission

In highly endemic areas, hepatitis B is most commonly spread from mother to child at birth (perinatal transmission) or through horizontal transmission (exposure to infected blood), especially from an infected child to an uninfected child during the first 5 years of life. The development of chronic infection is common in infants infected from their mothers or before the age of 5 years.

Hepatitis B is also spread by needlestick injury, tattooing, piercing and exposure to infected blood and body fluids, such as saliva and menstrual, vaginal and seminal fluids. Transmission of the virus may also occur through the reuse of contaminated needles and syringes or sharp objects either in health care settings, in the community or among persons who inject drugs. Sexual transmission is more prevalent in unvaccinated persons with multiple sexual partners.

Hepatitis B infection acquired in adulthood leads to chronic hepatitis in less than 5% of cases, whereas infection in infancy and early childhood leads to chronic hepatitis in about 95% of cases. This is the basis for strengthening and prioritizing infant and childhood vaccination.

The hepatitis B virus can survive outside the body for at least 7 days. During this time, the virus can still cause infection if it enters the body of a person who is not protected by the vaccine. The incubation period of the hepatitis B virus ranges from 30 to 180 days. The virus may be detected within 30 to 60 days after infection and can persist and develop into chronic hepatitis B, especially when transmitted in infancy or childhood.

Most people do not experience any symptoms when newly infected.

Some people have acute illness with symptoms that last several weeks:

• yellowing of the skin and eyes (jaundice)
• feeling very tired
• pain in the abdomen.

When severe, acute hepatitis can lead to liver failure, which can lead to death.

Although most people will recover from acute illness, some people with chronic hepatitis B will develop progressive liver disease and complications like cirrhosis and hepatocellular carcinoma (liver cancer). These diseases can be fatal.

HBV-HIV coinfection

About 1% of persons living with HBV infection (2.7 million people) are also infected with HIV. Conversely, the global prevalence of HBV infection in HIV-infected persons is 7.4%. Since 2015, WHO has recommended treatment for everyone diagnosed with HIV infection, regardless of the stage of disease. Tenofovir, which is included in the treatment combinations recommended as first-line therapy for HIV infection, is also active against HBV.

It is not possible on clinical grounds to differentiate hepatitis B from hepatitis caused by other viral agents; hence laboratory confirmation of the diagnosis is essential. Several blood tests are available to diagnose and monitor people with hepatitis B. Some laboratory tests can be used to distinguish acute and chronic infections, whilst other can assess and monitor the severity of liver disease. Physical examination, ultrasound, fibroscan can also be performed to assess degree of liver fibrosis and scarring and monitor progression of liver disease. WHO recommends that all blood donations be tested for hepatitis B to ensure blood safety and avoid accidental transmission.

As of 2022, 13% of all people estimated to be living with hepatitis B were aware of their infection, while 3% (7 million) of the people living with chronic hepatitis B were on treatment. According to latest WHO estimates, the proportion of children under five years of age chronically infected with HBV dropped to just under 1% in 2019 down from around 5% in the pre-vaccine era ranging from the 1980s to the early 2000s.

In settings with high Hepatitis B surface antigen seroprevalence in the general population (defined as  > 2% or  > 5% HBsAg seroprevalence), WHO recommends that all adults have access to and be offered HBsAg testing with linkage to prevention and care and treatment services as needed. WHO also recommends blood donor screening, routine testing for hepatitis B all pregnant women to provide the opportunity to institute measures for prevention of MTCT as well as focused or targeted testing of specific high-risk groups (including migrants from endemic regions, partners or family members of infected persons, and health-care workers PWID, people in prisons and other closed settings, MSM and sex workers, HIV-infected persons.

There is no specific treatment for acute hepatitis B. Chronic hepatitis B can be treated with medicines.

Care for acute hepatitis B should focus on making the person comfortable. They should eat a healthy diet and drink plenty of liquids to prevent dehydration from vomiting and diarrhoea.

Chronic hepatitis B infection can be treated with oral medicines, including tenofovir or entecavir.

Treatment can

• slow the advance of cirrhosis
• reduce cases of liver cancer
• improve long term survival.

Most people who start hepatitis B treatment must continue it for life.

With the updated Hepatitis B Guidelines, it is estimated that more than 50% of people with chronic hepatitis B infection will require treatment, depending on setting and eligibility criteria.

In low-income settings, most people with liver cancer present late in the course of the disease and die within months of diagnosis. In high-income countries, patients present to hospital earlier in the course of the disease and have access to surgery and chemotherapy, which can prolong life for several months to a few years. Liver transplantation is sometimes used in people with cirrhosis or liver cancer in technologically advanced countries, with varying success.

Hepatitis B is preventable with a vaccine.

All babies should receive the hepatitis B vaccine as soon as possible after birth (within 24 hours). This is followed by two or three doses of hepatitis B vaccine at least four weeks apart.

Booster vaccines are not usually required for people who have completed the three-dose vaccination series.

The vaccine protects against hepatitis B for at least 20 years and probably for life.

Hepatitis B can be passed from mother to child. This can be prevented by taking antiviral medicines to prevent transmission, in addition to the vaccine.

To reduce the risk of getting or spreading hepatitis B:

• practice safe sex by using condoms and reducing the number of sexual partners
• avoid sharing needles or any equipment used for injecting drugs, piercing, or tattooing
• wash your hands thoroughly with soap and water after coming into contact with blood, body fluids, or contaminated surfaces
• get a hepatitis B vaccine if working in a healthcare setting.

WHO response

Global health sector strategies on, respectively, HIV, viral hepatitis, and sexually transmitted infections for the period 2022–2030 (GHSSs)  guide the health sector in implementing strategically focused responses to achieve the goals of ending AIDS, viral hepatitis (especially chronic hepatitis B and C) and sexually transmitted infections by 2030.

The GHSS recommend shared and disease-specific country actions supported by actions by WHO and partners. They consider the epidemiological, technological, and contextual shifts of previous years, foster learnings across the disease areas, and create opportunities to leverage innovations and new knowledge for effective responses to the diseases. They call to scale up prevention, testing and treatment of viral hepatitis with a focus to reach populations and communities most affected and at risk for each disease, as well as addressing gaps and inequities. They promote synergies under a universal health coverage and primary health care framework and contribute to achieving the goals of the 2030 Agenda for Sustainable Development.

WHO organizes annual World Hepatitis Day campaigns to increase awareness and understanding of viral hepatitis. For World Hepatitis Day 2023, WHO focused on the theme “One life, one liver” to illustrate the importance of the liver for a healthy life and the need to scale up viral hepatitis prevention, testing and treatment to prevent liver diseases and achieve the 2030 hepatitis elimination target.

Global hepatitis report, 2024

Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection

World Hepatitis Day

Global health sector strategy on viral hepatitis

Guidelines & manuals

• Monitoring and evaluation of hepatitis B and C
• Manual for the development of national viral hepatitis plans

More about hepatitis

• WHO's work on hepatitis 
• Global Hepatitis Programme
• WHO's publications

Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Figures and Tables

The information on this page reflects the 2024 acute and chronic hbv case definition updates. for 2023 hbv case classification, use: 2023 case classification_full guidance pdf.

• Overview of Viral Hepatitis
• Statistics & Surveillance
• Populations & Settings
• State and Local Partners & Grantees
• Policy, Programs, and Science
• Resource Center

Tackling hepatitis B Virus with CRISPR/Cas9: advances, challenges, and delivery strategies

• Review Paper
• Published: 28 August 2024

Cite this article

• Dakshina M. Nair   ORCID: orcid.org/0009-0009-0922-0142 1 ,
• Leela Kakithakara Vajravelu 1 ,
• Jayaprakash Thulukanam 1 ,
• Vishnupriya Paneerselvam 1 ,
• Poornima Baskar Vimala 1 &
• Rahul Harikumar Lathakumari 1  

Hepatitis B virus (HBV) infection remains a significant global health challenge, with chronic HBV leading to severe liver diseases, including cirrhosis and hepatocellular carcinoma. Current treatments often fail to eradicate the virus, highlighting the need for innovative therapeutic strategies. The CRISPR/Cas9 system has emerged as a dynamic tool for precise genome editing and presents a promising approach to targeting and eliminating HBV infection. This review provides a comprehensive overview of the advances, challenges, and delivery strategies associated with CRISPR/Cas9-based therapies for HBV. We begin by elucidating the mechanism of the CRISPR/Cas9 system and then explore HBV pathogenesis, focusing on the role of covalently closed circular DNA (cccDNA) and integrated HBV DNA in maintaining chronic infection. CRISPR/Cas9 can disrupt these key viral reservoirs, which are critical for persistent HBV replication and associated liver damage. The application of CRISPR/Cas9 in HBV treatment faces significant challenges, such as off-target effects, delivery efficiency, and immune responses. These challenges are addressed by examining current approaches to enhance the specificity, safety, and efficacy of CRISPR/Cas9. A future perspective on the development and clinical translation of CRISPR/Cas9 therapies for HBV is provided, emphasizing the requirement for further research to improve delivery methods and ensure durable safety and effectiveness. This review underscores the transformative potential of CRISPR/Cas9 in combating HBV and sets the stage for future breakthroughs in the field.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save.

• Get 10 units per month
• Download Article/Chapter or eBook
• 1 Unit = 1 Article or 1 Chapter
• Cancel anytime

Price includes VAT (Russian Federation)

Instant access to the full article PDF.

Rent this article via DeepDyve

Institutional subscriptions

Similar content being viewed by others

Recent Advances in Use of Gene Therapy to Treat Hepatitis B Virus Infection

The impact of integrated hepatitis B virus DNA on oncogenesis and antiviral therapy

Crispr/cas9-based tools for targeted genome editing and replication control of hbv, data availability.

No datasets were generated or analyzed during the current study.

Fletcher GJ, Eapen CE, Abraham P (2020) Hepatitis B genotyping: the utility for the clinicians. Indian J Gastroenterol 39(4):315–320. https://doi.org/10.1007/s12664-019-00995-y

Article   PubMed   Google Scholar  

Kong H, Ju E, Yi K, Xu W, Lao YH, Cheng D, Zhang Q, Tao Y, Li M, Ding J (2021) Advanced nanotheranostics of CRISPR/Cas for viral hepatitis and hepatocellular carcinoma. Adv Sci (Weinh). 8:e2102051. https://doi.org/10.1002/advs.202102051

Article   CAS   PubMed   Google Scholar  

Simmonds P (2001) The origin and evolution of hepatitis viruses in humans. J Gen Virol 82(Pt 4):693–712. https://doi.org/10.1099/0022-1317-82-4-693

Biswas A, Banerjee A, Chandra PK, Datta S, Panigrahi R, Dutta D, De BK, Pal M, Guha SK, Chakrabarti S, Chakravarty R (2011) Variations in the functional domain of basal core promoter of hepatitis B virus among Eastern Indian patients with prevalence of genotypes A, C, and D among the same ethnic population. J Med Virol 83(2):253–260. https://doi.org/10.1002/jmv.21979

Piermatteo L, D’Anna S, Bertoli A, Bellocchi M, Carioti L, Fabeni L, Alkhatib M, Frazia S, Lichtner M, Mastroianni C, Sanctis G, Marignani M, Pasquazzi C, Iapadre N, Parruti G, Cappiello G, Vecchiet J, Malagnino V, Grelli S, Ceccherini-Silbertein F, Andreoni M, Sarmati L, Svicher V, Salpini R (2023) Unexpected rise in the circulation of complex HBV variants enriched of HBsAg vaccine-escape mutations in HBV genotype-D: potential impact on HBsAg detection/quantification and vaccination strategies. Emerg Microbes Infect 12(1):2219347. https://doi.org/10.1080/22221751.2023.2219347

Article   CAS   PubMed   PubMed Central   Google Scholar  

Block TM, Rawat S, Brosgart CL (2015) Chronic hepatitis B: a wave of new therapies on the horizon. Antiviral Res. 121:69–81. https://doi.org/10.1016/j.antiviral.2015.06.014

Zeisel MB, Lucifora J, Mason WS, Sureau C, Beck J, Levrero M, Kann M, Knolle PA, Benkirane M, Durantel D, Michel ML, Autran B, Cosset FL, Strick-Marchand H, Trépo C, Kao JH, Carrat F, Lacombe K, Schinazi RF, Barré-Sinoussi F, Delfraissy JF, Zoulim F (2015) Towards an HBV cure: state-of-the-art and unresolved questions–report of the ANRS workshop on HBV cure. Gut 64(8):1314–1326. https://doi.org/10.1136/gutjnl-2014-308943

Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, DeHertogh D, Wilber R, Zink RC, Cross A, Colonno R, Fernandes L, BEHoLD AI463027 study group (2006) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med. 354(10):1011–20. https://doi.org/10.1056/NEJMoa051287

Kar P, Goswami B, Mahanta J, Bhimo T, Das AK, Deka M, Lynrah KG, Kotwal MR, Bhaumik P, Jini M, Karna R, Karra VK, Kaur H (2022) Epidemiology, Genotyping, mutational and phylogenetic analysis of hepatitis B virus infection in North-East India. J Clin Exp Hepatol. 12(1):43–51. https://doi.org/10.1016/j.jceh.2021.04.002

Siederdissen HZC, Cornberg M (2016) Management of HBV and HBV/HDV-associated liver cirrhosis. Visc Med. 32(2):86–94. https://doi.org/10.1159/000445518

Article   Google Scholar  

Wursthorn K, Lutgehetmann M, Dandri M, Volz T, Buggisch P, Zollner B, Longerich T, Schirmacher P, Metzler F, Zankel M, Fischer C, Currie G, Brosgart C, Petersen J (2006) Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 44(3):675–684. https://doi.org/10.1002/hep.21282

Lin G, Zhang K, Li J (2015) Application of CRISPR/Cas9 technology to HBV. Int J Mol Sci 16(11):26077–26086. https://doi.org/10.3390/ijms161125950.

Liu H, Zakrzewicz D, Nosol K, Irobalieva RN, Mukherjee S, Bang-Sørensen R, Goldmann N, Kunz S, Rossi L, Kossiakoff AA, Urban S, Glebe D, Geyer J, Locher KP (2024) Structure of antiviral drug bulevirtide bound to hepatitis B and D virus receptor protein NTCP. Nat Commun 15(1):2476. https://doi.org/10.1038/s41467-024-46706-w

Nassal M (2015) HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut 64(12):1972–1984. https://doi.org/10.1136/gutjnl-2015-309809

Seeger C, Sohn JA (2014) Targeting Hepatitis B Virus With CRISPR/Cas9. Mol Ther Nucleic Acids 3(12):e216. https://doi.org/10.1038/mtna.2014.68

Ishino Y, Shinagawa H, Makino K, Amemura M, Nakata A (1987) Nucleotide sequence of the iap gene, responsible for alkaline phosphatase isozyme conversion in Escherichia coli, and identification of the gene product. J Bacteriol 169(12):5429–5433. https://doi.org/10.1128/jb.169.12.5429-5433.1987

Mojica FJ, Juez G, Rodríguez-Valera F (1993) Transcription at different salinities of Haloferax mediterranei sequences adjacent to partially modified PstI sites. Mol Microbiol 9(3):613–621. https://doi.org/10.1111/j.1365-2958.1993.tb01721.x

Asmamaw M, Zawdie B (2021) Mechanism and applications of CRISPR/Cas-9-mediated genome editing. Biologics 21(15):353–361. https://doi.org/10.2147/BTT.S326422

Makarova KS, Aravind L, Grishin NV, Rogozin IB, Koonin EV (2002) A DNA repair system specific for thermophilic archaea and bacteria predicted by genomic context analysis. Nucleic Acids Res 30(2):482–496. https://doi.org/10.1093/nar/30.2.482

Jansen R, Embden JD, Gaastra W, Schouls LM (2002) Identification of genes that are associated with DNA repeats in prokaryotes. Mol Microbiol 43(6):1565–1575. https://doi.org/10.1046/j.1365-2958.2002.02839.x

Makarova KS, Grishin NV, Shabalina SA, Wolf YI, Koonin EV (2006) A putative RNA-interference-based immune system in prokaryotes: computational analysis of the predicted enzymatic machinery, functional analogies with eukaryotic RNAi, and hypothetical mechanisms of action. Biol Direct 16(1):7. https://doi.org/10.1186/1745-6150-1-7

Article   CAS   Google Scholar  

Mojica FJ, Díez-Villaseñor C, García-Martínez J, Soria E (2005) Intervening sequences of regularly spaced prokaryotic repeats derive from foreign genetic elements. J Mol Evol 60(2):174–182. https://doi.org/10.1007/s00239-004-0046-3

Brouns SJ, Jore MM, Lundgren M, Westra ER, Slijkhuis RJ, Snijders AP, Dickman MJ, Makarova KS, Koonin EV, van der Oost J (2008) Small CRISPR RNAs guide antiviral defense in prokaryotes. Science 321(5891):960–964. https://doi.org/10.1126/science.1159689

Deltcheva E, Chylinski K, Sharma CM, Gonzales K, Chao Y, Pirzada ZA, Eckert MR, Vogel J, Charpentier E (2011) CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. Nature 471(7340):602–607. https://doi.org/10.1038/nature09886

Jinek M, Chylinski K, Fonfara I, Hauer M, Doudna JA, Charpentier E (2012) A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. https://doi.org/10.1126/science.1225829

Article   PubMed   PubMed Central   Google Scholar  

Mojica FJM, Díez-Villaseñor C, García-Martínez J, Almendros C (2009) Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology (Reading) 155(Pt 3):733–740. https://doi.org/10.1099/mic.0.023960-0

Mussolino C, Cathomen T (2013) RNA guides genome engineering. Nat Biotechnol 31(3):208–209. https://doi.org/10.1038/nbt.2527

Friedland AE, Tzur YB, Esvelt KM, Colaiácovo MP, Church GM, Calarco JA (2013) Heritable genome editing in C. elegans via a CRISPR-Cas9 system. Nat Methods. 10:741–3. https://doi.org/10.1038/nmeth.2532

Hwang WY, Fu Y, Reyon D, Maeder ML, Tsai SQ, Sander JD, Peterson RT, Yeh JR, Joung JK (2013) Efficient genome editing in zebrafish using a CRISPR-Cas system. Nat Biotechnol. 31:227–9. https://doi.org/10.1038/nbt.2501

Port F, Chen HM, Lee T, Bullock SL (2014) Optimized CRISPR/Cas tools for efficient germline and somatic genome engineering in Drosophila. Proc Natl Acad Sci U S A. 111:E2967-76. https://doi.org/10.1073/pnas.1405500111

Tu T, Douglas MW (2020) Hepatitis B virus infection: from diagnostics to treatments. Viruses 12(12):1366. https://doi.org/10.3390/v12121366

Iannacone M, Guidotti LG (2022) Immunobiology and pathogenesis of hepatitis B virus infection. Nat Rev Immunol 22(1):19–32. https://doi.org/10.1038/s41577-021-00549-4

Wang J, Xu ZW, Liu S, Zhang RY, Ding SL, Xie XM, Long L, Chen XM, Zhuang H, Lu FM (2015) Dual gRNAs guided CRISPR/Cas9 system inhibits hepatitis B virus replication. World J Gastroenterol 21(32):9554–9565. https://doi.org/10.3748/wjg.v21.i32.9554

Dong C, Qu L, Wang H, Wei L, Dong Y, Xiong S (2015) Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication. Antiviral Res 118:110–117. https://doi.org/10.1016/j.antiviral.2015.03.015

Seeger C, Mason WS (2015) Molecular biology of hepatitis B virus infection. Virology. https://doi.org/10.1016/j.virol.2015.02.031

Zhou Z, Li C, Tan Z, Sun G, Peng B, Ren T, He J, Wang Y, Sun Y, Wang F, Li W (2023) A spatiotemporally controlled recombinant cccDNA mouse model for studying HBV and developing drugs against the virus. Antiviral Res 216:105642. https://doi.org/10.1016/j.antiviral.2023.105642

Ramanan V, Shlomai A, Cox DB, Schwartz RE, Michailidis E, Bhatta A, Scott DA, Zhang F, Rice CM, Bhatia SN (2015) CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus. Sci Rep 2(5):10833. https://doi.org/10.1038/srep10833

Yang YC, Yang HC (2021) Recent progress and future prospective in HBV cure by CRISPR/Cas. Viruses 14(1):4. https://doi.org/10.3390/v14010004

Doudna JA, Charpentier E, Genome editing (2014) The new frontier of genome engineering with CRISPR-Cas9. Science. https://doi.org/10.1126/science.1258096

Kostyushev D, Brezgin S, Kostyusheva A, Zarifyan D, Goptar I, Chulanov V (2019) Orthologous CRISPR/Cas9 systems for specific and efficient degradation of covalently closed circular DNA of hepatitis B virus. Cell Mol Life Sci 76(9):1779–1794. https://doi.org/10.1007/s00018-019-03021-8

Liu X, Hao R, Chen S, Guo D, Chen Y (2015) Inhibition of hepatitis B virus by the CRISPR/Cas9 system via targeting the conserved regions of the viral genome. J Gen Virol 96(8):2252–2261. https://doi.org/10.1099/vir.0.000159

Martinez MG, Smekalova E, Combe E, Gregoire F, Zoulim F, Testoni B (2022) Gene editing technologies to target HBV cccDNA. Viruses 14(12):2654. https://doi.org/10.3390/v14122654

Mehta A, Merkel OM (2020) Immunogenicity of Cas9 protein. J Pharm Sci. 109(1):62–67. https://doi.org/10.1016/j.xphs.2019.10.003

Kosicki M, Tomberg K, Bradley A (2018) Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements. Nat Biotechnol. 36(8):765–771. https://doi.org/10.1038/nbt.4192

Li H, Sheng C, Wang S, Yang L, Liang Y, Huang Y, Liu H, Li P, Yang C, Yang X, Jia L, Xie J, Wang L, Hao R, Du X, Xu D, Zhou J, Li M, Sun Y, Tong Y, Li Q, Qiu S, Song H (2017) Removal of integrated hepatitis B Virus DNA using CRISPR-Cas9. Front Cell Infect Microbiol 22(7):91. https://doi.org/10.3389/fcimb.2017.00091

Hu JH, Miller SM, Geurts MH, Tang W, Chen L, Sun N, Zeina CM, Gao X, Rees HA, Lin Z, Liu DR (2018) Evolved Cas9 variants with broad PAM compatibility and high DNA specificity. Nature. 556(7699):57–63. https://doi.org/10.1038/nature26155

Kleinstiver BP, Pattanayak V, Prew MS, Tsai SQ, Nguyen NT, Zheng Z, Joung JK (2016) High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529(7587):490–5. https://doi.org/10.1038/nature16526

Martinez MG, Combe E, Inchauspe A, Mangeot PE, Delberghe E, Chapus F, Neveu G, Alam A, Carter K, Testoni B, Zoulim F (2022) CRISPR-Cas9 targeting of hepatitis B virus covalently closed circular DNA generates transcriptionally active episomal variants. mBio. 13:e0288821. https://doi.org/10.1128/mbio.02888-21

Hu P, Li Y, Zhang W, Liu R, Peng L, Xu R, Cai J, Yuan H, Feng T, Tian A, Yue M, Li J, Li W, Zhu C (2023) The spliceosome factor EFTUD2 promotes IFN Anti-HBV effect through mRNA splicing. Mediators Inflamm 23(2023):2546278. https://doi.org/10.1155/2023/2546278

Nishimasu H, Shi X, Ishiguro S, Gao L, Hirano S, Okazaki S, Noda T, Abudayyeh OO, Gootenberg JS, Mori H, Oura S, Holmes B, Tanaka M, Seki M, Hirano H, Aburatani H, Ishitani R, Ikawa M, Yachie N, Zhang F, Nureki O (2018) Engineered CRISPR-Cas9 nuclease with expanded targeting space. Science. 361(6408):1259–1262. https://doi.org/10.1126/science.aas9129

Ran FA, Cong L, Yan WX, Scott DA, Gootenberg JS, Kriz AJ, Zetsche B, Shalem O, Wu X, Makarova KS, Koonin EV, Sharp PA, Zhang F (2015) In vivo genome editing using staphylococcus aureus Cas9. Nature. 520(7546):186–91. https://doi.org/10.1038/nature14299

Zetsche B, Gootenberg JS, Abudayyeh OO, Slaymaker IM, Makarova KS, Essletzbichler P, Volz SE, Joung J, van der Oost J, Regev A, Koonin EV, Zhang F (2015) Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system. Cell. 163(3):759–71. https://doi.org/10.1016/j.cell.2015.09.038

Kim E, Koo T, Park SW, Kim D, Kim K, Cho HY, Song DW, Lee KJ, Jung MH, Kim S, Kim JH, Kim JH, Kim JS (2017) In vivo genome editing with a small Cas9 orthologue derived from campylobacter jejuni. Nat Commun 21(8):14500. https://doi.org/10.1038/ncomms14500

Slaymaker IM, Gao L, Zetsche B, Scott DA, Yan WX, Zhang F (2016) Rationally engineered Cas9 nucleases with improved specificity. Science. 351(6268):84–8. https://doi.org/10.1126/science.aad5227

Qi LS, Larson MH, Gilbert LA, Doudna JA, Weissman JS, Arkin AP, Lim WA (2013) Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression. Cell 152(5):1173–1183

Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR (2016) Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 533(7603):420–4. https://doi.org/10.1038/nature17946

Hu B, Zou Y, Zhang L, Tang J, Niedermann G, Firat E, Huang X, Zhu X (2019) Nucleofection with plasmid DNA for CRISPR/Cas9-mediated inactivation of programmed cell death protein 1 in CD133-specific CAR T cells. Hum Gene Ther 30(4):446–458. https://doi.org/10.1089/hum.2017.

Hendriks WT, Jiang X, Daheron L, Cowan CA (2015) TALEN- and CRISPR/Cas9-mediated gene editing in human pluripotent stem cells using lipid-based transfection. Curr Protoc Stem Cell Biol. https://doi.org/10.1002/9780470151808.sc05b03s34

Horii T, Arai Y, Yamazaki M, Morita S, Kimura M, Itoh M, Abe Y, Hatada I (2014) Validation of microinjection methods for generating knockout mice by CRISPR/Cas-mediated genome engineering. Sci Rep 28(4):4513. https://doi.org/10.1038/srep04513

Carey K, Ryu J, Uh K, Lengi AJ, Clark-Deener S, Corl BA, Lee K (2019) Frequency of off-targeting in genome edited pigs produced via direct injection of the CRISPR/Cas9 system into developing embryos. BMC Biotechnol 19(1):25. https://doi.org/10.1186/s12896-019-0517-7

McAndrews KM, Xiao F, Chronopoulos A, LeBleu VS, Kugeratski FG, Kalluri R (2021) Exosome-mediated delivery of CRISPR/Cas9 for targeting of oncogenic Kras G12D in pancreatic cancer. Life Sci Alliance 4(9):e202000875. https://doi.org/10.26508/lsa.202000875

Alallam B, Altahhan S, Taher M, Mohd Nasir MH, Doolaanea AA (2020) Electrosprayed alginate nanoparticles as CRISPR plasmid DNA delivery carrier: preparation, optimization, and characterization. Pharmaceuticals (Basel) 13(8):158. https://doi.org/10.3390/ph13080158

Lucifora J, Xia Y, Reisinger F, Zhang K, Stadler D, Cheng X, Sprinzl MF, Koppensteiner H, Makowska Z, Volz T, Remouchamps C, Chou WM, Thasler WE, Hüser N, Durantel D, Liang TJ, Münk C, Heim MH, Browning JL, Dejardin E, Dandri M, Schindler M, Heikenwalder M, Protzer U (2014) Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science. 343(6176):1221–8. https://doi.org/10.1126/science.1243462

Xia Y, Stadler D, Lucifora J, Reisinger F, Webb D, Hösel M, Michler T, Wisskirchen K, Cheng X, Zhang K, Chou WM, Wettengel JM, Malo A, Bohne F, Hoffmann D, Eyer F, Thimme R, Falk CS, Thasler WE, Heikenwalder M, Protzer U (2016) Interferon-γ and tumor necrosis factor-α produced by T cells reduce the HBV persistence form, cccDNA. Without Cytol Gastroenterol 150(1):194–205. https://doi.org/10.1053/j.gastro.2015.09.026

Kruse RL, Shum T, Tashiro H, Barzi M, Yi Z, Whitten-Bauer C, Legras X, Bissig-Choisat B, Garaigorta U, Gottschalk S, Bissig KD (2018) HBsAg-redirected T cells exhibit antiviral activity in HBV-infected human liver chimeric mice. Cytotherapy. 20(5):697–705. https://doi.org/10.1016/j.jcyt.2018.02.002

Li X, Zhao J, Yuan Q, Xia N (2017) Detection of HBV covalently closed circular DNA. Viruses 9(6):139. https://doi.org/10.3390/v9060139

Lin SR, Yang HC, Kuo YT, Liu CJ, Yang TY, Sung KC, Lin YY, Wang HY, Wang CC, Shen YC, Wu FY, Kao JH, Chen DS, Chen PJ (2014) The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates In Vivo. Mol Ther Nucleic Acids 3(8):e186. https://doi.org/10.1038/mtna.2014.38.PMID:25137139;PMCID:PMC4221598

Kayesh MEH, Amako Y, Hashem MA, Murakami S, Ogawa S, Yamamoto N, Hifumi T, Miyoshi N, Sugiyama M, Tanaka Y, Mizokami M, Kohara M, Tsukiyama-Kohara K (2020) Development of an in vivo delivery system for CRISPR/Cas9-mediated targeting of hepatitis B virus cccDNA. Virus Res 290:198191. https://doi.org/10.1016/j.virusres.2020.198191

Sakuma T, Masaki K, Abe-Chayama H, Mochida K, Yamamoto T, Chayama K (2016) Highly multiplexed CRISPR-Cas9-nuclease and Cas9-nickase vectors for inactivation of hepatitis B virus. Genes Cells 21(11):1253–1262. https://doi.org/10.1111/gtc.12437

Kurihara T, Fukuhara T, Ono C, Yamamoto S, Uemura K, Okamoto T, Sugiyama M, Motooka D, Nakamura S, Ikawa M, Mizokami M, Maehara Y, Matsuura Y (2017) Suppression of HBV replication by the expression of nickase- and nuclease dead-Cas9. Sci Rep 7(1):6122. https://doi.org/10.1038/s41598-017-05905-w

Liu Y, Zhao M, Gong M, Xu Y, Xie C, Deng H, Li X, Wu H, Wang Z (2018) Inhibition of hepatitis B virus replication via HBV DNA cleavage by Cas9 from staphylococcus aureus. Antiviral Res 152:58–67. https://doi.org/10.1016/j.antiviral.2018.02.011

Karimova M, Beschorner N, Dammermann W, Chemnitz J, Indenbirken D, Bockmann JH, Grundhoff A, Lüth S, Buchholz F, Schulze zur Wiesch J, Hauber J (2015) CRISPR/Cas9 nickase-mediated disruption of hepatitis B virus open reading frame S and X. Sci Rep 5:13734. https://doi.org/10.1038/srep13734

Stone D, Long KR, Loprieno MA, De Silva Feelixge HS, Kenkel EJ, Liley RM, Rapp S, Roychoudhury P, Nguyen T, Stensland L, Colón-Thillet R, Klouser LM, Weber ND, Le C, Wagoner J, Goecker EA, Li AZ, Eichholz K, Corey L, Tyrrell DL, Greninger AL, Huang ML, Polyak SJ, Aubert M, Sagartz JE, Jerome KR (2020) CRISPR-Cas9 gene editing of hepatitis B virus in chronically infected humanized mice. Mol Ther Methods Clin Dev 26(20):258–275. https://doi.org/10.1016/j.omtm.2020.11.014

Kostyusheva AP, Brezgin SA, Ponomareva NI, Goptar IA, Nikiforova AV, Gegechkori VI, Poluektova VB, Turkadze KA, Sudina AE, Chulanov VP, Kostyushev DS (2022) Antiviral activity of CRISPR/Cas9 ribonucleoprotein complexes on a hepatitis B virus model In Vivo. Mol Biol (Mosk). 56(6):884

Yang YC, Chen YH, Kao JH, Ching C, Liu IJ, Wang CC, Tsai CH, Wu FY, Liu CJ, Chen PJ, Chen DS, Yang HC (2020) Permanent inactivation of HBV Genomes by CRISPR/Cas9-mediated non-cleavage base editing. Mol Ther Nucleic Acids. 20:480–490. https://doi.org/10.1016/j.omtn.2020.03.005

Zhu W, Xie K, Xu Y, Wang L, Chen K, Zhang L, Fang J (2016) CRISPR/Cas9 produces anti-hepatitis B virus effect in hepatoma cells and transgenic mouse. Virus Res 2(217):125–132. https://doi.org/10.1016/j.virusres.2016.04.003

Download references

Author information

Authors and affiliations.

Department of Microbiology, SRM Medical College Hospital and Research Centre, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, Tamil Nadu, India

Dakshina M. Nair, Leela Kakithakara Vajravelu, Jayaprakash Thulukanam, Vishnupriya Paneerselvam, Poornima Baskar Vimala & Rahul Harikumar Lathakumari

You can also search for this author in PubMed   Google Scholar

Contributions

Dakshina M Nair: Writing—review and editing, Writing—original draft, Visualization, Validation, Resources, Methodology, Data curation, Conceptualization. Leela Kakithakara Vajravelu: Formal analysis, Conceptualization, Supervision. Jayaprakash Thulukanam: Visualization, Validation, Supervision. Vishnupriya Paneerselvam & Poornima Baskar Vimala: Visualization and Validation. Rahul Harikumar Lathakumari:: Formal analysis.

Corresponding author

Correspondence to Dakshina M. Nair .

Ethics declarations

Competing interests.

The authors declare that they do not have any known competing financial interests or personal relationships that could have appeared to influence the findings reported in this paper.

Additional information

Edited by Juergen Richt.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Nair, D.M., Vajravelu, L.K., Thulukanam, J. et al. Tackling hepatitis B Virus with CRISPR/Cas9: advances, challenges, and delivery strategies. Virus Genes (2024). https://doi.org/10.1007/s11262-024-02105-3

Download citation

Received : 03 August 2024

Accepted : 22 August 2024

Published : 28 August 2024

DOI : https://doi.org/10.1007/s11262-024-02105-3

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

• Hepatitis B
• CRISPR/Cas9
• Chronic infection
• Delivery strategies
• Find a journal
• Publish with us
• Track your research

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List
• v.57(21); 2018 Nov 1

A 79-year-old Woman with Acute Hepatitis B Caused by the Infection of Subgenotype D1 Hepatitis B Virus in Japan: A Case Study

Kosei hashimoto.

1 Division of Gastroenterology, Department of Medicine, Jichi Medical University School of Medicine, Japan

Kouichi Miura

Yoshinari takaoka, hiroaki nomoto, shunji watanabe, mamiko tsukui, naoki morimoto, norio isoda, shigeo nagashima.

2 Division of Virology, Department of Infection and Immunity, Jichi Medical University School of Medicine, Japan

Masaharu Takahashi

Hiroaki okamoto, hironori yamamoto.

A 79-year-old Japanese woman was diagnosed with acute hepatitis B based on laboratory tests showing positivity for IgM-class antibody against hepatitis B virus (HBV) core and hepatitis B surface antigen (HBsAg) as well as elevated transaminases. A phylogenetic analysis revealed that the HBV strain obtained from the patient belonged to genotype D/subgenotype D1, similar to strains circulating in foreign countries but different from those in Japan. The clinical course was favorable. HBsAg became negative within 10 weeks after the onset. To our knowledge, this is the first report of acute hepatitis B caused by subgenotype D1 HBV in Japan.

Introduction

Hepatitis B virus (HBV) infection causes acute hepatitis. HBV is transmitted by sexual intercourse, the use of HBV-infected medical devices or the transfusion of HBV-infected blood products. HBV infection can also become chronic, leading to liver cirrhosis and hepatocellular carcinoma (HCC). There are approximately 257 million and 1.2 million people with chronic HBV infection worldwide and in Japan, respectively ( 1 ). Because these patients represent potential sources of HBV infection, HBV infection remains a health burden worldwide.

There are at least 10 HBV genotypes (A-J) that have distinct geographic distributions ( 2 ). For instance, genotypes B and C are predominantly distributed in South-Eastern Asia, including Japan. Genotype A is predominant in North-Western Europe and North America. In contrast, genotype D is distributed globally, including Europe, the Mediterranean region and West-Central Asia. A Japanese nationwide study showed that genotypes A, B, C and D accounted for 4.1%, 17.5%, 77.6% and 0.6% of chronic HBV infections, respectively ( 3 ). Although native HBV genotypes are commonly observed as the cause of acute hepatitis B ( 4 ), the wave of globalization has changed the distribution of HBV genotypes in acute hepatitis B. At present, genotype A is the leading cause of acute hepatitis B in Japan, accounting for 46.7% of cases, followed by genotypes C (39.7%) and B (11.8%) ( 3 ). However, the prevalence of genotype D in Japan is still low in acute hepatitis (0.18%) as well as in chronic HBV infection (0.6%) ( 3 ).

In addition, HBV genotype D can be further divided into 10 subgenotypes (D1-D10) based on the nucleotide diversity over the entire genome ( 2 ). Of these subgenotypes, D2 is commonly observed in Ehime Prefecture in western Japan. HBV subgenotype D2 is believed to be a strain from Russia, as some asylums for Russian soldiers were located in Ehime during the Japanese-Russian War (1904-1905) ( 5 ). However, no other subgenotypes of genotype D have yet been reported in Japan.

We herein report a rare case of acute hepatitis B in an elderly woman caused by subgenotype D1 HBV.

Case Report

A 79-year-old Japanese woman was referred to our division due to abnormal liver function test results obtained in the division of Endocrinology and Metabolism of our hospital: 388 U/L for aspartate aminotransferase (AST) and 337 U/L for alanine aminotransferase (ALT). Regular blood tests as a follow-up for Graves' disease showed no abnormal liver function until two months before the admission. Because a follow-up examination revealed an elevation of transaminases (1,134 U/L for AST and 807 U/L for ALT), she was admitted to our hospital. She was an agriculture worker and had no history of alcohol intake, needle-stick injury, drug use or travel to foreign countries. Although she had been taking medication for Graves' disease from 2011, her thyroid function was within normal limits. The dosage of her medication for Graves' disease had not been changed. When she experienced subarachnoid hemorrhaging in 2011, a blood examination showed that her liver function was normal, and hepatitis B surface antigen (HBsAg) was negative. She had been receiving acupuncture care every week for chronic back pain since 2012. In addition, she had visited a nearby dental clinic for the treatment of caries four months before the admission. She had no family history of HBV infection.

On admission, there were no symptoms except for general fatigue. No skin lesions were observed. Laboratory tests were positive for HBsAg, IgM-class antibody against HBV core (IgM-HBcAb) and HBV DNA ( Table 1 ). Other viral infections, including those by hepatitis A virus, hepatitis E virus, hepatitis C virus, Epstein-Barr virus and cytomegalovirus, were absent, based on negative findings for acute markers of the corresponding viruses. Autoimmune hepatitis and primary biliary cholangitis were excluded by laboratory examinations. Although abdominal computed tomography (CT) showed a calculus in the gallbladder ( Fig. 1 ), no findings of acute cholecystitis or cholangitis were observed. We therefore made a diagnosis of acute hepatitis B.

Laboratory Data on Admission.

RBC: red blood cell, Ht: hematocrit, Plt: platelet, PT: prothrombin time, INR: international normalized ratio,TP: total protein, Alb: albumin, BUN: blood urea nitrogen, Cr: creatinine, T.Bil: total bilirubin, D.Bil: direct bilirubin, AST: aspartate aminotransferase, ALT: alanine aminotransferase, LDH: lactate dehydrogenase, γ-GTP : γ-glutamyl transpeptidase, ChE: cholinesterase, HBsAg: hepatitis B surface antigen, HBcAb: anti-hepatitis B core antibody, HBeAg: hepatitis B e antigen, HBeAb: anti-hepatitis B e antibody, HEVAb: anti-hepatitis E virus antibody, HCVAb: anti-hepatitis C virus antibody, ANA: anti-nuclear antibody, AMA: anti-mitochondrial antibody, ASMA: anti-smooth muscle antibody

CT shows a small calculus in the gallbladder without gallbladder enlargement or common bile duct dilatation.

Fig. 2 shows the clinical course of the present case. No encephalopathy was observed during the hospital course. The serum AST and ALT levels decreased promptly and returned to normal at seven weeks after the initial presentation. The prothrombin time remained in the normal range after admission. HBsAg and HBV DNA became undetectable at 10 weeks and 3 months, respectively. After seven months, anti-HBs antibody became positive. No anti-HBV medication or prednisolone was used for treatment during the clinical course.

The clinical course of the present case. N.E.: not examined

We identified the HBV genotype to be D, which is extremely rare in Japan, using an enzyme-linked immunosorbent assay (ELISA) ( 6 ). Thus, the full genomic sequence of the HBV strain (HB17-0791) recovered from the present patient was determined according to a previously described method ( 7 ) and deposited in the DDBJ/EMBL/GenBank databases under the accession number LC365689. A phylogenetic analysis confirmed that the HB17-0791 genome was classifiable as genotype D and further as subgenotype D1 ( Fig. 3 ). Of note, the HB17-0791 strain was different from the HBV strains in Ehime Prefecture, where subgenotype D2 HBV strains were predominantly distributed. The HB17-0791 strain in the current case was rather close to those circulating in China, India, Tunisia and Vietnam ( Fig. 3 ). There were no genetic mutations at the core promoter or pre-core regions of the HB17-0791 genome. Although the HBV strain was suspected of having been derived from foreign countries, we were unable to specify the origin of the HBV strain.

The phylogenetic tree constructed by the neighbor-joining method based on the entire nucleotide sequences of HBV isolates of subgenotypes D1-D10 using the HBV strains of genotypes A-C and E-J as outgroups. In addition to the HBV strain (HB17-0791) whose entire genomic sequence was determined in the present study (indicated with a closed box), 73 representative HBV strains of subgenotypes D1-D10 were included for comparison. The reported strains are indicated with the genotype/subgenotype and accession no. followed by the country of isolation. The subgenotype D2 HBV strains isolated in Ehime, Japan, are highlighted by closed circles. Bootstrap values (>70%) are indicated for the nodes as a percentage of the data obtained from 1000 resamplings. The scale bar is in units of nucleotide substitutions per site.

We herein report an elderly patient with acute hepatitis B caused by a rare subgenotype (D1) of HBV. To our knowledge, this is the first report of a case of subgenotype D1 HBV infection in Japan.

In the present case, we made a diagnosis of acute hepatitis B based on the extremely high titer of IgM-HBcAb (21.0 S/CO). Unfortunately, the data of HBcAb before the onset of acute hepatitis were not available. However, the patient had no factors with the potential to reactivate HBV, including the use of immuno-suppressive agents and anti-cancer drugs. In addition, the patient was not under surgical stress or in a condition of compromised immunity, such as cancer, arteriosclerosis or diabetes, which can also reactivate HBV ( 8 ). We therefore considered the possibility of HBV reactivation to be extremely low.

We were concerned about the clinical course of the present case, as few data are available regarding acute hepatitis B caused by subgenotype D1 HBV. Fortunately, the patient recovered from acute hepatitis without any serious problems despite being given no specific medications for HBV infection. It has been reported that the clinical course of acute hepatitis B varies among genotypes. For instance, the peak ALT levels in acute hepatitis B with genotype A (2,137±1,088 U/L) are significantly lower than those with genotypes B (3,078±2,111 U/L) or C (2,624±1,843 U/L) ( 3 ). In a study from India, the peak ALT value in acute hepatitis B caused by genotype D tended to be lower than that caused by genotype C ( 9 ). In contrast, the peak ALT level in Ehime Prefecture with genotype D was 2,236±2,202 U/L, which was higher than that with genotype A (1,425±630 U/L) ( 4 ). Although a weak immune response against HBV may lead to a delay in the disappearance of HBsAg, as in the cases with genotype A HBV, HBsAg became negative within 10 weeks after the disease onset in the present case. The chronicity of HBV genotype D is of interest; however, accurate data have not yet been published. In general, the chronicity of HBV genotype D is suspected to be low ( 10 , 11 ). Although the rate of fulminant hepatitis followed by acute hepatitis was unclear, HBV genotype D has been reported as a cause of fulminant hepatitis in Japan ( 12 ) as well as in foreign countries ( 13 , 14 ). Among cases with genotype D HBV, no significant differences were observed in the peak levels of ALT or total bilirubin between subgenotypes D1 and D2 ( 9 ). However, little information is available on the clinical course of patients with acute HBV subgenotype D1 infection.

In patients with chronic hepatitis B caused by subgenotype D2 HBV observed in Ehime Prefecture, the prevalence of liver cirrhosis and HCC was less common than in cases caused by genotype C ( 15 ). In Turkey, subgenotype D1 HBV is the major cause of chronic hepatitis B, being characterized by early HBeAg seroconversion, a low viral load and a relatively low incidence of liver cirrhosis and HCC ( 16 ). Thus, HBV genotype D seems to be associated with a less severe clinical course in cases of acute and chronic hepatitis.

The transmission route is a major concern in the present case. Horizontal transmission is the major mode in genotype D ( 10 ). Sexual transmission is the leading cause of acute hepatitis B in Japan ( 3 ). However, the patient denied sexual intercourse by a medical interview. In addition, she had no family history of HBV infection. We therefore suspected two potential routes of transmission: acupuncture care and dental treatment, both of which carry a risk of HBV transmission ( 17 , 18 ). The phylogenetic tree showed that the HBV strain in the present case was different from those in Ehime, Japan, instead being segregated into a cluster including strains isolated in China, India and Vietnam. As the patients had never been to theses foreign counties, we suspected that the isolated strain may have been transported from those countries via infected individuals because the distribution of genotype D HBV is extremely low in Japan, and the number of foreign residents is increasing in Tochigi Prefecture, where the patient lives (accounting for 1.82% of the population; http://www.pref.tochigi.lg.jp/f04/29-gaikokujinjumin.html ). The top five countries of origin among foreign residents of Tochigi Prefecture are China, the Philippines, Brazil, Vietnam and Peru. Furthermore, the prevalence of people with HBsAg is higher in these Asian countries and Peru than in Japan ( 19 ). In the literature, HBV genotype D is prevalent in China ( 20 ), Brazil ( 21 ), and Vietnam ( 22 ) but not in the Philippines ( 23 ) or Peru ( 24 ) ( Table 2 ). Furthermore, subgenotype D1 is observed in China ( 25 , 26 ). Thus, there is a chance of becoming infected with subgenotype D1 HBV in Japan. Because HBV carriers are often unaware of their HBV infection, HBV may be unknowingly transmitted from infected foreigners to susceptible residents in Japan. It is important to bear in mind that acupuncture and dental procedures carry a risk of HBV infection, and safe working environments must be established in order to prevent HBV infection.

The Prevalence of Chronic HBV Infection and HBV Genotypes.

In conclusion, we experienced a case of acute hepatitis B caused by an infection with subgenotype D1 HBV, which was identified for the first time in Japan. Further investigations are required, as HBV infection with non-native genotypes is likely to become increasingly frequent in Japan due to growing globalization ( 3 , 27 - 29 ).

The authors state that they have no Conflict of Interest (COI).

• Case report
• Open access
• Published: 28 August 2024

Concordant fatal congenital anomaly in twin pregnancy: a case report and review of the literature

• Amenu Diriba 1 ,
• Temesgen Tilahun   ORCID: orcid.org/0000-0003-4138-4066 1 ,
• Lammii Gonfaa 1 ,
• Jemal Gebi 1 ,
• Bikila Lemi 1 ,
• Jiregna Fyera 1 ,
• Suleiman Mazeng 1 ,
• Aschalew Legesse 1 &
• Dinaol Alemu 1  

Journal of Medical Case Reports volume  18 , Article number:  406 ( 2024 ) Cite this article

Metrics details

When a pregnant mother finds out she has a fetus with a congenital defect, the parents feel profound worry, anxiety, and melancholy. Anomalies can happen in singleton or twin pregnancies, though they are more common in twin pregnancies. In twins, several congenital defects are typically discordant.

Case summary

We present a rare case of concordant fatal anomaly in twin pregnancy in a 22-year-old African patient primigravida mother from Western Ethiopia who presented for routine antenatal care. An obstetric ultrasound scan showed anencephaly, meningomyelocele, and severe ventriculomegaly. After receiving the counseling, the patient was admitted to the ward, and the pregnancy was terminated with the medical option. Following a successful in-patient stay, she was given folic acid supplements and instructed to get preconception counseling before getting pregnant again.

The case demonstrates the importance of early obstetric ultrasound examination and detailed anatomic scanning, in twin pregnancies in particular. This case also calls for routine preconceptional care.

Peer Review reports

Introduction

A “congenital anomaly” is defined as any abnormal deviation from the expected structure, form, or function. “Malformations” are morphological abnormalities of organs or regions of the body resulting from an intrinsically abnormal developmental process, whereas “disruptions” are defects from interference with an initially normal developmental process [ 1 , 2 ].

Congenital anomalies present in twins also include any anomaly that may occur in singletons, including primary structural malformations, chromosomal defects, and genetic syndromes [ 1 , 2 ]. The anomalies may involve one or both twins [ 2 , 3 ]. The former is called discordant, while the latter is termed concordant [ 1 , 2 , 3 ]. Due to the anomaly’s multifactorial inheritance pattern, which is influenced by both genetic and environmental factors, twins are usually discordant for this anomaly, with only one co-twin affected [ 1 , 3 ].

However, some research has shown that identical twins have concordant anomalies such as neural tube defects [ 3 , 4 ]. Here we present a rare case of concordant congenital anomaly in twin pregnancy.

Case presentation

This 22-year-old African patient primigravida from western Ethiopia came to Wallaga University Referral Hospital for her second appointment as part of her routine prenatal care schedule. She said she had been amenorrheic for the past 4 months, but she could not recall the last time she had had a regular menstrual cycle. She received folic acid 5 mg (orally daily and iron sulphate 325 mg orally three times daily for 3 months, and two doses of tetanus–diphtheria vaccine during her prenatal care. However, she had no preconceptional care.

In the course of the index pregnancy, she had never experienced headaches, vaginal bleeding, blurred vision, or epigastric pain. In addition, she had no history of smoking tobacco, chewing khat, drinking alcohol, or using other forms of medication. She had never had bronchial asthma, hypertension, diabetes mellitus, or heart disease.

There was no history of twin pregnancies in her family. This patient was diagnosed with hyperemesis gravidarum and hospitalized to the gynecology ward a month prior to the current presentation. She was released from the hospital after 2 days, having improved. It proved that the pregnancy was twins at 11 weeks appropriate for gestational age (AGA). However, no fetal anomaly was detected.

On examination, she was healthy-looking. Her vital signs were blood pressure (BP) = 120/70 mmHg, pulse rate (PR) = 84 beats per minute, respiratory rate (RR) = 20 breaths per minute, and a temperature of 37.6 °C. She had slightly pale conjunctiva. An abdominal exam showed a 20-week-sized gravid uterus. The lymph glandular system, respiratory system, cardiovascular system, and genitalia were normal. On neurologic examination, reflexes were intact, and meningeal signs were negative.

Urinalysis; complete blood count; random blood sugar (RBS); serology for syphilis, hepatitis, and human immunodeficiency virus (HIV); obstetrics ultrasound; and blood group were done. Obstetrics ultrasound showed a twin intrauterine pregnancy with an anencephalic twin A and severe ventriculomegaly and lumbar myelo-meningocele in twin B (Table  1 ).

With the final diagnosis of a second-trimester twin pregnancy with a concordant fatal anomaly, the patient was admitted to the gynecology ward. In the ward, the patient was given mifepristone 200 mg orally. After 24 hours, 400 µg of misoprostol was inserted vaginally. A total of 8 hours later, she expelled twin A, weighing 120 g of anencephalic abortus with cervical, thoracic, and lumbar vertebral defect, and twin B, weighing 150 g of hydrocephalic abortus with a thoracic and lumbar vertebral defect, and protrusion of the intestine via the right side para umbilical area without the covering membrane (Fig.  1 A, B). The placenta was monochorionic.

A Twin abortuses with neural tube defects at Wallaga University Referral Hospital, Western Ethiopia, 2023. B Twin abortuses with neural tube defects and gastroschisis at Wallaga University Referral Hospital, Western Ethiopia, 2023

When compared with singleton pregnancies, the rates of congenital anomalies are higher with multiple pregnancies [ 5 , 6 ]. In fetuses in multiple gestations, these anatomic abnormalities are more commonly linked to monozygotic (MZ) twining than dizygotic (DZ) twining [ 2 , 7 ].

Anomalies may affect all organ systems, but the commonest involve cardiovascular and central nervous systems, followed by ophthalmic and gastrointestinal abnormalities [ 1 , 4 , 7 , 8 ]. The concordance rate of major congenital malformations is around 20% for monozygotic twins, with most dizygotic twin pairs being discordant [ 1 ]. Only in certain organ systems do monozygotic twins exhibit higher concordance rates than DZ twins [ 4 , 7 ]. Our case is MZ twins. In both twins, the neural nervous system was affected. The twin pairs had neural tube defects. One twin had gastroschisis.

Anomalies in singleton and twin pregnancies are associated with maternal exposure to various factors such as diazepam use, cigarette smoking, maternal obesity, and nutritional deficiencies [ 9 ]. Our case was complicated by hyperemesis gravidarum. Because of repeated vomiting, it could result in nutritional deficiency, which could in turn result in neural tube defects and other anomalies.

There is limited published evidence about screening for structural abnormalities in twin or higher order pregnancies [ 10 ]. Careful sonographic surveys of fetal anatomy are indicated in multifetal pregnancies because the risk for congenital anomalies is increased [ 11 ]. A complete fetal anatomic survey is therefore recommended for all twin gestations at 18–22 weeks’ gestational age [ 12 ]. The accuracy of ultrasonography for detecting congenital fetal anomalies in multiple gestations has not been adequately studied in large series [ 11 ].

Following diagnosis of an anomaly affecting only one fetus, practitioners may face the dilemma of expectant management versus selective termination. If the option of selective fetocide is considered, the main variable determining the technique to achieve this aim is chorionicity [ 13 , 14 , 15 ]. In a dichorionic pregnancy, passage of fetocidal agents from one twin into the circulation of the co-twin is unlikely due to the lack of placental anastomoses [ 13 , 14 ]. When monochorionic (MC) twins are complicated with discordant fetal anomalies, the management scheme will be much more complex [ 13 , 14 ]. In this case, selective termination needs to be performed by ensuring complete and permanent occlusion of both the arterial and venous flows in the umbilical cord of the affected twin. Bipolar cord coagulation under ultrasound guidance is associated with approximately 70–80% survival rates [ 14 , 15 ]. However, management of concordant fatal anomaly in twin pregnancy is not controversial [ 3 ]. In our case, both twins had fatal congenital anomalies, which required immediate termination of the pregnancy using misoprostol.

Availability of data and materials

The datasets used during the current study are available from the corresponding author on reasonable request.

Abbreviations

Hepatitis B surface antigen

Human immunodeficiency virus

Monozygotic

Rhesus factor

Venereal disease research laboratory

White blood count

Weber MA, Sebire NJ. Genetics and developmental pathology of twinning. Seminars Fetal Neonatal Med. 2010; 15(6): 313–318). https://www.sciencedirect.com/science/article/pii/S1744165X10000466 .

Cunningham F, Leveno KJ, Dashe JS, Hoffman BL, Spong CY, Casey BM. eds. Multifetal Pregnancy. Williams Obstetrics, 26e . McGraw Hill; 2022. Accessed February 01, 2024.  https://accessmedicine-mhmedical-com-443.webvpn.sysu.edu.cn/content.aspx?bookid=2977&sectionid=263825445 .

Momo RJ, Sama JD, Meka E, Temgoua MN, Foumane P. Challenge in the management of twin pregnancy with anencephaly of one fetus in a low- income country: a case presentation. J Gynecol Obstet. 2019;7(3):81–4.

Article   Google Scholar  

Jung YM, Lee SM, Oh S, Lyoo SH, Park CW, Lee SD, Park JS, Jun JK. The concordance rate of non-chromosomal congenital malformations in twins based on zygosity: a retrospective cohort study. BJOG. 2021;128(5):857–64. https://doi.org/10.1111/1471-0528.16463 .

Article   CAS   PubMed   Google Scholar  

Ogochukwu, Ugwu Rosemary and Eneh Augusta Unnoma. “Concordant congenital abnormalities in twins: report of five cases”; 2011. https://www.semanticscholar.org/paper/Concordant-congenital-abnormalities-in-twins%3A-of-Ogochukwu-Unnoma/0537e055cc465e842e15354b53e03b8909f272f2 .

Piro E, Schierz IAM, Serra G, et al . Growth patterns and associated risk factors of congenital malformations in twins. Ital J Pediatr. 2020;46:73. https://doi.org/10.1186/s13052-020-00838-z .

Article   PubMed   PubMed Central   Google Scholar  

Unal ER, Newman RB. Multiple Gestations. Gabbe’s Obstetrics: Normal and Problem Pregnancies, 39, 751–783.e4. https://www.clinicalkey.com .

Tsoraides SS, Pacheco PE, Pearl RH. Concordant VACTERL anomalies in identical twins. Clin Surg. 2016;1:1145.

Google Scholar  

Singh S, Kayastha A, Thapa A, Thapa B, Dahal S. Omphalocele, exstrophy of cloaca, imperforate anus, and spinal defects complex: a case report. JNMA J Nepal Med Assoc. 2023;61(260):375–8. https://doi.org/10.31729/jnma.8048 .

Bricker L. Multiple pregnancy: diagnosis and screening. In: Kumar B, Alfirevic Z, eds. Fetal Medicine. Royal College of Obstetricians and Gynaecologists Advanced Skills. Cambridge University Press; 2016:302–310. https://www.cambridge.org/core/books .

Malone FD, Dalton ME. Multiple Gestation: Clinical Characteristics and Management. creasy and Resnik’s maternal fetal medicine, 8e: 654–678.

Frates MC. Multifetal pregnancy. Diagnostic ultrasound, 5e, 1115–1132. https://dokumen.pub/diagnostic-ultrasound-5nbsped.html .

Wataganara T, Nawapun K, Phithakwatchara N. Fetal anomalies in twin pregnancies. Donald School J Ultrasound Obstet Gynecol. 2016;10(3):308–12.

Rustico MA, Baietti MG, Coviello D, Orlandi E, Nicolini U. Managing twins discordant for fetal anomaly. Prenat Diagn. 2005;25(9):766–71. https://doi.org/10.1002/pd.1260 .

Langedock A, Lewi L. Twin pregnancies discordant for fetal anomaly. In: Khalil A, Lewi L, Lopriore E, editors. Twin and higher-order pregnancies. Cham: Springer; 2021. https://doi.org/10.1007/978-3-030-47652-6_10 .

Chapter   Google Scholar  

Download references

Acknowledgements

We thank the patient for allowing the publication of this case report.

No funding source.

Author information

Authors and affiliations.

Department of Obstetrics and Gynecology, School of Medicine, Wollega University, Nekemte, Ethiopia

Amenu Diriba, Temesgen Tilahun, Lammii Gonfaa, Jemal Gebi, Bikila Lemi, Jiregna Fyera,  Suleiman Mazeng, Aschalew Legesse & Dinaol Alemu

You can also search for this author in PubMed   Google Scholar

Contributions

All authors made a significant contribution to the work reported, whether that was in the conception, study design, execution, acquisition of data, analysis, and interpretation, or in all these areas; they took part in drafting, revising, or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted, and agree to be accountable for all aspects of the work.

AD is an assistant professor in the Department of Obstetrics and Gynecology, Institute of Health Sciences, Wollega University; TT is an associate professor of Obstetrics & Gynecology, Institute of Health Sciences, Wollega University; LG is an assistant professor in the Department of Obstetrics and gynecology, Institute of Health Sciences, Wollega University; JG is an assistant professor in the Department of Obstetrics and Gynecology, Institute of Health Sciences, Wollega University; JF is an assistant professor in the Department of Obstetrics and Gynecology, Institute of Health Sciences, Wollega University; BL is an assistant professor in the Department of Obstetrics and Gynecology, Institute of Health Sciences, Wollega University; S is an obstetrics and gynecology resident at the Institute of Health Sciences, Wollega University; AL is an obstetrics and gynecology resident at the Institute of Health Sciences, Wollega University; and DA is an obstetrics and gynecology resident at the Institute of Health Sciences, Wollega University.

Corresponding author

Correspondence to Temesgen Tilahun .

Ethics declarations

Ethics approval and consent to participate.

Ethical clearance was obtained from the Research Ethics Review Committee of Wallaga University Referral Hospital. The study protocol is performed per the relevant guidelines.

Consent for publication

Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

There are no competing interests.

Additional information

Publisher’s note.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ .

Reprints and permissions

About this article

Cite this article.

Diriba, A., Tilahun, T., Gonfaa, L. et al. Concordant fatal congenital anomaly in twin pregnancy: a case report and review of the literature. J Med Case Reports 18 , 406 (2024). https://doi.org/10.1186/s13256-024-04732-8

Download citation

Received : 05 February 2024

Accepted : 28 June 2024

Published : 28 August 2024

DOI : https://doi.org/10.1186/s13256-024-04732-8

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

• Twin pregnancy
• Anencephaly
• Meningomyelocele
• Ventriculomegaly
• Gastroschisis

Journal of Medical Case Reports

ISSN: 1752-1947

• Submission enquiries: Access here and click Contact Us
• General enquiries: [email protected]

• Health, Pharma & Medtech ›

State of Health

Countries with the highest share of hepatitis B infections worldwide in 2022

In 2022, China had the highest share of hepatitis B infections worldwide with 31.5 percent of cases that year, followed by India with 11.7 percent. This statistic shows the countries with the highest proportion of hepatitis B infections worldwide in 2022.

Countries with the highest proportion of hepatitis B infections worldwide in 2022*

Additional Information

Show sources information Show publisher information Use Ask Statista Research Service

* These countries account for two-thirds of all hepatitis B cases worldwide.

Other statistics on the topic

• Rate of hepatitis B-related deaths in the U.S. in 2022, by age
• Hepatitis B immunization coverage in the U.S. among one-year-olds, 2000-2022
• New cases of hepatitis in the U.S. 1970-2022
• Number of hepatitis A infections in the U.S. from 2015 to 2022

• Immediate access to statistics, forecasts & reports
• Usage and publication rights
• Download in various formats

* For commercial use only

Basic Account

• Free Statistics

Starter Account

• Premium Statistics

Professional Account

• Free + Premium Statistics
• Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Statistics on " Hepatitis in the U.S. "

• New cases of hepatitis A and B 1970-2022
• Number of viral hepatitis-related deaths in the U.S. from 2018-2022, by type
• Rate of viral hepatitis-related deaths in the U.S. from 2018-2022, by type
• Share of U.S. teenagers who had select vaccinations 2022-2023
• Rate of hepatitis A infections in the U.S. from 2018 to 2022
• Number of hepatitis A infections in the U.S. in 2022, by state
• Hepatitis A infection rate in the U.S. in 2022, by state
• Rate of hepatitis A-related deaths in the U.S. from 2018-2022, by gender
• Number of hepatitis B infections in the U.S. from 2015-2022
• Rate of hepatitis B infections in the U.S. from 2018-2022
• Number of hepatitis B infections in the U.S. in 2022, by state
• Rate of hepatitis B infections in the U.S. in 2022, by state
• Rate of hepatitis B-related deaths in the U.S. from 2018-2022, by gender
• Rate of hepatitis B-related deaths in the U.S. in 2022, by race/ethnicity
• Number of acute hepatitis C infections in the U.S. from 2015 to 2022
• Rate of acute hepatitis C infections in the U.S. from 2018 to 2022
• Number of acute hepatitis C infections in the U.S. in 2022, by state
• Rate of acute hepatitis C infections in the U.S. in 2022, by state
• Share of people with hepatitis C in the U.S. 2013-2022, by clearance step & gender
• Share of people with hepatitis C in the U.S. 2013-2022, by viral clearance step & age
• Maternal hepatitis C infection rate in the U.S. 2016-2021
• Rate of hepatitis C-related deaths in the U.S. from 2018-2022, by gender

Other statistics that may interest you Hepatitis in the U.S.

• Basic Statistic New cases of hepatitis in the U.S. 1970-2022
• Premium Statistic New cases of hepatitis A and B 1970-2022
• Basic Statistic Number of viral hepatitis-related deaths in the U.S. from 2018-2022, by type
• Premium Statistic Rate of viral hepatitis-related deaths in the U.S. from 2018-2022, by type
• Premium Statistic Hepatitis B immunization coverage in the U.S. among one-year-olds, 2000-2022
• Premium Statistic Share of U.S. teenagers who had select vaccinations 2022-2023

Hepatitis A

• Premium Statistic Number of hepatitis A infections in the U.S. from 2015 to 2022
• Premium Statistic Rate of hepatitis A infections in the U.S. from 2018 to 2022
• Premium Statistic Number of hepatitis A infections in the U.S. in 2022, by state
• Basic Statistic Hepatitis A infection rate in the U.S. in 2022, by state
• Basic Statistic Rate of hepatitis A-related deaths in the U.S. from 2018-2022, by gender

Hepatitis B

• Premium Statistic Number of hepatitis B infections in the U.S. from 2015-2022
• Premium Statistic Rate of hepatitis B infections in the U.S. from 2018-2022
• Basic Statistic Number of hepatitis B infections in the U.S. in 2022, by state
• Premium Statistic Rate of hepatitis B infections in the U.S. in 2022, by state
• Basic Statistic Rate of hepatitis B-related deaths in the U.S. from 2018-2022, by gender
• Premium Statistic Rate of hepatitis B-related deaths in the U.S. in 2022, by age
• Premium Statistic Rate of hepatitis B-related deaths in the U.S. in 2022, by race/ethnicity

Hepatitis C

• Premium Statistic Number of acute hepatitis C infections in the U.S. from 2015 to 2022
• Basic Statistic Rate of acute hepatitis C infections in the U.S. from 2018 to 2022
• Basic Statistic Number of acute hepatitis C infections in the U.S. in 2022, by state
• Premium Statistic Rate of acute hepatitis C infections in the U.S. in 2022, by state
• Premium Statistic Share of people with hepatitis C in the U.S. 2013-2022, by clearance step & gender
• Basic Statistic Share of people with hepatitis C in the U.S. 2013-2022, by viral clearance step & age
• Basic Statistic Maternal hepatitis C infection rate in the U.S. 2016-2021
• Basic Statistic Rate of hepatitis C-related deaths in the U.S. from 2018-2022, by gender

Further Content: You might find this interesting as well

• Open access
• Published: 23 August 2024

From discovery to treatment: tracing the path of hepatitis E virus

• Arash Letafati 1 , 2   na1 ,
• Zahra Taghiabadi 2   na1 ,
• Mahshid Roushanzamir 2 , 3 ,
• Bahar Memarpour 2 , 4 ,
• Saba Seyedi 2 ,
• Ali Vasheghani Farahani 2 ,
• Masoomeh Norouzi 2 ,
• Saeideh Karamian 2 ,
• Arghavan Zebardast 2 ,
• Marzieh Mehrabinia 2 ,
• Omid Salahi Ardekani 2 ,
• Tina Fallah 2 ,
• Fatemeh Khazry 2 ,
• Samin Fathi Daneshvar 2 &
• Mehdi Norouzi 1 , 2  

Virology Journal volume  21 , Article number:  194 ( 2024 ) Cite this article

400 Accesses

1 Altmetric

Metrics details

The hepatitis E virus (HEV) is a major cause of acute viral hepatitis worldwide. HEV is classified into eight genotypes, labeled HEV-1 through HEV-8. Genotypes 1 and 2 exclusively infect humans, while genotypes 3, 4, and 7 can infect both humans and animals. In contrast, genotypes 5, 6, and 8 are restricted to infecting animals. While most individuals with a strong immune system experience a self-limiting infection, those who are immunosuppressed may develop chronic hepatitis. Pregnant women are particularly vulnerable to severe illness and mortality due to HEV infection. In addition to liver-related complications, HEV can also cause extrahepatic manifestations, including neurological disorders. The immune response is vital in determining the outcome of HEV infection. Deficiencies in T cells, NK cells, and antibody responses are linked to poor prognosis. Interestingly, HEV itself contains microRNAs that regulate its replication and modify the host’s antiviral response. Diagnosis of HEV infection involves the detection of HEV RNA and anti-HEV IgM/IgG antibodies. Supportive care is the mainstay of treatment for acute infection, while chronic HEV infection may be cleared with the use of ribavirin and pegylated interferon. Prevention remains the best approach against HEV, focusing on sanitation infrastructure improvements and vaccination, with one vaccine already licensed in China. This comprehensive review provides insights into the spread, genotypes, prevalence, and clinical effects of HEV. Furthermore, it emphasizes the need for further research and attention to HEV, particularly in cases of acute hepatitis, especially among solid-organ transplant recipients.

Introduction

As an enteric RNA virus, HEV can cause both disease outbreaks and sporadic cases. This virus belongs to the Hepeviridae family and is characterized as a single-stranded, positive-sense RNA virus. Contamination of the water supply is the main cause of virus outbreaks, although there are evidence suggests that the virus may also spread through person-to-person transmission. After a significant hepatitis outbreak in Kashmir in 1978, it was initially established as a distinct infectious agent. The virus was subsequently found in the fecal specimens of Soviet military recruits posted in Afghanistan in 1981 [ 1 , 2 , 3 ]. Human-infecting HEV genotypes can be found in the species Paslahepevirus balayani and Rocahepevirus ratti [ 4 ]. HEV consists of two major species: mammalian HEV, which leads to acute hepatitis in humans and is harbored by pigs and possibly other animals, and avian HEV, accountable for a condition known as big liver and spleen disease in chickens [ 5 , 6 ]. HEV RNA becomes detectable in blood and stool roughly three weeks after infection. Viremia typically persists for three to six weeks, while the virus continues to be shed in stool for about four to six weeks [ 7 ]. Typically, the incubation period of HEV infection ranges from 2 to 6 weeks [ 8 ]. Increasing age and living in low socioeconomic conditions are contributing risk factors for HEV infection [ 9 ].

A comprehensive study estimated the worldwide anti-HEV IgG seroprevalence at 12.47%, the pooled anti-HEV IgM seroprevalence at 1.47%, and the pooled prevalence of HEV RNA-positive in the general population at 0.20% [ 10 ]. In the overall population, the mortality rate varies from 0.5 to 4%. However, for pregnant women infected with HEV, the mortality rate escalates to as high as 30% [ 11 ]. In immunocompromised individuals, this infection can potentially become a chronic and significant medical issue, particularly for those who have undergone solid organ transplants as well as for patients with HIV, leukemia, and lymphoma [ 12 ]. According to a systematic review and meta-analysis, the prevalence of HEV infection among organ transplant recipients ranges from 6 to 29.6%, while among HIV-positive patients, it ranges from 3.5 to 19.4% [ 13 ]. The occurrence of HEV infection differs across various global regions, primarily due to distinct genotypes [ 14 ]. HEV has eight different genotypes, but only five of them are linked to human diseases and are designated as HEV-1 through HEV-4 and HEV-7 [ 15 ]. HEV-1 and HEV-2 are prevalent in developing nations like those in Africa, Asia, and Mexico, while HEV-3 and HEV-4 are more prevalent in developed countries. Genotypes 1 and 2 are typically linked to human infection, often resulting in outbreaks in regions with inadequate sanitation. Genotypes 3 and 4 are typically transmitted through consuming undercooked meat or potentially via contact with infected animals. HEV strains originating from animals such as rabbits, pigs, camels, and rats possess zoonotic potential [ 16 , 17 ]. In endemic region, HEV primarily transferred via the fecal-oral route, often via the pollution of drinking water [ 5 ]. Other modes of transmission, such as contaminated food, maternal-fetal (vertical transmission), and modes involving injection, are less frequent [ 18 ]. Remarkably, the age-specific seroprevalence patterns of HEV differ significantly from those of HAV, despite both viruses sharing similar transmission routes in regions where these diseases are prevalent [ 19 ].

This comprehensive review explores the complexities of mammalian HEV, highlighting its transmission routes, various genotypes, global prevalence patterns, and the range of clinical manifestations it can cause. Emphasizing the critical need for expanded research efforts, particularly in the domain of acute hepatitis, the text underscores the importance of heightened scrutiny, especially within vulnerable populations such as recipients of solid-organ transplants. By deepening our understanding of these aspects, we aim to pave the way for more effective strategies for the management and prevention of this infectious pathogen.

Evolutionary history

In 2000, phylogenetic studies on four different HEV strains and a re-evaluation of conserved regions in the capsid, helicase, and polymerase showed that HEV should not be classified in the Caliciviridae family. Instead, it was repositioned into an unassigned clade with an uncertain taxonomic status, although it exhibited a closer relationship to the Togaviridae family [ 20 ]. Within the “alpha-like” major groupings, this ultimately clarified the virus’s classification, resolving its placement within both the “Picorna-like” upper-level groupings and the “alpha-like” supergroup. With the increasing availability of sequences, it became increasingly evident that HEV was significantly differentiated from various viral genera and lineages. Consequently, it was designated as its genus ( Hepevirus ) by 2004 and later as its distinct family ( Hepeviridae ) in 2009 [ 21 , 22 ]. In 2014, the classification of Hepeviridae underwent a reassessment, resulting in the creation of two new genera: Orthohepevirus and Piscihepevirus [ 23 ] (Fig.  1 ).

A timeline chronology of key advancements in the field of hepatitis E virus [ 6 , 177 , 178 , 179 , 180 , 181 , 182 , 183 , 184 ]

Capsid proteins of the hepatitis virus are crucial for its classification, serving as key distinguishing features [ 24 ]. Despite an in-depth examination of the non-structural protein-encoding region, the source of the HEV capsid remained inconclusive, as the Benyviridae family comprises non-enveloped rod-shaped plant viruses, while HEV capsids exhibit a T = 3 icosahedral structure, comprise approximately 180 copies of the capsid protein [ 25 , 26 ]. Icosahedral capsids are characterized by a triangulation number such as T1, T3, T4, etc., indicating identical equilateral triangles constructed by subunits [ 27 ]. Surprisingly, it wasn’t until 2011 that it was discovered that the HEV capsid protein had its closest structural resemblance to capsids found in members of the Astroviridae family, which infect vertebrates [ 28 ]. Astroviruses , akin to HEV, possess a T = 3 icosahedral capsid structure. However, they are affiliated with the “Picorna-like” supergroup of viruses. Presently, the enigma of HEV’s origin persists, as the non-structural protein-encoding region is categorized within the “alpha-like” supergroup, as opposed to the structural region [ 25 ].

HEV’s taxonomy

HEV belongs to the family Hepeviridae , which is categorized into two main subfamilies: Orthohepevirinae (encompassing four genera) and Parahepevirinae (only one genus: Piscihepevirus ) based on international committee on taxonomy of viruses (ICTV) report in 2022 [ 29 , 30 ]. Whitin the Orthohepevirinae subfamily, genera Paslahepevirus and Rocahepevirus can infect humans, wild and domestic mammals, while Chirohepevirus affects bats and Avihepevirus infects birds [ 30 ]. Paslahepevirus includes two species: P. balayani and P. alci (specific to moose). P. balayani , formerly known as Orthohepevirus A , infects humans and various mammals. It has 8 distinct genotypes, with genotypes 1–4 causing significant human disease. Genotypes 1 and 2 lead to large epidemics in developing countries, while zoonotic infections with genotypes 3 and 4 cause sporadic and clustered cases of HEV [ 31 , 32 ].

Virion structure and genome organization

HEV has a genome consisting of positive-sense, single-stranded RNA, approximately 7.2 kb in size. This RNA genome features a 7-methylguanosine RNA cap at the 5′ terminus and a polyadenylated tail at the 3′ end [ 33 ]. The viral genetic material usually contains three open reading frames (ORFs), specifically known as ORF1, ORF2, and ORF3. However, a fourth ORF (ORF4), which can be found in ORF1, is exclusive to genotype 1 (G-1 HEV) strains and ORF4-specific antibodies are present in G-1 HEV case serum [ 34 ]. ORF1 extends about 5 kb in length and is located at the 5′ end of the genome, while ORF2 is around 2 kb and is positioned at the 3′ end. Notably ORF3 consists of 372 bases, with its 5′ end sharing an overlap of merely 4 nucleotides with ORF1 and its 3′ end overlapping with ORF2 by 331 nucleotides [ 35 , 36 ]. As well, ORF1 represents a substantial polyprotein harboring numerous functional domains crucial for virus replication. On the contrary, ORF2 and ORF3 originate from a 2.2 sub-genomic RNA generated during virus replication, fulfilling functions in virus assembly and egress, respectively [ 37 ]. In HEV-infected cells, the quantity of sub-genomic RNA copies is notably greater than that of their genomic RNA equivalents [ 37 ] (Fig.  2 ). ORF2 is crucial for HEV assembly, facilitating the packaging and folding of viral RNA and the formation of viral particles. Strategies include disrupting ORF2’s binding to RNA elements at the 5′ end of the genomic RNA and targeting ORF2 oligomerization to form the capsid, both of which could be hopeful approaches for antiviral drug development. Alternatively, ORF3 facilitates viral particle release by connecting assembled particles to the ESCRT (endosomal sorting complexes required for transport) pathway through its attachment to the ESCRT component Tsg101 (tumor susceptibility gene 101) [ 38 ]. Furthermore, the ORF4 protein interacts with viral helicase, RNA-dependent RNA polymerase (RdRp), X, eukaryotic elongation factor 1 isoform-1 (eEF1α1), and tubulinβ, forming a protein complex. ORF4 and eEF1α1 together boost viral RdRp activity. In addition, it was reported that a proteasome-resistant ORF4 mutant greatly increased HEV replication [ 34 ].

Hepatitis E virus genome: The genome organization of the Hepatitis E Virus (HEV) involves a single-stranded positive-sense RNA molecule, approximately 7.2 kilobases in length. At its 5’ end, the RNA molecule begins with a 7-methylguanosine RNA cap, while at the 3’ terminus, it is polyadenylated. Notably, the HEV genome consists of three consistently conserved open reading frames (ORFs) present in all identified HEV strains: ORF1, ORF2, and ORF3. ORF1 is responsible for encoding nonstructural polyproteins, which contain various functional domains including methyltransferase (Met), X domain, helicase (Hel), hypervariable region (HVR), RNA-dependent RNA polymerase (RdRp), Y domain, and papain-like cysteine protease (PCP). ORF2 encodes the structural capsid protein, which comprises P, S, and M domains. The capsid protein is essential for viral assembly and its interaction with the immune system of the host. ORF3 contains a highly conserved PxxP motif and encodes a small protein that has been demonstrated in vitro to bind with various proteins involved in cellular signal transduction [ 185 , 186 , 187 , 188 , 189 , 190 , 191 , 192 , 193 , 194 ]

Epidemiology

Five genotypes of HEV have been identified that can cause harm. Among these genotypes, genotype 1 and genotype 2 exclusively affect humans. Genotype 3 and genotype 4 are associated with animal reservoirs, specifically found in wild boars, deer, swine, and rabbits [ 39 , 40 ]. Recently, a new genotype, genotype 7, has been discovered, which is primarily found in camels. There has been a documented case of human infection with this genotype, involving an individual who owned camels and had previously undergone a liver transplant in the United Arab Emirates [ 41 ]. Genotype 1 strains of HEV have been identified in various regions, including China, Pakistan, Nepal, the Indian subcontinent, Afghanistan, Bangladesh, and several sub-Saharan African countries. In contrast, genotype 2 strains are prevalent in the Central African Republic, Chad, Nigeria, Mexico, and Sudan. Genotype 3 strains have been found in Central and Southern Japan, as well as in the United States, other North American countries, Europe, Australia, and New Zealand. Moreover, genotype 4 is known to exist in northern Japan, China, India, and several European countries, including France and Germany. It is important to note that genotype 7 has only been detected in the United Arab Emirates, and there is limited research available regarding its geographic distribution [ 42 , 43 ].

HEV genotype 1 strain-induced outbreaks are commonly associated with the transmission of the virus through contaminated water sources. India has experienced recurring outbreaks since the initial outbreak in Delhi in 1955. These outbreaks have affected hundreds or even thousands of individuals, demonstrating a significant impact observed during the period from 1975 to 1994 [ 42 ]. This outbreak affected over 200 villages with a total population of 600,000. It resulted in 20,083 cases of jaundice and 600 deaths within a seven-week period. Pregnant women, in all three trimesters, were more frequently infected with HEV compared to men and non-pregnant women aged 15–45 years [ 18 , 44 ]. Another significant epidemic occurred between 1986 and 1988, leaving a lasting impact on the affected region. During this period, there were approximately 120,000 reported cases of HEV infection. This epidemic claimed the lives of 765 individuals, with 51 of them being pregnant women [ 42 ]. The most extensive outbreak of HEV in India occurred from December 1990 to April 1991 in Kanpur. This outbreak had a significant impact, with a staggering 79,000 reported cases of clinical hepatitis [ 45 ]. Indeed, HEV outbreaks have been documented in various Asian countries, including Uzbekistan, Indonesia, Japan, Vietnam, Iraq, Pakistan, Bangladesh, Nepal, Myanmar, China, and Turkmenistan [ 46 ].

Moreover, in the United States, individuals of African descent seem to have a reduced occurrence of HEV infection. Data from the national health and nutrition examination survey (NHANES) indicate that the prevalence of anti-HEV IgG was 14.5% among non-Hispanic blacks, 22.1% among non-Hispanic whites, and 20.3% among Mexican-Americans [ 47 ]. In non-Hispanic black individuals, research has shown that the presence of specific gene polymorphisms within the apolipoprotein E gene (APOE) is associated with lower anti-HEV IgG seroprevalence. The APOE gene plays a role in regulating lipoprotein metabolism. Among individuals with these gene polymorphisms, specifically the APOE ε4 allele, there was significantly lower seropositivity for HEV compared to those with the APOE ε2 allele [ 48 ]. In South Africa, where genotype 1 of the virus has persisted, the occurrence of anti-HEV IgG was discovered to be less common among black blood donors when compared to white or mixed-race donors. This disparity suggests that there may be variations in HEV exposure and immune responses among different racial and ethnic groups in South Africa [ 49 ].

• Transmission

HEV causes widespread outbreaks of viral hepatitis transmitted through contaminated water and is the leading cause of sporadic cases of acute hepatitis and severe liver failure in these regions [ 50 ]. Transmission to humans from various species, including pigs, rabbits, deer, camels, and rats, has been well-documented for HEV strains. This typically occurs by eating raw or undercooked meat from infected animals or through direct contact with infected animals [ 51 ].

HEV is predominantly spread by the fecal-oral pathway [ 50 ]. Epidemics have a shared point of origin when the epidemic curve is markedly condensed, usually spanning approximately six to eight weeks due to contamination [ 18 ]. Studies have demonstrated that localities that consume different water supplies for drinking, particularly safeguarded well water, both before and during epidemics, do not experience the disease [ 18 ]. Epidemics can stem from the pollution of river water utilized for drinking, sewage disposal, washing, and bathing. Typically, outbreaks in these environments tend to happen in the winter months when water levels drop, leading to a rise in water contamination due to higher concentrations of contaminants [ 50 ]. Groundwater, crops, and waterways can all be subject to contamination. The act of openly in backyards and open fields can act as an extra origin of fecal pollution for groundwater, crops, and water bodies [ 18 , 52 ].

The transmission route of sporadic diseases triggered by HEV-1 and HEV-2 is also currently being studied [ 18 ]. The transmission of sporadic HEV infection within families was a rare incidence. Human infections are typically contracted through three primary pathways: direct contact with infected animals, zoonotic foodborne consumption, and environmental contamination caused by the runoff of animal waste. The spread of HEV-3 and HEV-4 via food-borne zoonotic routes has also been proposed [ 53 ]. Wild boars, sika deer, and domestic pigs play a part in the cross-infection of HEV [ 4 ]. Consuming partially cooked flesh or liver (considered a culinary delicacy in numerous nations) might be the cause of autochthonous (locally acquired) cases and outbreaks of HEV [ 54 ]. A commonly observed method of HEV transmission is the consumption of raw liver from grocery stores or Corsican figatelli sausage in Europe [ 55 ]. These livers and sausages frequently contain live HEV. Work-related contact with domestic pig farms, manure, and sewage is a notable risk for HEV infections in multiple regions [ 56 , 57 , 58 , 59 ]. It was reported that swine veterinarians had a 1.9 times higher likelihood of being seropositive for HEV compared to non-swine veterinarians [ 60 ]. Additionally, environmental contamination can result from pig slurry through various routes. Employing pig slurry as fertilizer for pastures can result in the contamination of agricultural produce such as raspberries, strawberries, and various vegetables commonly used in salads [ 61 , 62 ]. Run-off from outdoor pig farms can contaminate coastal waters [ 63 , 64 ], affecting marine life, such as fish and shellfish [ 65 ].

Despite its main focus on the liver, HEV has exhibited the ability to replicate in various tissues, resulting in extrahepatic effects like neurological symptoms, myositis, renal and hematologic complications in HEV-infected individuals [ 66 , 67 ]. Through experimental infections of animals with HEV, researchers have detected negative-strand viral RNA, a sign of continuous viral reproduction. This replication isn’t limited to the liver; it is also present in the pig’s intestinal tract, colon, and lymph nodes [ 68 ]. Similarly, rabbit models have shown negative-strand RNA intermediates in the liver, kidney, small intestine, spleen, and stomach [ 69 ].

As well, patients with HEV, whether in acute or chronic cases have presented neurological manifestations, yet the actual prevalence and the underlying pathogenic mechanisms are not definitively established [ 8 ]. Given that HEV is disseminated through the fecal-oral transmission route, it is most probable that the primary site for the virus’s initial replication is the gastrointestinal system. From there, the virus can infiltrate the bloodstream and impact other organs [ 70 , 71 ]. Furthermore, the association between HEV and kidney disorders is indicated by renal complications [ 72 , 73 ]. The recent confirmation of this link is based on the discovery of HEV in urine samples from individuals with both acute and chronic virus infections, as well as in monkeys. Furthermore, immunohistochemical evidence has revealed the existence of afflicted cells within the kidneys of these animals [ 74 ].

Overall, although HEV is primarily associated with liver infections, its ability to replicate in various tissues highlights its broader impact on human health. Ongoing research into the prevalence and mechanisms of these complications is crucial for developing targeted interventions and improving patient outcomes.

Clinical features

The clinical features of HEV infection resemble those of other hepatitis viruses and include a broad spectrum of symptoms. The prevailing form of illness is acute icteric hepatitis, usually commencing with several days of flu-like symptoms, such as fever, chills, abdominal discomfort, loss of appetite, queasiness, emesis, and diarrhea. Additional symptoms may encompass pale or clay-colored stools, darkened urine, joint pain, asthenia, and a temporary macular skin rash. Subsequently, these initial symptoms are succeeded by the development of jaundice, marked by the darkening of urine and lightening of stool color. Itchiness may also manifest. Fever and other preliminary symptoms typically wane quickly once jaundice sets in [ 75 ]. At times, HEV infection can manifest entirely without symptoms and go unnoticed. The precise frequencies of asymptomatic infection and anicteric hepatitis remain unknown but are thought to be more common than icteric disease [ 75 , 76 , 77 ]. Laboratory tests reveal elevated levels of bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma-glutamyl transferase, and alkaline phosphatase [ 78 ]. Serum aminotransferase and bilirubin levels typically commence their normalization within 6 weeks [ 77 ].

A minority of patients may encounter severe variants of the condition, including fulminant or subacute hepatic failure [ 77 ]. Pregnant women, particularly those in the second and third trimesters, are more susceptible to the virus during outbreaks and have a higher risk of complications. Additionally, HEV-infected pregnant women may witness a greater incidence of miscarriages, stillbirths, and deaths among newborns [ 79 , 80 , 81 , 82 , 83 ]. Severe liver damage can result in sub-massive or massive necrosis, causing the collapse of liver tissue [ 75 , 79 , 84 , 85 ].

Other complications associated with HEV

Hepatitis E infection has been linked to a diverse range of extra-hepatic manifestations, primarily affecting the neurological, renal, cardiac, and hematological systems [ 86 ] (Fig.  3 ). Neurological manifestations, increasingly recognized as complications of HEV infection, are the most frequent extrahepatic symptoms. Multiple neurological disorders have been reported in Europe (74%) and the Southeast Asia Region (SEAR), particularly in Bangladesh, India, and France (15%). Guillain-Barré syndrome (37%) and Neuralgic amyotrophy (39%) are the most common neurological conditions linked to HEV infection [ 87 ]. According to the systematic review by Rawla et al., neuralgic amyotrophy was observed in 102 out of 179 patients (56.98%), while Guillain-Barré syndrome was present in 36 out of 179 patients (20.11%) [ 88 ]. One patient was diagnosed with myasthenia gravis, and two others had poly-neuromyopathy. Additionally, six patients experienced mononeuritis multiplex, while five suffered from meningo-radiculitis and cerebral ischemia. Transverse myelitis was found in one patient, peripheral neuropathy in three patients, and vestibular neuritis in one patient. Lastly, one patient was affected by myositis [ 88 ]. According to the results of case report experiment, a renal transplant recipient experienced encephalopathy, unsteady walking, Lhermitte’s sign, difficulty emptying the bladder, and peripheral sensory nerve damage as a result of long-term HEV infection [ 89 ]. These findings highlight the potential involvement of the nervous and musculoskeletal systems in HEV infections, emphasizing the need for healthcare professionals to be vigilant in recognizing and monitoring these disorders in infected patients for appropriate management and treatment.

The extra-hepatic manifestations of HEV infection can be depicted as follows: HEV is associated with myocarditis and acute pancreatitis, affecting the heart and pancreas respectively. Neurological and hematological symptoms include Guillain-Barré syndrome, Bell’s palsy, neuralgic amyotrophy, thrombocytopenia, hemolytic anemia, and aplastic anemia. Additionally, skeletal-related manifestations of HEV infection can result in polyarthritis [ 73 , 79 , 86 , 90 , 93 , 195 , 196 , 197 , 198 , 199 , 200 , 201 , 202 , 203 , 204 , 205 , 206 , 207 , 208 ]

A study was conducted to report the extra-hepatic manifestations of hepatitis E virus through a retrospective review of data from 106 cases of autochthonous hepatitis E (105 acute and 1 chronic) [ 90 ]. Eight cases (7.5%) presented with neurological syndromes, including brachial neuritis, Guillain-Barré syndrome, peripheral neuropathy, neuromyopathy, and vestibular neuritis. One patient had a cardiac arrhythmia, twelve patients (11.3%) had thrombocytopenia, fourteen (13.2%) had lymphocytosis, and eight (7.5%) had lymphopenia, none of which had any clinical consequences. Moreover, monoclonal gammopathy was documented in seventeen cases (26%) [ 90 ].

Additionally, in other studies, a 32-year-old male with acute HEV infection was reported to have leukocytosis [ 91 ]. Another case involved a 48-year-old male who experienced massive hemolysis, leading to renal failure, also associated with acute HEV infection [ 92 ]. Long QT syndrome (LQTS) and Torsades de Pointe (TdPe) (a specific type of ventricular tachycardia( were observed in one case involving a 62-year-old woman with acute HEV infection [ 93 ]. The observation of this unusual case highlights the importance of our awareness and understanding of the mechanisms behind LQTS, which will aid in identifying at-risk patients and minimizing their exposure to risk factors.

The occurrence of acute pancreatitis due to HEV infection is uncommon. Somani et al. describe a case where severe acute pancreatitis developed in a 35-year-old man with jaundice lasting one week. His serum tested positive for IgM anti-HEV and negative for hepatitis A, B, and C viruses. Despite undergoing hemodialysis and blood transfusion, the patient experienced refractory hypotension and did not respond to inotropic medications. His condition rapidly deteriorated, leading to a fatal outcome. This case illustrates that hepatitis E virus infection can lead to severe acute pancreatitis accompanied by multiorgan failure [ 94 ].

These results indicate that a range of extra-hepatic manifestations can occur with hepatitis E. However, it’s important to mention that most of these disorders were observed in isolated cases or limited numbers of patients. Further investigations are needed to enhance our knowledge of the pathogenesis, clinical characteristics, and optimal management strategies for HEV-related digestive system disorders.

Vulnerability to HEV infection

Susceptibility to HEV infection is influenced by various factors. In nations where the disease is widespread and where transmission primarily occurs through the fecal/oral route, the availability of safe public water supplies and effective waste management systems is essential [ 95 ]. While race does not appear to influence HEV infection, there is a notable geographical bias [ 96 ]. Tropical and subtropical countries with poor socioeconomic and hygienic conditions are more prone to HEV outbreaks. Asia, Africa, and Mexico have experienced epidemics, while Latin America, industrialized areas, and certain European countries have not reported outbreaks except for Mexico [ 97 , 98 , 99 , 100 , 101 ]. Bolivia, Chile, Cuba, and Mexico have endemic HEV [ 96 ]. Second, a sex-related bias is observed in HEV infection, with males being at higher risk of developing clinical hepatitis in contrast to females [ 96 ]. The gender distribution among adults varies from an equal 1:1 ratio to a 3:1 ratio, favoring males [ 96 ]. The causes for this bias are not well understood, but they may be linked to occupational and social roles. However, children with clinical HEV do not show a sex bias [ 96 , 99 ].

Third, age is a factor in HEV infection rates and clinical disease. During HEV epidemics, individuals aged 15 to 40 have the highest infection and clinical disease rates. Children generally have lower infection rates and are less likely to be affected by clinical HEV compared to adults [ 102 , 103 ]. Studies in India and Vietnam indicate that children under 10 have a lower prevalence of HEV, although acute HEV can still occur in children, albeit rarely [ 96 ].

Fourth, pregnant women are especially at risk of developing severe illness if they contract HEV. Pregnant women affected by HEV displayed pooled Case Fatality Rates (CFRs) of 20.8% [ 104 ]. Pregnant women infected with the virus are at a higher risk of developing fulminant hepatic failure (FHF) and experiencing adverse outcomes such as abortion, premature delivery, or neonatal death. Several factors contribute to the heightened susceptibility and seriousness of HEV infection among pregnant women [ 80 ].

Hormonal and immunological changes throughout pregnancy could influence the seriousness of HEV infection, even though there is a lack of supporting data. Limited access to adequate medical care and nutrition in developing countries further contributes to higher maternal morbidity and mortality associated with HEV [ 105 ]. The compromised immune system of pregnant women, combined with factors like malaria, parasitic infections, and other viral and bacterial infections that are widespread in developing countries, weaken their immune response, making them more susceptible to HEV infection [ 105 , 106 ]. Therefore, those who live in tropical and subtropical areas with poor socioeconomic and hygienic circumstances, as well as men, people in their 15–40 s, and pregnant women are susceptible to HEV infection [ 96 ].

Immune responses

HEV infection can become chronic in immunocompromised cases (e.g. HIV cases, recipients of organ transplants, hematologic malignant conditions) [ 107 , 108 , 109 ]. Studies show reduced CD2, CD3, and CD4 lymphocytes in transplant recipients who develop chronic HEV compared to those who resolve the infection [ 107 ]. This suggests that compromised T-cell responses in immunocompromised individuals can hinder the elimination of the virus, leading to a persistent HEV infection [ 110 ]. Research have shown that it is the immune response, as opposed to direct harm to hepatocytes by the virus, that likely underlies the expression of HEV symptoms, such as self-limiting acute viral hepatitis (AVH) and acute liver failure (ALF) [ 111 ]. The concurrent appearance of icteric symptoms, an increase in antibodies, and a reduction in viral load support this idea [ 112 ]. In a study on HEV-induced acute hepatitis, elevated levels of anti-HEV IgM and IgG antibodies discovered. Individuals experiencing liver failure showed increased levels of gamma interferon (IFN-γ), tumor necrosis factor alpha (TNF-α), interleukin-2 (IL-2), and IL-10 compared to those with self-limiting acute hepatitis. Remarkably, HEV RNA was present in cases of AVH but not in individuals with liver failure. Given that most ALF patients developed encephalopathy and underwent testing within a fortnight of symptom onset, and patients with AVH were sampled about 14 days after symptom onset, the absence of HEV RNA in liver failure cases is unlikely to be solely attributed to the time between disease onset and sampling. These findings suggest that both Th1- and Th2-type immune responses may contribute in the development of liver failure in symptomatic HEV patients [ 113 ].

NK and T-cells are crucial in the immune response to HEV infection. A study on acute HEV infection compared to healthy individuals, observed that HEV patients exhibited reduced percentages of CD3+/CD69+/IFN-γ and CD3+/CD69+/TNF-α, along with elevated proportions of CD4 + cells. Interestingly, the quantities of CD69+/IL-4 cells and CD8 + cells showed no significant difference between HEV patients and healthy individuals. It is suggested that the increase in CD4 + cells in patients may signal an augmentation in the population of NK cells [ 114 ]. A study on acute HEV patients revealed reduced proportions of NK and NKT cells among MCs in HEV patients compared to controls. However, there was a significantly higher proportion of activated NK cells in patients. The decrease in the total count of NK and NKT cells in PBMCs (peripheral blood mononuclear cells) could result from the specific accumulation or apoptosis of these cells in the livers of infected individuals. It is suggested that the decreased presence of NK cells in pregnant women may contribute to their increased vulnerability to severe HEV, as it diminishes their capacity to eliminate the virus from the liver [ 115 ].

The proliferation of CD4 + T cells producing IFN- γ and TNF-α in HEV patients also contributes to restricting HEV replication and assisting in the resolution of the infection. The increase in disease severity has an inverse correlation with the expansion of T cells producing cytokines specific to the antigen. Individuals experiencing disease exhibited diminished proliferation of CD4 + T cells when stimulated by pORF3, leading to decreased levels of IFN-γ and TNF-α production in contrast to those with mild disease. As these cytokines are recognized for their role in regulating viral replication, the absence of an increase in HEV-specific T cells producing cytokines in patients with fulminant HEV might lead to immune system failure in controlling HEV replication, resulting in more extensive liver injury. Recent research has supported this idea, as it reveals higher levels of HEV-RNA in the bloodstream of patients with fulminant HEV, in contrast to individuals with uncomplicated disease [ 116 ]. TNF-α not only contributes to hepatocyte death but also plays a role in liver tissue regeneration. Studies have shown that the TNF-α-mediated nuclear factor (NF)-kB pathway plays a role in the process of liver regeneration, a vital process for recovering liver function post-injury. As a result, a less robust TNF-α reaction in fulminant HEV might obstruct the recovery procedure [ 117 , 118 , 119 ].

Most patients become anti-HEV IgG positive over time, but the duration of IgG persistence remains unknown due to variations in sensitivity among different enzyme-linked immunosorbent assay (ELISA) assays. Nevertheless, in India, anti-HEV IgG can be identified for a minimum of 14 years after the outbreak [ 120 ]. Patients with uncomplicated HEV had a higher anti-HEV IgG-secreting cells compared to healthy controls [ 119 ]. The count of these cells was notably greater in individuals with fulminant HEV when compared to those with uncomplicated disease. B cells producing antigen-specific IgG were assessed by stimulating PBMCs with polyclonal agents. These findings represent the complete population of HEV-specific memory B cells, offering an indirect indication of antigen-specific IgG levels after HEV exposure. The link between memory B-cells and illness severity suggests these cells and anti-HEV antibodies may cause liver damage in HEV cases [ 119 ].

MicroRNA (miRNAs)

With a high degree of conservation, microRNAs (miRNAs) are classified as small non-coding RNAs and make up approximately 1% of the human genome. They possess the capacity to interact with approximately 60% of messenger RNAs (mRNAs) [ 121 ]. Besides viral transcripts, HEV is also capable of producing diverse miRNAs. The investigation of these miRNAs has predominantly hinged on predictive models, which are then confirmed through experimental validation using either in vivo or in vitro infection models. The lack of a suitable infectious model for HEV, characterized by slow replication in cell-cultured systems, has been a significant challenge in this research [ 122 ]. Nine potential HEV-miRNAs for HEV-1 have been revealed through predictive computational modeling, known as HEV-MD1, -MD2, -MD3, -MD31, -MD35, -MD39, -MR9, -MR10 and, -MR25 [ 123 ]. It has been proposed that the potential target sites for these HEV-miRNAs can be found at both the 3’-end and 5’-end of human mRNA. It is predicted that these HEV-miRNAs will specifically interact with genes involved in lipid and nitrogen metabolism, transmembrane transport, cellular differentiation, membrane organization, chromosome organization, and cell-cell signaling [ 123 ]. HEV is present in a state where it is enveloped within the liquid above cell cultures that are infected, as well as in the blood of individuals who have acute HEV infection. This finding implies that the virus might utilize these miRNAs to facilitate the process of envelopment and dissemination of its offspring within the host [ 26 ]. For instance, there have been forecasts suggesting that HEV-MD2 plays a role in controlling the synthesis of cyclin G-associated kinase (GAK), a pivotal element in clathrin trafficking and receptor signaling [ 123 , 124 ].

Until now, the primary miRNAs that have been thoroughly studied for their impact on HEV replication are miR-122 and miR-214 [ 125 , 126 ]. The gene encoding miR-122 is located on chromosome 18 within the human genome [ 127 ]. The miRNA identified as the most abundant in the human liver has been extensively studied for its involvement in cholesterol metabolism, liver cell differentiation, and the development of liver diseases such as hepatocellular carcinoma triggered by HCV and HBV [ 128 , 129 ]. The interaction between miRNA-122 and the virus has a significant impact on viral replication. Specifically, the direct complementarity between miRNA-122 and a specific binding site on the viral genome, usually found in the RdRp region of the ORF1 gene, enhances viral replication [ 126 ]. Research has highlighted differences in the expression levels of certain miRNAs in HEV RNA-positive individuals when compared to negative blood donors. Specifically, these miRNAs include miR-1285, 151-3p, 302b, 526b, 520b, 627-5p, 628-3p, and 365 [ 130 ]. Furthermore, pregnant women with acute self-limiting HEV-1 infection exhibited a distinct expression pattern when compared to non-pregnant women. The presence of miR-188, 365a, 190b, 365b, 374c, 450a-1, 450b, 4482, 450a-2, 616, 2115, 580, 504, 3117, 4772, and 5690 was identified, enabling differentiation between acute infection, self-limiting acute infection, and acute liver failure [ 131 ](Table  1 ).

HEV diagnosis is achievable using direct or indirect testing techniques. Direct diagnosis involves the measurement of HEV RNA in blood or stool samples, while indirect diagnosis is based on identifying the host’s immune response to HEV infection [ 73 ]. The diagnosis often involves employing nucleic acid amplification techniques (NATs) to analyze HEV RNA in biological specimens like stools, serum, and liver biopsy [ 133 ]. Direct methods identify viral particles, proteins, or nucleic acids in the samples by RT-PCR and immune-electron microscopy. Moreover, indirect tests have elevated sensitivity than anti-HEV IgM and IgG [ 134 ].

Optimal diagnosis of acute HEV infection is achieved by combining serological testing and NAT assays [ 135 ]. Indirect diagnosis involves the display of IgM and IgG anti-HEV antibodies in the serum using ELISA. The presence of IgM antibodies indicates acute infection and becoming detectable four days after jaundice begins [ 133 ]. Enzyme immunoassays rely on detection of anti-HEV antibodies or HEV capsid antigen. However, HEV antigen can remain for months after ribavirin clears HEV RNA, suggesting it doesn’t indicate infectious virions, thus its diagnostic role is unclear [ 3 ]. Anti-HEV IgM levels reach their peak at clinical presentation and remain relatively high for about 8 weeks, but subsequently decline rapidly. On the other hand, HEV IgG levels increase after the onset of symptoms, peak at approximately 4 weeks, and are retained at a high level for over a year [ 135 ].

The “gold standard” for confirming acute HEV infection is by identifying HEV RNA in biological samples like serum and feces [ 134 , 135 ]. HEV RNA is detectable in fecal samples from the onset of symptoms and for up to six weeks thereafter, as well as in serum for four weeks from the start of the illness. Nevertheless, the accuracy of molecular tests for detecting HEV RNA depends on early patient presentation, timely sample collection, and appropriate transport and processing. Since viral RNA quantities may be minimal, and the timeframe for detecting HEV can be limited, the lack of detectable viral RNA does not necessarily indicate the absence of HEV infection [ 133 , 136 ]. In most of the commercially accessible tests for detecting HEV RNA, the NAT technique is used. This technique comprises reverse transcriptase-polymerase chain reaction (RT-PCR), real-time PCR, and the loop-mediated isothermal amplification assay [ 137 , 138 ].

In conclusion, the diagnosis of HEV involves a combination of direct and indirect testing methods. Direct tests detect HEV RNA, while indirect tests measure the immune response through the identification of specific antibodies. Detecting HEV RNA in biological samples is considered the gold standard for confirming acute HEV infection. Nevertheless, it’s essential to take into account the limitations and the timing of these diagnostic approaches [ 133 , 135 , 139 ].

Since the HEV infection is may self-limiting, most patients do not require specific treatment. Hospitalization in an intensive care unit is imperative for individuals suffering from acute or acute-on-chronic liver failure. Interventions to address cerebral edema must be implemented, and there may be a need for liver transplantation [ 5 ]. At present, there are no approved medications for HEV treatment, but patients receive broad-spectrum antiviral drugs, such as PegIFN2alpha and ribavirin [ 140 ].

Ribavirin is given orally twice a day, starting with a daily dose of 600 to 1000 mg, which varies based on the patient’s hemoglobin level and comorbidities. If the hemoglobin level decreases or patients experience symptoms related to anemia, the dosage is decreased. Typically, the intended treatment duration for chronic HEV is 5 months, based on earlier reports suggesting that a shorter treatment period of 3 months could lead to viral relapse [ 141 ]. A 3-month treatment regimen of pegylated interferon therapy (weekly dose of 135 µg) was administered to a kidney transplant patient under hemodialysis with chronic HEV infection and successfully attained sustained viral response [ 142 ]. In the case of solid organ transplant (SOT) patients with chronic infection, the initial approach to treatment involves reducing immunosuppressive therapy, specifically medications that affect T-cell function. If HEV is not successfully cleared, the next step is administering ribavirin as the sole therapy [ 143 ].

Pegylated-interferon-α has proven effective in the treatment of certain liver transplant recipients, and a hemodialysis patient managed to achieve HEV clearance after a three-month treatment regimen. Nevertheless, it is generally not recommended to use interferon for individuals who have undergone kidney, pancreas, heart, or lung transplants. This is because interferon can activate the immune system and enhance the risk of acute rejection [ 144 , 145 ].

Treatment failure

A systematic review and meta-analysis on chronic HEV cases (395 cases) reported a 78% sustained virological response (SVR) with ribavirin administration. Rapid virological response (RVR) was achieved by 25%, while relapse was observed in 18% of cases. Second ribavirin treatment caused a 76% SVR [ 146 ]. Although ribavirin is the key treatment for HEV infection, examination of the evolutionary changes within the HEV population inside a host showed that ribavirin efficacy could be compromised and cause treatment failures [ 147 ]. HEV genome alterations were observed, particularly during ribavirin monotherapy in infected patients [ 148 ]. In a chronically HEV-infected patient who failed ribavirin treatment due to a fully resistant phenotype, the Y1320H, K1383N, and G1634R mutations in the viral RdRp were linked to ribavirin resistance. In vitro investigation showed that the Y1320H and G1634R mutations and the hypervariable region insertion increased viral replication [ 149 ]. In line with previous studies, research confirmed that the Y1320H mutation increases viral replication during acute HEV-3ra infection in rabbits [ 150 ]. However, study on solid-organ transplant cases with chronic HEV yielded divergent results, asserting that the presence of the 1634R variant at the onset of ribavirin treatment does not confer complete resistance to ribavirin. Among 63 patients, 42 achieved SVR while 21 did not, with the 1634R variant detected in 36.5% (23/63) of cases. The 1634R variant was found in 31% of baseline plasma samples of SVR cases and in 47.6% of non-SVR cases. This mutation did not affect the initial drop in viral RNA, and a second extended ribavirin treatment resulted in SVR in 70% of the non-SVR patients, despite the mutation [ 151 ]. In the context of HEV genetic heterogeneity induced by ribavirin, Meister et al. reported that the single-nucleotide variant (SNV) in ORF2 of HEV caused by ribavirin, generates defective HEV particles that act as immune decoys. The SNV of HEV ORF2 resulted in smaller, noninfectious particles, capable of interfering with antibody neutralization. This variant may act as an immune decoy despite its loss of infectiousness [ 152 ].

Given HEV’s global spread and its potential to cause large outbreaks in low-income countries, there is an urgent need for a widely available HEV vaccine [ 153 ]. Initial findings from the inaugural human trial carried out at the Walter Reed Army Institute of Research in the US recommended that the recombinant HEV (rHEV) vaccine was both safe and immunogenic. The vaccine consists of polypeptide from insect cells (Sf9) infected with recombinant baculoviruses encompassing a ORF2 of HEV from a 1987 outbreak in Sargodha, Pakistan [ 154 ]. The rHEV vaccine was evaluated in 1,794 healthy adults from Nepal who were vulnerable to HEV infection, in 3 doses (at months 0, 1, and 6). The vaccine had an efficacy rate of 95.5% [ 155 ].

Several potential HEV vaccines are presently under development. Nevertheless, Hecolin ® is the sole licensed vaccine accessible in China since 2012. It consists of a recombinant truncated ORF2 protein HEV239 (aa368-606) that includes 23 nm VLPs which expressed in Escherichia coli [ 156 ]. It has undergone multiple clinical trials involving the application of three doses at intervals of 0, 1, and 6 months. In the phase III clinical study that included 48,693 in vaccine group and 48,663 in placebo group ranging from 16 to 65 years of age, it was proven that this vaccine is effective and few and mild side effects related to it were reported [ 157 ]. A recent clinical trial showed Hecolin’s safety and immunogenicity, with all participants seroconverting after one month and maintaining IgG responses through six months [ 158 ].

In addition to Hecolin, several candidate vaccines for HEV are presently in development, and they primarily focus on the ORF2 structural capsid protein, which envelops the viral particles [ 156 ]. Multiple expression systems are utilized during the advancement of these vaccines [ 159 , 160 ]. A limited number of vaccines are currently in development to offer combined protection against two separate pathogens: hepatitis E and A including HE vaccine HEVp179 and inactivated HA vaccine [ 161 ]. Nonetheless, only a single vaccine for HEV has obtained licensing for use in China [ 162 ]. Further investigation is needed to establish its effectiveness in populations at high risk, particularly pregnant women, utilizing fast-tracked vaccine schedules that are appropriate for circumstances involving an outbreak [ 163 ].

Development of new drug

Ribavirin clears the HEV just in 80% of treated patients and, like pegylated interferon-alpha, is unsuitable for use in pregnancy, underscoring the urgent need for alternative therapies [ 164 ]. Sofosbuvir is a prodrug that undergoes triphosphorylation within cells and functions as an analogue of the uridine nucleotide [ 165 ]. It is a candidate for HEV treatment that showed inconclusive efficacy [ 164 ]. Dao Thi et al. reported that Sofosbuvir could hinder the replication of G3-HEV in subgenomic replicon systems and full-length infectious clones and pairing Sofosbuvir with Ribavirin enhances the antiviral impact [ 166 ]. However, a Phase II pilot study on 9 patients indicated that using Sofosbuvir alone doesn’t successfully eliminate HEV RNA in patients suffering from chronic HEV and exhibited just a modest anti-HEV efficacy [ 167 ]. Moreover, André et al. found that a single amino acid change (A1343V) in the ORF1 region of HEV may reduce the effectiveness of sofosbuvir treatment in 8 out of 9 patients [ 168 ]. In the context of screening leading drug repurposing, Guo et al. identified vidofludimus calcium and pyrazofurin as new HEV treatments. Both drugs effectively suppress HEV replication in human primary liver organoids, reducing the pyrimidine nucleotide pool, enhancing the antiviral effects of IFN-α against HEV, and successfully inhibiting HEV mutants (Y1320H, G1634R) associated with ribavirin treatment failure [ 169 ]. The nucleoside analogue 2’-C-methylcytidine effectively blocked HEV replication and maintained its potency over long-term use. Nevertheless, combining it with Ribavirin has counterproductive effects [ 170 ]. NITD008 is an adenosine nucleoside analogue that acts as an RdRp inhibitor and could be HEV treatment. It showed less effectiveness in cells derived from neurons compared to those from hepatoma [ 171 ]. In another study, favipiravir (polymerase inhibitor), when used together with sofosbuvir, had an additive impact against HEV and inhibited HEV RNA copies by nearly 90% [ 172 ]. Efforts to discover alternative treatments for cases where ribavirin is ineffective will persist.

Control measures

The prevention of HEV infections can be accomplished through primary approaches such as access to clean drinking water, managing human waste properly, promoting good personal hygiene practices and generating immunity via vaccination [ 5 ]. In developed nations, prevention is a more intricate process due to multiple routes of infection that are not fully understood. However, there are several recommended approaches It is recommended to cook meat products thoroughly, follow proper handling procedures for raw meat. As well, vaccination against HEV has become a realistic possibility [ 173 ].

To avoid HEV infection, safeguarding water supplies, and appropriate removal of human feces is of utmost importance. In outbreak settings, it’s essential to adhere to strict sanitation protocols, boiling and chlorination of water. Enhancements in the storage, treatment, and distribution of drinking water, along with improved community sanitation and sewage control, can contribute to a reduction in HEV transmission. In high-risk communities, promoting knowledge about personal and environmental hygiene for better health is equally significant. Surveillance for HEV can aid in early outbreak identification and recommendation of prophylactic measures. Chlorination water supplies and boiling importing drinking water during suspected HEV epidemics are additional preventive measures [ 5 , 174 ]. However, it is important to note that there have been instances where the introduction of chlorine into the water distribution system during an HEV epidemic, such as the one in Darfur, Sudan in 2004, was found to be insufficient to preventing new infections [ 175 ]. Travelers to endemic regions should implement habits like staying away from untreated drinking water, avoiding iced beverages of unknown quality, and refraining from consuming raw shellfish, fruits, or vegetables. Vaccines for HEV are obtainable in China, but they lack FDA endorsement and research on immunoglobulin prophylaxis for HEV prevention is controversial [ 83 , 176 ].

Future perspectives

Hepatitis E is a public health concern, especially in developing countries with poor sanitation. In the context of HEV diagnosis, HEV RNA is present in the blood and stool for a relatively short period, making timely PCR testing crucial for accurate detection. Additionally, diagnosing HEV in transplant patients using serological methods can be challenging due to the effects of immunosuppressive drugs. Improved diagnostic capabilities and increased awareness about this infection will likely lead to better detection and reporting of HEV cases. The HEV vaccine (Hecolin) is currently available, and ongoing research aims to expand vaccination availability globally. Hecolin is administered in a three-dose schedule, providing longer duration of immunity and higher efficacy. However, in developing countries with poor sanitation where HEV is endemic, adhering to a multi-dose schedule can be challenging. These regions often face limited access to healthcare facilities, logistical difficulties, and increased costs related to vaccine storage, transportation, and administration. Developing a single-dose vaccine with long-term immunity and high efficacy could overcome these obstacles and significantly aid in eradicating the virus in the future. Research into antiviral treatments specifically targeting HEV is ongoing. Future breakthroughs could offer effective treatment options for those infected, particularly immunocompromised individuals or patients who have not responded to ribavirin treatment. Enhanced management protocols for HEV, especially during pregnancy and for patients with chronic infections, could improve outcomes. Improved sanitation and access to clean water in developing countries will be crucial in reducing HEV transmission. Understanding the genotypic variability and pathogenesis of HEV will aid in developing targeted interventions and treatments. Research on zoonotic transmission of HEV from animals to humans can lead to better control measures in both agricultural and food industries. However, despite advancements, complete eradication of HEV faces challenges due to its zoonotic nature and the need for widespread vaccine coverage and improved global sanitation.

Data availability

No datasets were generated or analysed during the current study.

Khuroo MS. Discovery of Hepatitis E: the epidemic non-A, non-B hepatitis 30 years down the memory lane. Virus Res. 2011;161(1):3–14.

Article   CAS   PubMed   Google Scholar  

von Wulffen M, Westhölter D, Lütgehetmann M, Pischke S. Hepatitis E: still waters run deep. J Clin Translational Hepatol. 2018;6(1):40.

Google Scholar  

Aslan AT, Balaban HY. Hepatitis E virus: epidemiology, diagnosis, clinical manifestations, and treatment. World J Gastroenterol. 2020;26(37):5543.

Article   CAS   PubMed   PubMed Central   Google Scholar  

Zahmanova G, Takova K, Lukov GL, Andonov A. Hepatitis E Virus in domestic ruminants and virus excretion in Milk—A potential source of zoonotic HEV infection. Viruses. 2024;16(5):684.

Aggarwal R, Jameel S. Hepatitis E. Hepatology. 2011;54(6):2218–26.

Article   PubMed   Google Scholar  

Payne C, Ellis T, Plant S, Gregory A, Wilcox G. Sequence data suggests big liver and spleen disease virus (BLSV) is genetically related to hepatitis E virus. Vet Microbiol. 1999;68(1–2):119–25.

Dalton HR, Kamar N, Baylis SA, Moradpour D, Wedemeyer H, Negro F. EASL Clinical Practice guidelines on Hepatitis E virus infection. J Hepatol. 2018;68(6):1256–71.

Article   Google Scholar  

Belei O, Ancusa O, Mara A, Olariu L, Amaricai E, Folescu R, et al. Current paradigm of hepatitis E virus among pediatric and adult patients. Front Pead. 2021;9:721918.

Fernández Villalobos NV, Kessel B, Rodiah I, Ott JJ, Lange B, Krause G. Seroprevalence of hepatitis E virus infection in the Americas: estimates from a systematic review and meta-analysis. PLoS ONE. 2022;17(6):e0269253.

Article   PubMed   PubMed Central   Google Scholar  

Li P, Liu J, Li Y, Su J, Ma Z, Bramer WM, et al. The global epidemiology of hepatitis E virus infection: a systematic review and meta-analysis. Liver Int. 2020;40(7):1516–28.

Zahmanova G, Takova K, Tonova V, Koynarski T, Lukov LL, Minkov I, et al. The re-emergence of Hepatitis E Virus in Europe and Vaccine Development. Viruses. 2023;15(7):1558.

Kenney SP, Meng X-J. Therapeutic targets for the treatment of hepatitis E virus infection. Expert Opin Ther Targets. 2015;19(9):1245–60.

Buescher G, Ozga AK, Lorenz E, Pischke S, May J, Addo MM, et al. Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and meta-analysis. Liver Int. 2021;41(3):449–55.

Carratalà A, Joost S. Population density and water balance influence the global occurrence of hepatitis E epidemics. Sci Rep. 2019;9(1):10042.

Santos-Silva S, López-López P, Gonçalves HM, Rivero-Juarez A, Van der Poel WH, Nascimento MSJ, et al. A systematic review and Meta-analysis on Hepatitis E Virus Detection in Farmed ruminants. Pathogens. 2023;12(4):550.

Ali MM, Gul M, Imran M, Ijaz M, Azeem S, Ullah A, et al. Molecular identification and genotyping of hepatitis E virus from Southern Punjab. Pakistan Sci Rep. 2024;14(1):223.

Primadharsini PP, Nagashima S, Okamoto H. Genetic variability and evolution of hepatitis E virus. Viruses. 2019;11(5):456.

Khuroo MS, Khuroo MS, Khuroo NS. Transmission of Hepatitis E Virus in developing countries. Viruses. 2016;8(9):253.

Vitral CL, da Silva-Nunes M, Pinto MA, de Oliveira JM, Gaspar AMC, Pereira RCC, et al. Hepatitis A and E seroprevalence and associated risk factors: a community-based cross-sectional survey in rural Amazonia. BMC Infect Dis. 2014;14:1–9.

Berke T, Matson D. Reclassification of the Caliciviridae into distinct genera and exclusion of hepatitis E virus from the family on the basis of comparative phylogenetic analysis. Arch Virol. 2000;145:1421–36.

Emerson SU, Nguyen H, Graff J, Stephany DA, Brockington A, Purcell RH. In vitro replication of hepatitis E virus (HEV) genomes and of an HEV replicon expressing green fluorescent protein. J Virol. 2004;78(9):4838–46.

King AM, Lefkowitz E, Adams MJ, Carstens EB. Virus taxonomy: ninth report of the International Committee on Taxonomy of viruses. Elsevier; 2011.

Nerc J, Szeleszczuk P. Classification, structure and molecular diagnostics of avian hepatitis E virus. 2019.

Yamashita T, Mori Y, Miyazaki N, Cheng RH, Yoshimura M, Unno H et al. Biological and immunological characteristics of hepatitis E virus-like particles based on the crystal structure. Proceedings of the National Academy of Sciences. 2009;106(31):12986-91.

Kelly AG, Netzler NE, White PA. Ancient recombination events and the origins of hepatitis E virus. BMC Evol Biol. 2016;16:1–18.

Wang B, Meng X-J. Structural and molecular biology of hepatitis E virus. Comput Struct Biotechnol J. 2021;19:1907–16.

Parvez MK. Geometric architecture of viruses. World J Virol. 2020;9(2):5.

Dong J, Dong L, Méndez E, Tao Y. Crystal structure of the human astrovirus capsid spike. Proc Natl Acad Sci. 2011;108(31):12681–6.

Prpić J, Baymakova M. Hepatitis E virus (HEV) infection among humans and animals: epidemiology, clinical characteristics, treatment, and prevention. MDPI; 2023. p. 931.

Purdy MA, Drexler JF, Meng X-J, Norder H, Okamoto H, Van der Poel WH, et al. ICTV virus taxonomy profile: Hepeviridae 2022. J Gen Virol. 2022;103(9):001778.

Article   CAS   Google Scholar  

Di Profio F, Sarchese V, Palombieri A, Fruci P, Lanave G, Robetto S, et al. Current knowledge of hepatitis E virus (HEV) epidemiology in ruminants. Pathogens. 2022;11(10):1124.

Kamani L, Padhani ZA, Das JK, Hepatitis E. Genotypes, strategies to prevent and manage, and the existing knowledge gaps. JGH Open. 2021;5(10):1127–34.

Proudfoot A, Hyrina A, Holdorf M, Frank AO, Bussiere D. First crystal structure of a nonstructural hepatitis E viral protein identifies a putative novel zinc-binding protein. J Virol. 2019;93(13). https://doi.org/10.1128/jvi . 00170 – 19.

Nair VP, Anang S, Subramani C, Madhvi A, Bakshi K, Srivastava A, et al. Endoplasmic reticulum stress induced synthesis of a novel viral factor mediates efficient replication of genotype-1 hepatitis E virus. PLoS Pathog. 2016;12(4):e1005521.

Graff J, Torian U, Nguyen H, Emerson SU. A bicistronic subgenomic mRNA encodes both the ORF2 and ORF3 proteins of hepatitis E virus. J Virol. 2006;80(12):5919–26.

Magden J, Takeda N, Li T, Auvinen P, Ahola T, Miyamura T, et al. Virus-specific mRNA capping enzyme encoded by hepatitis E virus. J Virol. 2001;75(14):6249–55.

Yin X, Li X, Ambardekar C, Hu Z, Lhomme S, Feng Z. Hepatitis E virus persists in the presence of a type III interferon response. PLoS Pathog. 2017;13(5):e1006417.

Ju X, Ding Q. Hepatitis E virus assembly and release. Viruses. 2019;11(6):539.

Meng X, Hepatitis E. Virus: animal reservoirs and zoonotic risk. Vet Microbiol. 2010;140(3–4):256–65.

Song Y-J, Park W-J, Park B-J, Lee J-B, Park S-Y, Song C-S, et al. Hepatitis E virus infections in humans and animals. Clin Experimental Vaccine Res. 2014;3(1):29–36.

Lee G-H, Tan B-H, Teo EC-Y, Lim S-G, Dan Y-Y, Wee A, et al. Chronic infection with camelid hepatitis E virus in a liver transplant recipient who regularly consumes camel meat and milk. Gastroenterology. 2016;150(2):355–7. e3.

Nelson KE, Labrique AB, Kmush BL. Epidemiology of genotype 1 and 2 hepatitis E virus infections. Cold Spring Harbor Perspect Med. 2019;9(6):a031732.

Bouamra Y, Gérolami R, Arzouni J-P, Grimaud J-C, Lafforgue P, Nelli M, et al. Emergence of autochthonous infections with hepatitis E virus of genotype 4 in Europe. Intervirology. 2013;57(1):43–8.

Khuroo MS. Discovery of Hepatitis E and its impact on global health: a journey of 44 years about an incredible human-interest story. Viruses. 2023;15(8):1745.

Naik S, Aggarwal R, Salunke P, Mehrotra N. A large waterborne viral hepatitis E epidemic in Kanpur, India. Bull World Health Organ. 1992;70(5):597.

CAS   PubMed   PubMed Central   Google Scholar  

Hakim MS, Wang W, Bramer WM, Geng J, Huang F, de Man RA, et al. The global burden of hepatitis E outbreaks: a systematic review. Liver Int. 2017;37(1):19–31.

Kuniholm MH, Purcell RH, McQuillan GM, Engle RE, Wasley A, Nelson KE. Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988–1994. J Infect Dis. 2009;200(1):48–56.

Zhang L, Yesupriya A, Chang MH, Teshale E, Teo CG. Apolipoprotein E and protection against hepatitis E viral infection in American non-hispanic blacks. Hepatology. 2015;62(5):1346–52.

Lopes T, Cable R, Pistorius C, Maponga T, Ijaz S, Preiser W, et al. Racial differences in seroprevalence of HAV and HEV in blood donors in the Western Cape, South Africa: a clue to the predominant HEV genotype? Epidemiol Infect. 2017;145(9):1910–2.

Khuroo M, Hepatitis E. the enterically transmitted non-A, non-B hepatitis. 1991.

Wang B, Meng X-J. Hepatitis E virus: host tropism and zoonotic infection. Curr Opin Microbiol. 2021;59:8–15.

Fenaux H, Chassaing M, Berger S, Gantzer C, Bertrand I, Schvoerer E. Transmission of hepatitis E virus by water: an issue still pending in industrialized countries. Water Res. 2019;151:144–57.

Yugo DM, Meng X-J, Hepatitis. E virus: foodborne, waterborne and zoonotic transmission. Int J Environ Res Public Health. 2013;10(10):4507–33.

Miyashita K, Kang JH, Saga A, Takahashi K, Shimamura T, Yasumoto A, et al. Three cases of acute or fulminant hepatitis E caused by ingestion of pork meat and entrails in Hokkaido, Japan: zoonotic food-borne transmission of hepatitis E virus and public health concerns. Hepatol Res. 2012;42(9):870–8.

Colson P, Borentain P, Queyriaux B, Kaba M, Moal V, Gallian P, et al. Pig liver sausage as a source of hepatitis E virus transmission to humans. J Infect Dis. 2010;202(6):825–34.

Bouwknegt M, Engel B, Herremans M, Widdowson M, Worm H, Koopmans M, et al. Bayesian estimation of hepatitis E virus seroprevalence for populations with different exposure levels to swine in the Netherlands. Epidemiol Infect. 2008;136(4):567–76.

Rutjes SA, Lodder WJ, Lodder-Verschoor F, Van den Berg HH, Vennema H, Duizer E, et al. Sources of hepatitis E virus genotype 3 in the Netherlands. Emerg Infect Dis. 2009;15(3):381.

Sarno E, Martin A, McFarland S, Johne R, Stephan R, Greiner M. Estimated exposure to hepatitis E virus through consumption of swine liver and liver sausages. Food Control. 2017;73:821–8.

Walachowski S, Dorenlor V, Lefevre J, Lunazzi A, Eono F, Merbah T, et al. Risk factors associated with the presence of hepatitis E virus in livers and seroprevalence in slaughter-age pigs: a retrospective study of 90 swine farms in France. Epidemiol Infect. 2014;142(9):1934–44.

Taus K, Schmoll F, El-Khatib Z, Auer H, Holzmann H, Aberle S, et al. Occupational swine exposure and Hepatitis E virus, Leptospira, Ascaris suum seropositivity and MRSA colonization in Austrian veterinarians, 2017–2018—A cross‐sectional study. Zoonoses Public Health. 2019;66(7):842–51.

Ward P, Müller P, Letellier A, Quessy S, Simard C, Trottier Y-L, et al. Molecular characterization of hepatitis E virus detected in swine farms in the province of Quebec. Can J Vet Res. 2008;72(1):27.

Brassard J, Gagné M-J, Généreux M, Côté C. Detection of human food-borne and zoonotic viruses on irrigated, field-grown strawberries. Appl Environ Microbiol. 2012;78(10):3763–6.

Steyer A, Naglič T, Močilnik T, Poljšak-Prijatelj M, Poljak M. Hepatitis E virus in domestic pigs and surface waters in Slovenia: prevalence and molecular characterization of a novel genotype 3 lineage. Infect Genet Evol. 2011;11(7):1732–7.

Tyrrel S, Quinton J. Overland flow transport of pathogens from agricultural land receiving faecal wastes. J Appl Microbiol. 2003;94(s1):87–93.

Namsai A, Louisirirotchanakul S, Wongchinda N, Siripanyaphinyo U, Virulhakul P, Puthavathana P, et al. Surveillance of hepatitis A and E viruses contamination in shellfish in Thailand. Lett Appl Microbiol. 2011;53(6):608–13.

Rivero-Juarez A, Lopez-Lopez P. Hepatitis E infection in HIV-infected patients. Front Microbiol. 2019;10:470960.

Dalton HR, Kamar N, Van Eijk JJ, Mclean BN, Cintas P, Bendall RP, et al. Hepatitis E virus and neurological injury. Nat Reviews Neurol. 2016;12(2):77.

Williams TPE, Kasorndorkbua C, Halbur P, Haqshenas G, Guenette D, Toth T, et al. Evidence of extrahepatic sites of replication of the hepatitis E virus in a swine model. J Clin Microbiol. 2001;39(9):3040–6.

Liu P, Bu Q-N, Wang L, Han J, Du R-J, Lei Y-X, et al. Transmission of hepatitis E virus from rabbits to cynomolgus macaques. Emerg Infect Dis. 2013;19(4):559.

Debing Y, Moradpour D, Neyts J, Gouttenoire J. Update on hepatitis E virology: implications for clinical practice. J Hepatol. 2016;65(1):200–12.

Shahini E, Argentiero A, Andriano A, Losito F, Maida M, Facciorusso A, et al. Hepatitis E Virus: what more do we need to know? Medicina. 2024;60(6):998.

Kamar N, Mansuy JM, Esposito L, Legrand-Abravanel F, Peron JM, Durand D, et al. Acute hepatitis and renal function impairment related to infection by Hepatitis E virus in a renal allograft recipient. Am J Kidney Dis. 2005;45(1):193–6.

Kamar N, Bendall R, Legrand-Abravanel F, Xia N-S, Ijaz S, Izopet J, et al. Hepatitis E. Lancet. 2012;379(9835):2477–88.

Geng Y, Zhao C, Huang W, Harrison TJ, Zhang H, Geng K, et al. Detection and assessment of infectivity of hepatitis E virus in urine. J Hepatol. 2016;64(1):37–43.

Aggarwal R, Krawczynski K, Hepatitis E. An overview and recent advances in clinical and laboratory research. J Gastroenterol Hepatol. 2000;15(1):9–20.

Izopet J, Lhomme S, Chapuy-Regaud S, Mansuy JM, Kamar N, Abravanel F. HEV and transfusion-recipient risk. Transfus Clin Biol. 2017;24(3):176–81.

Aggarwal R. Clinical presentation of hepatitis E. Virus Res. 2011;161(1):15–22.

Teshale EH, Hu DJ, Hepatitis E. Epidemiology and prevention. World J Hepatol. 2011;3(12):285–91.

Pischke S, Hartl J, Pas SD, Lohse AW, Jacobs BC, Van der Eijk AA. Hepatitis E virus: infection beyond the liver? J Hepatol. 2017;66(5):1082–95.

Nasir M, Wu GY. HEV and HBV Dual Infection: a review. J Clin Transl Hepatol. 2020;8(3):313–21.

Lhomme S, Marion O, Abravanel F, Chapuy-Regaud S, Kamar N, Izopet J, Hepatitis. E Pathogenesis Viruses. 2016;8(8).

Urooj S, Anjum S, Iqbal F, Abduh MS, Akhtar H, Javed S, et al. Hepatitis E Virus: Epidemiology, clinical aspects, and its significance as a major pregnancy risk. Livers. 2023;3(3):507–28.

Wu C, Wu X, Xia J. Hepatitis E virus infection during pregnancy. Virol J. 2020;17:1–11.

Peron J, Bureau C, Poirson H, Mansuy J, Alric L, Selves J, et al. Fulminant liver failure from acute autochthonous hepatitis E in France: description of seven patients with acute hepatitis E and encephalopathy. J Viral Hepatitis. 2007;14(5):298–303.

Butler DC, Lewin DN, Batalis NI. Differential diagnosis of hepatic necrosis encountered at autopsy. Acad Forensic Pathol. 2018;8(2):256–95.

Fousekis FS, Mitselos IV, Christodoulou DK. Extrahepatic manifestations of hepatitis E virus: an overview. Clin Mol Hepatol. 2020;26(1):16.

Jha AK, Kumar G, Dayal VM, Ranjan A, Suchismita A. Neurological manifestations of hepatitis E virus infection: an overview. World J Gastroenterol. 2021;27(18):2090.

Rawla P, Raj JP, Kannemkuzhiyil AJ, Aluru JS, Thandra KC, Gajendran M. A systematic review of the extra-hepatic manifestations of hepatitis E virus infection. Med Sci. 2020;8(1):9.

CAS   Google Scholar  

de Vries MA, Samijn JP, de Man R, Boots JM. Hepatitis E-associated encephalopathy in a renal transplant recipient. Case Rep. 2014;2014:bcr2014204244.

Woolson K, Forbes A, Vine L, Beynon L, McElhinney L, Panayi V, et al. Extra-hepatic manifestations of autochthonous hepatitis E infection. Aliment Pharmacol Ther. 2014;40(11–12):1282–91.

Vallabhajosyula S, Prabhu M, Stanley W, Vallabhajosyula S. 510: Multiorgan Dysfunction from Hepatitis E infection. Crit Care Med. 2018;46(1):240.

Karki P, Malik S, Mallick B, Sharma V, Rana SS. Massive hemolysis causing renal failure in acute hepatitis E infection. J Clin Translational Hepatol. 2016;4(4):345.

Aiqin Z, Dongming X, Kejun T, Yun Z. Long qt syndrome and Torsades De Points in a patient with acute hepatitis E virus infection: an unusual case. Heart. 2012;98(Suppl 2):E222–3.

Somani SK, Ghosh A, Awasthi G. Severe acute pancreatitis with pseudocyst bleeding due to hepatitis E virus infection. Clin J Gastroenterol. 2009;2(1):39–42.

Petrik J, Lozano M, Seed CR, Faddy HM, Keller AJ, Prado Scuracchio PS, et al. Hepat E Vox Sang. 2016;110(1):93–130.

Smith JL. A review of hepatitis E virus. J Food Prot. 2001;64(4):572–86.

Evans AS. Viral infections of humans: epidemiology and control. Springer Science & Business Media; 2013.

Aggarwal R, Naik S. Epidemiology of hepatitis E: past, present and future. 1997.

Balayan M. Epidemiology of hepatitis E virus infection. J Viral Hepatitis. 1997;4(3):155–66.

Bradley DW. Hepatitis E: epidemiology, aetiology and molecular biology. Rev Med Virol. 1992;2(1):19–28.

Langer B, Frösner G. Relative importance of the enterically transmitted human hepatitis viruses type A and E as a cause of foreign travel associated hepatitis. Import Virus Infections. 1996:171–9.

Ahmad T, Nasir S, Musa TH, AlRyalat SAS, Khan M, Hui J. Epidemiology, diagnosis, vaccines, and bibliometric analysis of the 100 top-cited studies on Hepatitis E virus. Hum Vaccines Immunotherapeutics. 2021;17(3):857–71.

Maral I, Budakoglu I, Ceyhan M, Atak A, Bumin M. Hepatitis E virus seroepidemiology and its change during 1 year in primary school students in Ankara, Turkey. Clin Microbiol Infect. 2010;16(7):831–5.

Jin H, Zhao Y, Zhang X, Wang B, Liu P. Case-fatality risk of pregnant women with acute viral hepatitis type E: a systematic review and meta-analysis. Epidemiol Infect. 2016;144(10):2098–106.

Taherkhani R, Farshadpour F. Epidemiology of hepatitis E in pregnant women and children in Iran: a general overview. J Clin Translational Hepatol. 2016;4(3):269.

JOSEPH G PASTOREK I. The ABCs of hepatitis in pregnancy. Clin Obstet Gynecol. 1993;36(4):843–54.

Kamar N, Selves J, Mansuy J-M, Ouezzani L, Péron J-M, Guitard J, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med. 2008;358(8):811–7.

Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med. 2009;361(10):1025–7.

Songtanin B, Molehin AJ, Brittan K, Manatsathit W, Nugent K. Hepatitis E virus infections: Epidemiology, genetic diversity, and clinical considerations. Viruses. 2023;15(6):1389.

Kemming J, Gundlach S, Panning M, Huzly D, Huang J, Lütgehetmann M, et al. Mechanisms of CD8 + T-cell failure in chronic hepatitis E virus infection. J Hepatol. 2022;77(4):978–90.

Krain LJ, Nelson KE, Labrique AB. Host immune status and response to hepatitis E virus infection. Clin Microbiol Rev. 2014;27(1):139–65.

Zhang JZ, Im SW, Lau SH, Chau TN, Lai ST, Ng SP, et al. Occurrence of hepatitis E virus IgM, low avidity IgG serum antibodies, and viremia in sporadic cases of non-A, -B, and -C acute hepatitis. J Med Virol. 2002;66(1):40–8.

Saravanabalaji S, Tripathy AS, Dhoot RR, Chadha MS, Kakrani AL, Arankalle VA. Viral load, antibody titers and recombinant Open Reading Frame 2 Protein-Induced Th1/Th2 cytokines and Cellular Immune responses in self-limiting and Fulminant Hepatitis E. Intervirology. 2009;52(2):78–85.

Srivastava R, Aggarwal R, Jameel S, Puri P, Gupta VK, Ramesh VS, et al. Cellular immune responses in acute hepatitis E virus infection to the viral open reading frame 2 protein. Viral Immunol. 2007;20(1):56–65.

Srivastava R, Aggarwal R, Bhagat MR, Chowdhury A, Naik S. Alterations in natural killer cells and natural killer T cells during acute viral hepatitis E. J Viral Hepat. 2008;15(12):910–6.

Wu J, Ling B, Guo N, Zhai G, Li M, Guo Y. Immunological manifestations of hepatitis e-associated acute and chronic liver failure and its regulatory mechanisms. Front Med. 2021;8:725993.

Bruccoleri A, Gallucci R, Germolec DR, Blackshear P, Simeonova P, Thurman RG, et al. Induction of early-immediate genes by tumor necrosis factor alpha contribute to liver repair following chemical-induced hepatotoxicity. Hepatology. 1997;25(1):133–41.

Yamada Y, Kirillova I, Peschon JJ, Fausto N. Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. Proc Natl Acad Sci U S A. 1997;94(4):1441–6.

Srivastava R, Aggarwal R, Sachdeva S, Alam MI, Jameel S, Naik S. Adaptive immune responses during acute uncomplicated and fulminant hepatitis E. J Gastroenterol Hepatol. 2011;26(2):306–11.

Khuroo MS, Kamili S, Dar MY, Moecklii R, Jameel S. Hepatitis E and long-term antibody status. Lancet. 1993;341(8856):1355.

Shrivastava S, Steele R, Ray R, Ray RB. MicroRNAs: role in hepatitis C virus pathogenesis. Genes Dis. 2015;2(1):35–45.

Xu L-D, Zhang F, Peng L, Luo W-T, Chen C, Xu P, et al. Stable expression of a hepatitis E virus (HEV) RNA replicon in two mammalian cell lines to assess mechanism of innate immunity and antiviral response. Front Microbiol. 2020;11:603699.

Baruah V, Bose S. Computational identification of hepatitis E virus-encoded microRNAs and their targets in human. J Med Virol. 2019;91(8):1545–52.

Chaikuad A, Keates T, Vincke C, Kaufholz M, Zenn M, Zimmermann B, et al. Structure of cyclin G-associated kinase (GAK) trapped in different conformations using nanobodies. Biochem J. 2014;459(1):59–69.

Patil RN, Karpe YA. Uncovering the roles of miR-214 in hepatitis E virus replication. J Mol Biol. 2020;432(19):5322–42.

Haldipur B, Bhukya PL, Arankalle V, Lole K. Positive regulation of hepatitis E virus replication by microRNA-122. J Virol. 2018;92(11):01999–17. https://doi.org/10.1128/jvi .

Jopling C. Liver-specific microRNA-122: Biogenesis and function. RNA Biol. 2012;9(2):137–42.

Hu J, Xu Y, Hao J, Wang S, Li C, Meng S. MiR-122 in hepatic function and liver diseases. Protein Cell. 2012;3(5):364–71.

Spaniel C, Honda M, Selitsky SR, Yamane D, Shimakami T, Kaneko S, et al. microRNA-122 abundance in Hepatocellular Carcinoma and Non-tumor Liver tissue from Japanese patients with persistent HCV versus HBV infection. PLoS ONE. 2013;8(10):e76867.

McGowan K, Simpson KJ, Petrik J. Expression profiles of exosomal MicroRNAs from HEV-and HCV-infected blood donors and patients: a pilot study. Viruses. 2020;12(8):833.

Trehanpati N, Sehgal R, Patra S, Vyas A, Vasudevan M, Khosla R et al. miRNA signatures can predict acute liver failure in hepatitis E infected pregnant females. Heliyon. 2017;3(4).

Golkocheva-Markova E. Micro RNAs—The Small Big Players in Hepatitis E Virus Infection: A Comprehensive Review. Biomolecules. 2022;12(11):1543.

Mirazo S, Ramos N, Mainardi V, Gerona S, Arbiza J. Transmission, diagnosis, and management of hepatitis E: an update. Hepatic Medicine: Evid Res. 2014:45–59.

Ahmed A, Ali IA, Ghazal H, Fazili J, Nusrat S. Mystery of hepatitis e virus: recent advances in its diagnosis and management. Int J Hepatol. 2015;2015.

Huang S, Zhang X, Jiang H, Yan Q, Ai X, Wang Y, et al. Profile of acute infectious markers in sporadic hepatitis E. PLoS ONE. 2010;5(10):e13560.

Kar P, Karna R. A review of the diagnosis and management of hepatitis E. Curr Treat Options Infect Dis. 2020;12:310–20.

Lan X, Yang B, Li BY, Yin XP, Li XR, Liu JX. Reverse transcription-loop-mediated isothermal amplification assay for rapid detection of hepatitis E virus. J Clin Microbiol. 2009;47(7):2304–6.

Sauleda S, Ong E, Bes M, Janssen A, Cory R, Babizki M, et al. Seroprevalence of hepatitis E virus (HEV) and detection of HEV RNA with a transcription-mediated amplification assay in blood donors from C atalonia (S pain). Transfusion. 2015;55(5):972–9.

Abravanel F, Chapuy-Regaud S, Lhomme S, Miedougé M, Peron J-M, Alric L, et al. Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients. J Clin Virol. 2013;58(4):624–8.

Velavan TP, Pallerla SR, Johne R, Todt D, Steinmann E, Schemmerer M, et al. Hepatitis E: an update on one health and clinical medicine. Liver Int. 2021;41(7):1462–73.

Pischke S, Hardtke S, Bode U, Birkner S, Chatzikyrkou C, Kauffmann W, et al. Ribavirin treatment of acute and chronic hepatitis E: a single-centre experience. Liver Int. 2013;33(5):722–6.

Kamar N, Abravanel F, Garrouste C, Cardeau-Desangles I, Mansuy JM, Weclawiak H, et al. Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. Nephrol Dialysis Transplantation. 2010;25(8):2792–5.

Kamar N, Dalton HR, Abravanel F, Izopet J. Hepatitis E virus infection. Clin Microbiol Rev. 2014;27(1):116–38.

Lhomme S, Marion O, Abravanel F, Izopet J, Kamar N. Clinical manifestations, Pathogenesis and treatment of Hepatitis E Virus infections. J Clin Med. 2020;9(2):331.

Kamar N, Rostaing L, Abravanel F, Garrouste C, Esposito L, Cardeau-Desangles I, et al. Pegylated interferon-α for treating chronic hepatitis E virus infection after liver transplantation. Clin Infect Dis. 2010;50(5):e30–3.

Gorris M, van Der Lecq BM, van Erpecum KJ, de Bruijne J. Treatment for chronic hepatitis E virus infection: a systematic review and meta-analysis. J Viral Hepatitis. 2021;28(3):454–63.

Todt D, Gisa A, Radonic A, Nitsche A, Behrendt P, Suneetha PV, et al. In vivo evidence for Ribavirin-induced mutagenesis of the hepatitis E virus genome. Gut. 2016;65(10):1733–43.

Todt D, Meister TL, Steinmann E. Hepatitis E virus treatment and Ribavirin therapy: viral mechanisms of nonresponse. Curr Opin Virol. 2018;32:80–7.

Debing Y, Ramière C, Dallmeier K, Piorkowski G, Trabaud M-A, Lebossé F, et al. Hepatitis E virus mutations associated with Ribavirin treatment failure result in altered viral fitness and Ribavirin sensitivity. J Hepatol. 2016;65(3):499–508.

Wang B, Mahsoub HM, Li W, Heffron CL, Tian D, Hassebroek AM, et al. Ribavirin treatment failure-associated mutation, Y1320H, in the RNA-dependent RNA polymerase of genotype 3 hepatitis E virus (HEV) enhances virus replication in a rabbit HEV infection model. Mbio. 2023;14(2):e03372–22.

Lhomme S, Kamar N, Nicot F, Ducos J, Bismuth M, Garrigue V, et al. Mutation in the hepatitis E virus polymerase and outcome of Ribavirin therapy. Antimicrob Agents Chemother. 2016;60(3):1608–14.

Article   CAS   PubMed Central   Google Scholar  

Meister TL, Brüggemann Y, Nocke MK, Ulrich RG, Schuhenn J, Sutter K et al. A ribavirin-induced ORF2 single-nucleotide variant produces defective hepatitis E virus particles with immune decoy function. Proceedings of the National Academy of Sciences. 2022;119(34):e2202653119.

Peron J-M, Larrue H, Izopet J, Buti M. The pressing need for a global HEV vaccine. J Hepatol. 2023;79(3):876–80.

Safary A. Perspectives of vaccination against hepatitis E. Intervirology. 2001;44(2–3):162–6.

Shrestha MP, Scott RM, Joshi DM, Mammen MP Jr, Thapa GB, Thapa N, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med. 2007;356(9):895–903.

Cao Y, Bing Z, Guan S, Zhang Z, Wang X. Development of new hepatitis E vaccines. Hum Vaccines Immunotherapeutics. 2018;14(9):2254–62.

Zhu F-C, Zhang J, Zhang X-F, Zhou C, Wang Z-Z, Huang S-J, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet. 2010;376(9744):895–902.

Kao CM, Rostad CA, Nolan LE, Peters E, Kleinhenz J, Sherman JD et al. A phase 1, Double-Blinded, placebo-controlled clinical trial to evaluate the safety and immunogenicity of HEV-239 (Hecolin) vaccine in Healthy US adults. J Infect Dis. 2024:jiae148.

Sehgal D, Malik PS, Jameel S. Purification and diagnostic utility of a recombinant hepatitis E virus capsid protein expressed in insect larvae. Protein Exp Purif. 2003;27(1):27–34.

Trabelsi K, Kamen A, Kallel H. Development of a vectored vaccine against hepatitis E virus. Vaccine. 2014;32(24):2808–11.

Dong C, Dai X, Meng J-H. The first experimental study on a candidate combined vaccine against hepatitis A and hepatitis E. Vaccine. 2007;25(9):1662–8.

Innis BL, Lynch JA. Immunization against hepatitis E. Cold Spring Harbor Perspect Med. 2018;8(11):a032573.

Kim J-H, Nelson KE, Panzner U, Kasture Y, Labrique AB, Wierzba TF. A systematic review of the epidemiology of hepatitis E virus in Africa. BMC Infect Dis. 2014;14(1):1–13.

Kinast V, Burkard TL, Todt D, Steinmann E. Hepatitis E virus drug development. Viruses. 2019;11(6):485.

Gabrielli F, Alberti F, Russo C, Cursaro C, Seferi H, Margotti M, et al. Treatment options for hepatitis A and E: a non-systematic review. Viruses. 2023;15(5):1080.

Thi VLD, Debing Y, Wu X, Rice CM, Neyts J, Moradpour D, et al. Sofosbuvir inhibits Hepatitis E virus replication in vitro and results in an additive effect when combined with Ribavirin. Gastroenterology. 2016;150(1):82–5. e4.

Cornberg M, Pischke S, Müller T, Behrendt P, Piecha F, Benckert J, et al. Sofosbuvir monotherapy fails to achieve HEV RNA elimination in patients with chronic hepatitis E–the HepNet SofE pilot study. J Hepatol. 2020;73(3):696–9.

Gömer A, Klöhn M, Jagst M, Nocke MK, Pischke S, Horvatits T, et al. Emergence of resistance-associated variants during sofosbuvir treatment in chronically infected hepatitis E patients. Hepatology. 2023;78(6):1882–95.

Guo H, Liu D, Liu K, Hou Y, Li C, Li Q, et al. Drug repurposing screen identifies vidofludimus calcium and pyrazofurin as novel chemical entities for the development of hepatitis E interventions. Virol Sin. 2024;39(1):123–33.

Qu C, Xu L, Yin Y, Peppelenbosch MP, Pan Q, Wang W. Nucleoside analogue 2’-C-methylcytidine inhibits hepatitis E virus replication but antagonizes Ribavirin. Arch Virol. 2017;162:2989–96.

Jagst M, Gömer A, Todt D, Steinmann E. Performance of sofosbuvir and NITD008 in extrahepatic neuronal cells against HEV. Antiviral Res. 2024:105922.

Hooda P, Al-Dosari M, Sinha N, Parvez MK, Sehgal D. Inhibition of HEV replication by FDA-Approved RdRp inhibitors. ACS Omega. 2023;8(44):41570–8.

Dalton HR, Bendall R, Ijaz S, Banks M. Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis. 2008;8(11):698–709.

Khuroo MS, Khuroo MS. Hepatitis E: an emerging global disease–from discovery towards control and cure. J Viral Hepatitis. 2016;23(2):68–79.

Guthmann J-P, Klovstad H, Boccia D, Hamid N, Pinoges L, Nizou J-Y, et al. A large outbreak of hepatitis E among a displaced population in Darfur, Sudan, 2004: the role of water treatment methods. Clin Infect Dis. 2006;42(12):1685–91.

Labrique AB, Thomas DL, Stoszek SK, Nelson KE. Hepatitis E: an emerging infectious disease. Epidemiol Rev. 1999;21(2):162–79.

Balayan M, Andjaparidze A, Savinskaya S, Ketiladze E, Braginsky D, Savinov A, et al. Evidence for a virus in non-A, non-B hepatitis transmitted via the fecal-oral route. Intervirology. 1983;20(1):23–31.

Zhao C, Ma Z, Harrison TJ, Feng R, Zhang C, Qiao Z, et al. A novel genotype of hepatitis E virus prevalent among farmed rabbits in China. J Med Virol. 2009;81(8):1371–9.

Woo PC, Lau SK, Teng JL, Tsang AK, Joseph M, Wong EY, et al. New Hepatitis E virus genotype in camels, the Middle East. Emerg Infect Dis. 2014;20(6):1044.

Drexler JF, Seelen A, Corman VM, Fumie Tateno A, Cottontail V, Melim Zerbinati R, et al. Bats worldwide carry hepatitis E virus-related viruses that form a putative novel genus within the family Hepeviridae. J Virol. 2012;86(17):9134–47.

Batts W, Yun S, Hedrick R, Winton J. A novel member of the family Hepeviridae from cutthroat trout (Oncorhynchus clarkii). Virus Res. 2011;158(1–2):116–23.

Takahashi M, Tanaka T, Takahashi H, Hoshino Y, Nagashima S, Jirintai f, et al. Hepatitis E Virus (HEV) strains in serum samples can replicate efficiently in cultured cells despite the coexistence of HEV antibodies: characterization of HEV virions in blood circulation. J Clin Microbiol. 2010;48(4):1112–25.

Johne R, Plenge-Bonig A, Hess M, Ulrich RG, Reetz J, Schielke A. Detection of a novel hepatitis E-like virus in faeces of wild rats using a nested broad-spectrum RT-PCR. J Gen Virol. 2010;91(3):750–8.

Meng X-J, Purcell RH, Halbur PG, Lehman JR, Webb DM, Tsareva TS et al. A novel virus in swine is closely related to the human hepatitis E virus. Proceedings of the National Academy of Sciences. 1997;94(18):9860-5.

Koonin EV, Gorbalenya AE, Purdy MA, Rozanov MN, Reyes GR, Bradley DW. Computer-assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: delineation of an additional group of positive-strand RNA plant and animal viruses. Proceedings of the National Academy of Sciences. 1992;89(17):8259-63.

Karpe YA, Lole KS. Deubiquitination activity associated with hepatitis E virus putative papain-like cysteine protease. Microbiology Society; 2011.

Karpe YA, Lole KS. RNA 5′-triphosphatase activity of the hepatitis E virus helicase domain. J Virol. 2010;84(18):9637–41.

Agrawal S, Gupta D, Panda SK. The 3′ end of hepatitis E virus (HEV) genome binds specifically to the viral RNA-dependent RNA polymerase (RdRp). Virology. 2001;282(1):87–101.

Jameel S, Zafrullah M, Ozdener MH, Panda SK. Expression in animal cells and characterization of the hepatitis E virus structural proteins. J Virol. 1996;70(1):207–16.

Torresi J, Li F, Locarnini SA, Anderson DA. Only the non-glycosylated fraction of hepatitis E virus capsid (open reading frame 2) protein is stable in mammalian cells. J Gen Virol. 1999;80(5):1185–8.

Zhou Y-H, Purcell RH, Emerson SU. A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus. Vaccine. 2005;23(24):3157–65.

Nagashima S, Takahashi M, Jirintai n, Tanaka T, Yamada K, Nishizawa T, et al. A PSAP motif in the ORF3 protein of hepatitis E virus is necessary for virion release from infected cells. J Gen Virol. 2011;92(2):269–78.

Nagashima S, Takahashi M, Jirintai S, Tanaka T, Nishizawa T, Yasuda J, et al. Tumour susceptibility gene 101 and the vacuolar protein sorting pathway are required for the release of hepatitis E virions. J Gen Virol. 2011;92(12):2838–48.

Nagashima S, Jirintai S, Takahashi M, Kobayashi T, Tanggis, Nishizawa T, et al. Hepatitis E virus egress depends on the exosomal pathway, with secretory exosomes derived from multivesicular bodies. J Gen Virol. 2014;95(10):2166–75.

Dalton HR, van Eijk JJ, Cintas P, Madden RG, Jones C, Webb GW, et al. Hepatitis E virus infection and acute non-traumatic neurological injury: a prospective multicentre study. J Hepatol. 2017;67(5):925–32.

Van Eijk JJ, Dalton HR, Ripellino P, Madden RG, Jones C, Fritz M, et al. Clinical phenotype and outcome of hepatitis E virus–associated neuralgic amyotrophy. Neurology. 2017;89(9):909–17.

van den Berg B, van der Eijk AA, Pas SD, Hunter JG, Madden RG, Tio-Gillen AP, et al. Guillain-Barré syndrome associated with preceding hepatitis E virus infection. Neurology. 2014;82(6):491–7.

Perrin HB, Cintas P, Abravanel F, Gerolami R, d’Alteroche L, Raynal J-N, et al. Neurologic disorders in immunocompetent patients with autochthonous acute hepatitis E. Emerg Infect Dis. 2015;21(11):1928.

Wang Y, Wang S, Wu J, Jiang Y, Zhang H, Li S, et al. Hepatitis E virus infection in acute non-traumatic neuropathy: a large prospective case-control study in China. EBioMedicine. 2018;36:122–30.

Mengel AM, Stenzel W, Meisel A, Büning C. Hepatitis E–induced severe myositis. Muscle Nerve. 2016;53(2):317–20.

Marion O, Abravanel F, Del Bello A, Esposito L, Lhomme S, Puissant-Lubrano B, et al. Hepatitis E virus–associated cryoglobulinemia in solid‐organ–transplant recipients. Liver Int. 2018;38(12):2178–89.

Premkumar M, Rangegowda D, Vashishtha C, Bhatia V, Khumuckham JS, Kumar B. Acute viral hepatitis E is associated with the development of myocarditis. Case Rep Hepatol. 2015;2015.

Kishore J, Sen M. Parvovirus B19-induced thrombocytopenia and anemia in a child with fatal fulminant hepatic failure coinfected with hepatitis A and E viruses. J Trop Pediatr. 2009;55(5):335–7.

Peter J, Stallmach A, Tannapfel A, Bruns T. Acute-on-chronic liver failure with complicating Pancreatitis after Autochthonous Hepatitis E infection. Hepat Monthly. 2017;17(11).

Thakur A, Basu PP. Acute non-fulminant viral Hepatitis E presenting with acute pancreatitis—an unusual presentation. Malaysian J Med Sciences: MJMS. 2017;24(4):102.

Dumoulin FL, Liese H. Acute hepatitis E virus infection and autoimmune thyroiditis: yet another trigger? Case Rep. 2012;2012:bcr1220115441.

Del Bello A, Guilbeau-Frugier C, Josse AG, Rostaing L, Izopet J, Kamar N. Successful treatment of hepatitis E virus‐associated cryoglobulinemic membranoproliferative glomerulonephritis with Ribavirin. Transpl Infect Disease. 2015;17(2):279–83.

Guinault D, Ribes D, Delas A, Milongo D, Abravanel F, Puissant-Lubrano B, et al. Hepatitis E virus–induced cryoglobulinemic glomerulonephritis in a nonimmunocompromised person. Am J Kidney Dis. 2016;67(4):660–3.

Download references

Acknowledgements

Not applicable.

Author information

Arash Letafati and Zahra Taghiabadi contributed equally to this work.

Authors and Affiliations

Department of Virology, Faculty of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Arash Letafati & Mehdi Norouzi

Research Center for Clinical Virology, Tehran University of Medical Science, Tehran, Iran

Arash Letafati, Zahra Taghiabadi, Mahshid Roushanzamir, Bahar Memarpour, Saba Seyedi, Ali Vasheghani Farahani, Masoomeh Norouzi, Saeideh Karamian, Arghavan Zebardast, Marzieh Mehrabinia, Omid Salahi Ardekani, Tina Fallah, Fatemeh Khazry, Samin Fathi Daneshvar & Mehdi Norouzi

Department of Pharmacological and Biomolecular Science, University of Milan, Milan, Italy

Mahshid Roushanzamir

Shahid Chamran University of Ahvaz, Ahvaz, Iran

Bahar Memarpour

You can also search for this author in PubMed   Google Scholar

Contributions

A.L: Conceptualization, Supervision. Z.T, B.M, S.S, A.V.F, M.N, S.K, A.Z, M.M, S.F, M.N: writing original draft, tables. O.S.A, T.F, F.K, M.R: Investigation, validation, Review and editing.

Corresponding author

Correspondence to Arash Letafati .

Ethics declarations

Ethics approval and consent to participate.

Not applicable .

Consent for publication

All authors agree.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/ .

Reprints and permissions

About this article

Cite this article.

Letafati, A., Taghiabadi, Z., Roushanzamir, M. et al. From discovery to treatment: tracing the path of hepatitis E virus. Virol J 21 , 194 (2024). https://doi.org/10.1186/s12985-024-02470-3

Download citation

Received : 05 May 2024

Accepted : 14 August 2024

Published : 23 August 2024

DOI : https://doi.org/10.1186/s12985-024-02470-3

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

• Pathogenesis

Virology Journal

ISSN: 1743-422X

• Submission enquiries: [email protected]